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ASTRACT 
THE CONTRIBUTION OF SYSTEM XC- TO PREFRTONAL CORTICAL 
MEDIATED BEHAVIORS ASSOCIATED WITH SCHIZOPHRENIA 
 
 
Victoria B. Lutgen, B.S. 
 
Marquette University, 2012 
 
Schizophrenia is a debilitating disorder involving impaired cognition, 
disorganized thinking, and auditory hallucinations that has a tremendous unmet medical 
need, potentially because current antipsychotics insufficiently target the pathophysiology 
of the disease. The neural basis of schizophrenia appears to involve abnormal activity 
within the dorsolateral prefrontal cortex (PFC) in which efferent neurons exhibit 
disorganized firing patterns.   Synchronization of cortical activity is regulated by complex 
inter-neuronal connections, which is compromised in schizophrenia.  Schizophrenic’s 
exhibit reduced PFC volume that may reflect reduced arborization leading to diminished 
inter-neuronal connectivity.  An unexplored explanation is that reduced volume reflects 
changes in astrocytes, cells positioned to control synchronized firing at up to 100K 
synapses.  Glutamate release, including from system xc- which exchanges one 
intracellular glutamate for an extracellular cystine, is emerging as a component of 
astrocytic neuronal regulation and is altered in the PFC of schizophrenics. To determine 
the importance of system xc- dysregulation, we examined the impact of increased or 
decreased activity to glutamate levels in the PFC and PFC mediated behaviors that are 
used to model schizophrenia.  
 
Decreased system xc- activity, achieved using the inhibitor sulfasalazine (SSZ), 
produced a phenotype that mirrored aspects of schizophrenia and reduced extracellular 
glutamate levels in the PFC.  Specifically, SSZ produced deficits in sensorimotor gating, 
cognition, and anxiety – all of which involve the PFC and are altered in schizophrenia.  
Similar to schizophrenia, system xc- dysregulation was detected, and appears to be central 
to the cognitive deficits in the methylazoxymethanol acetate (MAM) neurodevelopmental 
model of schizophrenia.   
 
Increased system xc- activity, achieved using the cysteine prodrug N-
acetylcysteine, reversed multiple behavioral deficits present in preclinical models of 
schizophrenia.  Namely, N-acetylcysteine reversed sensorimotor gating deficits produced 
by phencyclidine, an acute model of schizophrenia, and reversal learning deficits in the 
MAM model.  Notably, chronic N-acetylcysteine attenuated behavioral deficits and 
normalized aspects of system xc- activity in MAM-treated rats.    
 
  Collectively, these data position system xc- as a key regulator of behavioral 
output from the prefrontal cortex and indicate that system xc- dysregulation in 
schizophrenia may be an important component of the pathology of the disease.  In 
addition, increased system xc- may represent an effective therapeutic endpoint.       
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This dissertation will characterize the involvement of system xc- or the cystine-
glutamate antiporter in schizophrenia.  Specifically, acute and neurodevelopmental 
models of schizophrenia will be utilized to examine whether cystine-glutamate exchange 
is altered in these models.  In addition, the ability of direct manipulation of system xc- to 
produce behavioral deficits similar to those observed in schizophrenia will be examined. 
 
OVERVIEW OF SCHIZOPHRENIA: 
 
Schizophrenia is a debilitating lifelong neuropsychiatric disorder affecting up to 
1% of the world’s population (Lewis and Lieberman, 2000; McGrath et al., 2008).  It is 
characterized by a range of symptoms including positive (hallucinations, paranoia, 
delusions), negative (anhedonia, blunted affect, social deficits) and cognitive deficits 
(executive function, behavioral flexibility, memory, attention, learning) (Andreasen, 
1995; Elvevag and Goldberg, 2000; Blanchard and Cohen, 2006).  Cognitive deficits, 
particularly executive functioning which includes directed attention and planning 
working memory (Smith and Jonides, 1999; Eisenberg and Berman, 2010), are the best 
predictors of functional disability of the disorder and are poorly treated with current 
antipsychotic medication (Elvevag and Goldberg, 2000; Liddle, 2000; Kurtz et al., 2005; 
Lewis and Moghaddam, 2006).  Further, schizophrenics have persistent cognitive 
impairments below psychiatrically healthy groups (Heinrichs and Zakzanis, 1998).  The 
typical diagnosis occurs in late teens to early twenties with the onset of positive 
symptoms, however, negative symptoms such as social withdrawal and cognitive deficits 
typically occur throughout neurodevelopment (Andreasen, 1995; Chua and Murray, 
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1996).  The estimated lifetime cost of each schizophrenic in the United States can exceed 
over US$2 million dollars (Blomqvist et al., 2006) and therefore discovering treatments 
that target cognitive deficits will not only improve quality of life for the patient, but also 
alleviate some financial burden on society. 
 The etiology of schizophrenia remains largely unknown.  The genetic contribution 
is supported by twin studies where a monozygotic twin has a greater chance of 
developing schizophrenia than a dizygotic twin if the other is affected (Sullivan et al., 
2003; Gottesman and Wolfgram, 1991; Kendler, 2001).  However, 40% of 
schizophrenics have no familial history of schizophrenia (Gottesman and Erlenmeyer-
Kimling, 2001).  Further, there is no single causative gene directly linked to the illness 
and likely results from multiple risk genes acting additively to predispose an individual to 
schizophrenia (Weinberger et al., 2001; Lewis and Levitt, 2002; Harrison and 
Weinberger, 2005).  Current research suggests that there are multiple contributing factors 
including genetic predisposition and environmental stressors leading to abnormal 
neurodevelopment (Weinberger, 1987; Chua and Murray, 1996; Lewis and Levitt, 2002; 
Lang et al., 2007; Brown, 2011).  Pre and perinatal stressors that have been linked to 
increased risk of developing schizophrenia include maternal malnutrition, infections, 
stress and obstetrical complications (Lewis and Levitt, 2002; Lante et al., 2007; 
Malaspina et al., 2008; Brown, 2011; Brown and Patterson, 2011).  Likely, schizophrenia 
results from a combination of genetics and environmental stressors leading to abnormal 
neurodevelopment and the wide range of symptoms associated with this disorder.  
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STRUCTURAL ABNORMALITIES:  
 
Dorsolateral prefrontal cortex: Abnormal dorsolateral prefrontal cortical activity has 
been found in schizophrenics in the absence of neurodegeneration or lesions (Bunney and 
Bunney, 2000; Callicott et al., 2003; Eisenberg and Berman, 2010).  The rodent analog to 
human dorsolateral prefrontal cortex is the medial prefrontal cortex (Uylings et al., 2003). 
Pyramidal neurons comprise about 75% of total neurons in this region, are the main 
source of glutamate and the main targets of the majority of glutamate containing axons; 
the remaining 25% are interneurons (Lewis, 2004).  Schizophrenics have decreased 
dorsolateral prefrontal cortex volume (Andreasen et al., 1994; Nopoulos et al., 1995; 
Cannon et al., 2002; Giuliani et al., 2005; Fornito et al., 2009) in the absence of a change 
in neuronal number (Akbarian et al., 1995b; Thune et al., 2001).  However, there is 
evidence of increased pyramidal neuron density (Selemon et al., 1995, 1998) and 
decreased pyramidal neuron soma size with the greatest reductions found in deep layer 3 
(Rajkowska et al., 1998; Glantz and Lewis, 1997; Pierri et al., 2001; Sweet et al., 2003; 
Sweet et al., 2004).  Reduced soma size correlates to measures of the dendritic tree 
(Hayes and Lewis, 1996; Jacobs et al., 1997) and axonal arbor (Gilbert and Kelly, 1975; 
Lund et al., 1975) indicating reductions in those structures as well.  In support, decreased 
synapsin, a marker for axon terminals (Glantz and Lewis, 1997) has been found in 
schizophrenics suggesting a decrease in the number of terminals.  Further, a decrease in 
neuropil (axon terminals, dendritic spines, glial processes that occupy space between 
neurons) has also been suggested (Selemon and Goldman-Rakic, 1999).  All of these 
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findings suggest abnormal connectivity within the dorsolateral prefrontal cortex of 
schizophrenics.   
Abnormal dorsolateral prefrontal cortex activity has been shown using functional 
magnetic resonance imaging (fMRI) which measures changes in blood flow although 
there is some controversy.  Studies have found both hyper and hypofrontality in 
schizophrenics (for review see Eisenberg and Berman, 2010); increased activity is 
thought to result from inefficient prefrontal processing (Callicott et al., 2003; Manoach et 
al., 1999; Potkin et al., 2009).  To explain these controversial results, authors suggest an 
inverted U-shaped load-response curve where as task demand increases, there is elevated 
prefrontal cortical activity which peaks out at physiological capacity, after which, activity 
falls (Fletcher et al., 1998).  Further, the curve appears to be shifted to the left in 
schizophrenics (Perlstein et al., 2003; Jansma et al., 2004) so lower tasks will result in 
hyperactivation (inefficient signaling with similar performance to controls) and 
hypoactivation occurs during more difficult tasks (when schizophrenic’s performance is 
likely to be worse than controls) compared to controls (Callicott et al., 2003; Manoach, 
2003).     
Hyper and hypofrontality is less relevant when considering the contribution of 
synchronized pyramidal cell activity creating oscillations in the prefrontal cortex and 
hippocampus (Buzsaki and Draguhn, 2004) which have been shown to be necessary for 
cognitive processing (Howard et al., 2003; Haenschel et al., 2009; Lewis et al., 2012).  
Different frequencies of oscillation magnitude have been identified including slow 
oscillations in delta (0.5-3 Hz) theta (3-8 Hz) and beta (8-30 Hz ) ranges to fast 
oscillations in gamma (30-90 Hz) and ultrafast (90-200 Hz) ranges (Buzsaki and 
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Draguhn, 2004; Gonzalez-Burgos and Lewis, 2008).  Greater oscillation magnitude 
occurs with a greater amount of regular and synchronized pyramidal neuron activity.  
One neuron regularly firing generates rhythmic postsynaptic membrane potential in all 
target cells.  Greater neuronal synchrony amplifies the postsynaptic membrane potential 
generating synchronization in a greater population of target cells leading to network 
oscillations (Gonzalez-Burgos and Lewis, 2008).  Fast oscillation gamma bands have 
been linked to cognitive processing (Lisman and Idiart, 1995; Lisman, 1999; Howard et 
al., 2003; Tallon-Baudry et al., 2004; Sejnowski and Paulsen, 2006).  Parvalbumin (PV) 
containing, basket cell GABAergic interneuron activity is necessary and sufficient for 
high frequency gamma oscillations based on axonal positioning onto pyramidal neuronal 
soma, innervation of numerous pyramidal neurons and the high degree of interneuronal 
connectivity (Buzsaki and Draguhn, 2004; Gonzalez-Burgos and Lewis, 2008).    
Schizophrenics have irregular prefrontal gamma range oscillations which may contribute 
to symptoms of the illness (Spencer et al., 2003; Cho et al., 2006; Uhlhaas et al., 2006; 
Haenschel et al., 2009; Carlino et al., 2012).  Taken together, evidence supports abnormal 
dorsolateral prefrontal cortical function underlying symptoms of schizophrenia. 
Additional structural abnormalities: Additional structures have been implicated in 
schizophrenia including the hippocampus, mediodorsal thalamus, striatum and anterior 
cingulate cortex.  Specifically in the hippocampus reports of reduced hippocampal 
volume (Nelson et al., 1998; Wright et al., 2000; Honea et al., 2005; Weiss et al., 2005) 
and pyramidal cell size (Benes et al., 1991; Arnold et al., 1995; Zaidel et al., 1997) but 
see (Highley et al., 2003) who reported no changes.  Additionally, reduced dendritic 
spine density (Rosoklija et al., 2000), synaptic protein levels (Browning et al., 1993; 
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Young et al., 1998; Sawada et al., 2005) and alterations in ionotropic glutamatergic 
receptors (Harrison et al., 1991; Gao et al., 2000) are also observed.  Further, it has been 
suggested that early abnormal hippocampal activity and connectivity to the dorsolateral 
prefrontal cortex results in blunted maturation of the dorsolateral prefrontal cortex 
resulting in aberrant connectivity back to the hippocampus (Lipska et al., 2002).  Also, 
aberrant hippocampal-prefrontal interactions have been observed following executive 
tasks specifically working memory (Meyer-Lindenberg et al., 2005).  Further 
investigations of cortical-subcortical interactions and the precise involvement of each 
structure are necessary to understand abnormal activity and the contributions of each 
structure to the pathophysiology of schizophrenia.  
 
PATHOPHYSIOLOGY OF SCHIZOPHRENIA: NEUROTRANSMITTERS 
 
 Along with structural abnormalities observed in schizophrenia, many 
neurotransmitter systems have also been implicated in the pathophysiology of the 
disorder.  The dopamine hypothesis was the first to emerge since dopamine agonists 
including amphetamine induce a schizophrenia-like psychosis and the first antipsychotics 
acted as antagonists at dopamine type 2 receptors; however, these medications treat 
positive systems with few having any effect on negative or cognitive deficits (Coyle, 
2006; Carlsson, 2006).  More recently abnormal glutamate and GABA neurotransmission 
have emerged as popular theories underlying schizophrenia that have gained support and 
will be discussed in greater depth.  This section will give a brief overview of abnormal 
activity of each of these neurotransmitter systems that is observed in schizophrenia.  Of 
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note are the contributions of other neurotransmitters implicated in schizophrenia 
including serotonin and acetylcholine (Meltzer et al., 2003; Tandon, 1999) which will not 
be discussed. 
 
PATHOPHYSIOLOGY OF SCHIZOPHRENIA: GLUTAMATE 
 
Glutamate is the main excitatory neurotransmitter in the body and glutamate 
receptors mediate half of synaptic transmission throughout the central nervous system 
(Hollmann and Heinemann, 1994).  N-methyl-D-aspartate (NMDA) receptor 
hypofunction has gained attention when receptor antagonists were shown to induce 
positive, negative and cognitive deficits in healthy humans and rats and exacerbates 
symptoms in schizophrenics (Luby et al., 1959; Pearlson, 1981; Javitt and Zukin, 1991; 
Krystal et al., 1994; Verma and Moghaddam, 1996; Malhotra et al., 1997b; Adler et al., 
1999; Newcomer et al., 1999; Coyle, 2004).  Phencyclidine and ketamine are non-
competitive, open channel blockers of the NMDA receptor inhibiting influx of Ca2+; 
these drugs have also been shown to block type 2 dopamine receptors.  However, it is 
thought that the psychotomimetic effects are due to inhibition of the NMDA receptor 
(Javitt and Zukin, 1991; Vollenweider and Geyer, 2001).  Further support for NMDA 
receptor hypofunction in schizophrenia are elevated levels of kynurenic acid and N-acetyl 
aspartyl glutamate (NAAG) which are endogenous NMDA receptor antagonists although 
NAAG is also an agonist at the metabotropic glutamate 3 receptor (Schwarcz et al., 2001; 
Tsai et al., 1995; Berger et al., 1999; Hakak et al., 2001).  Additionally, the NMDA 
receptor co-agonists D-serine and glycine, necessary for receptor activity, are decreased 
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in schizophrenics (Sumiyoshi et al., 2004; Neeman et al., 2005; Hashimoto et al., 2003a).  
Lastly, there are reports of altered NMDA receptor expression.  However, these findings 
are not present in all schizophrenics and not always replicated across studies; based on 
this controversy, NMDA receptor expression will not be discussed in detail (Akbarian et 
al., 1996; Mirnics et al., 2000; Dracheva et al., 2001; Kristiansen et al., 2006; Kristiansen 
et al., 2007).  It is likely that NMDA receptor hypofunction in schizophrenics results 
from a combination of altered levels of co-agonists or antagonists, altered redox state 
(discussed below in the glutathione section), altered expression and abnormal trafficking 
of the NMDA receptor.  However, further investigations are necessary to establish the 
nature of NMDA receptor hypofunction. 
 It is hypothesized that phencyclidine and ketamine target NMDA receptors 
located on GABAergic interneurons leading to pyramidal cell disinhibition (Jones and 
Buhl, 1993; Lei and McBain, 2002; Maccaferri and Dingledine, 2002; Homayoun and 
Moghaddam, 2007; Lewis et al., 2012).  This leads to subsequent disinhibition of 
pyramidal cell firing elevating synaptic neurotransmitter release shown in rodents by 
electrophysiological methods (Jackson et al., 2004), metabolic imaging methods 
(Vaisanen et al., 2004; Sharp et al., 2001) and increased glutamate concentrations 
(Moghaddam et al., 1997; Homayoun et al., 2005).  Elevated glutamate levels will over 
stimulate non-NMDA glutamate receptors including α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors shown by AMPA receptor antagonists 
normalizing dopamine levels and behavioral measures induced by NMDA receptor 
antagonists (Moghaddam et al., 1997).  Thus NMDA receptor antagonists result in 
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abnormal firing in the prefrontal cortex and cognitive deficits associated with 
schizophrenia. 
 Metabotropic glutamate receptors (mGluR) have also been implicated in 
schizophrenia.  Of the eight known receptor types divided into three groups based on G 
protein coupling specificity and sequence homology, group I mGluRs, particularly 
mGluR5, and group II mGluRs constituting mGluR2 and mGlur3, have been identified as 
potential targets for the treatment of schizophrenia.  mGlurR5 is coupled to Gq/11 to 
increase intracellular Ca2+   (for review see De Blasi et al., 2001; Ribeiro et al., 2010) and 
physically interacts with and potentiates the NMDA receptor through scaffolding proteins 
to enhance synaptic transmission (Attucci et al., 2001; Ehlers, 1999; Doherty et al., 2000; 
Mannaioni et al., 2001; Marino and Conn, 2002).  Metabotropic group II glutamate 
receptors (mGluR2/3) are located on both presynaptic and postsynaptic neurons in the 
synaptic and extrasynaptic space; mGluR3 is also expressed on astrocytes (Phillips et al., 
2000; Tamaru et al., 2001).  Further, mGlur2/3 couples to Gi/o leading to reduced 
intracellular Ca2+ and inhibition of Ca2+ mediated synaptic neurotransmitter release (Flor 
et al., 1995; Conn and Pin, 1997).  Interestingly, preclinical studies provide evidence of 
mGluR2/3 agonist normalizing NMDA antagonist-induced increase in glutamate 
(Moghaddam and Adams, 1998; Lorrain et al., 2003) and reducing many behavioral 
abnormalities induced by NMDA receptor antagonism (Moghaddam and Adams, 1998; 
Cartmell et al., 1999; Krystal et al., 2003; Baker et al., 2008).  Further, clinical trials have 
yielded positive results with mGluR2/3 agonists in schizophrenia treatment (Patil et al., 
2007; Mosolov et al., 2010).  However, one study did not find a significant benefit with 
mGluR2/3 agonist but they also failed to see improvements with antipsychotic 
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medication (Kinon et al., 2011) suggesting it was a failed trial.  Thus stimulating 
metabotropic glutamate receptors may represent a novel target in the development of 
schizophrenia treatments.   
 When studying glutamatergic activity it is important to not only consider 
glutamate receptors but also the location of receptors and glutamate itself.  Vesicular 
glutamate is released into the synapse, activates postsynaptic receptors and is quickly and 
efficiently cleared by astrocytes through excitatory amino acid transporters 1 and 2 
(EAAT1 and EAAT2) (Rothstein et al., 1994; Rothstein et al., 1996).  The non-synaptic 
pool of glutamate is in part supplied by the non-vesicular cystine-glutamate antiporter or 
system xc- (Baker et al., 2002b; Massie et al., 2011; De Bundel et al., 2011).  System xc- 
exchanges one intracellular glutamate for an extracellular cystine (Baker et al., 2002b).  
This has been shown by blocking system xc- or genetic knockouts of active subunit of 
system xc- having significantly reduced extrasynaptic glutamate in multiple brain regions 
(Baker et al., 2002b; Moran et al., 2005; De Bundel et al., 2011; Massie et al., 2011).  
Extrasynaptic glutamate can activate extrasynaptic glutamate receptors including 
mGluR2/3 and NMDA receptors.  Further, xCT expression is altered in the dorsolateral 
prefrontal cortex of schizophrenics (Baker et al., 2008).  Taken together, glutamate 
neurotransmission is a complex regulated network which has the ability to produce 
behavioral deficits associated with schizophrenia and other neuropsychiatric disorders 
when glutamate transmission is disturbed or altered. 
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PATHOPHYSIOLOGY OF SCHIZOPHRENIA: GABA 
 
Numerous studies implicate abnormal GABAergic interneuron activity in the 
dorsolateral prefrontal cortex in schizophrenia.  First, two isoforms of glutamic acid 
decarboxylase of 65 and 67 kDa (GAD65 and GAD67) synthesize GABA; GAD67 
synthesizes the majority of GABA (Asada et al., 1997; Waagepetersen et al., 1999).  
GAD67 expression is activity dependent (Jones, 1990; Akbarian and Huang, 2006); 
decreased cortical activity reduces GAD67 levels (Benson et al., 1994; Jiao et al., 2006) 
whereas increased cortical activity increases GAD67 expression (Liang and Jones, 1997; 
Esclapez and Houser, 1999).  In schizophrenics, GAD67 is decreased in the PV expressing 
subset of GABAergic interneurons (Akbarian et al., 1995b; Volk et al., 2000; Hashimoto 
et al., 2003b).  Vesicular GABA release activates postsynaptic receptors (GABAA and 
GABAB) typically generating inhibitory postsynaptic potentials (IPSPs) on postsynaptic 
targets (Gonzalez-Burgos and Lewis, 2008).  GABA diffuses out of the synaptic cleft and 
is taken up by GABA transporters (GAT) (for review see Misgeld et al., 1995; Bak et al., 
2006).  Of the number of different subclasses of GABAergic interneurons, fast-spiking 
PV expressing neurons are altered in schizophrenics (for review see Lewis et al., 2012).  
First, PV containing GABAergic interneurons have either basket or chandelier cell 
morphology (for review see DeFelipe, 1997).  Basket cell PV containing interneurons 
synapse on pyramidal cell bodies and proximal dendrites thereby having a large impact 
on pyramidal neuronal activity (Jones and Buhl, 1993; Bartos et al., 2007).  Further, one 
interneuron synapses on each pyramidal neuron multiple times and each interneuron can 
contact multiple pyramidal cells and other similar interneurons (Gonzalez-Burgos and 
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Lewis, 2008).  GABAergic interneurons also contain gap junctions allowing for fast 
communication between cells and for synchronization between interneurons (Tamas et 
al., 2000).  This enables interneurons to generate oscillations by synchronizing a network 
of pyramidal neurons.  PV is a calcium-binding protein that buffers Ca2+ in the 
presynaptic terminal impacting Ca2+ regulated neuronal processes such as excitation and 
synaptic activity (Chard et al., 1993; Pauls et al., 1996; Savic et al., 2001).   
Schizophrenics have decreased PV mRNA in the dorsolateral prefrontal cortex 
(Hashimoto et al., 2003b; Mellios et al., 2009; Fung et al., 2010) although the number of 
PV neurons appears to be unchanged (Woo et al., 1997). 
 Experiments have demonstrated the capacity of PV neurons to inhibit pyramidal 
neuron activity.  PV GABAergic interneurons have also been shown necessary for 
network oscillations (Cobb et al., 1995; Bartos et al., 2007; Gulyas et al., 2010; Lewis et 
al., 2012).  PV neurons receive excitatory input from surrounding pyramidal neurons and 
interneurons as well as projecting neurons (Behrens et al., 2007).  Excitatory synapses 
contain both NMDA and AMPA receptors.  Studies have shown that NMDA receptor 
antagonists binding within the pore preferentially block receptors on GABA interneurons 
due to the increased activation and firing rate of these cells in comparison to surrounding 
neurons.  This results in disinhibition of pyramidal cells, increased pyramidal neuron 
activity and elevated glutamate release (Jones and Buhl, 1993; Moghaddam and Adams, 
1998; Lorrain et al., 2003; Homayoun and Moghaddam, 2007; Amitai et al., 2011).  Loss 
of inhibition also leads to network desynchronization and reduced gamma oscillations 
contributing to behavioral deficits (Sohal et al., 2009; Cobb et al., 1995; Cardin et al., 
2009).  Interestingly, chronic NMDA receptor antagonism results in a loss of PV and 
14 
 
GAD67 expression (Braun et al., 2007; Amitai et al., 2011) lending further support for the 
link between NMDA receptor antagonists and GABAergic interneurons.     
Schizophrenic GABA system alterations appear to result from abnormal activity 
and not from a change in number (Benes et al., 1996; Woo et al., 1997).  Further, changes 
in PV basket cells are thought to contribute to abnormal dorsolateral prefrontal activity 
(for review see Lewis et al., 2012).  As stated above, GAD67 and PV mRNA is reduced in 
PV cells (Akbarian et al., 1995b; Volk et al., 2000; Hashimoto et al., 2003b; Curley et al., 
2011; Mellios et al., 2009; Fung et al., 2010) with no change in GAT1 expression in the 
dorsolateral prefrontal cortex of schizophrenics (Woo et al., 1998).  Also, mRNA for 
GABAA α1 receptor, thought to mediate basket cell inputs onto pyramidal soma, are 
significantly reduced in prefrontal cortex (Akbarian et al., 1995a; Hashimoto et al., 
2008a; Hashimoto et al., 2008b; Beneyto et al., 2011) although no changes in receptor 
expression has also been observed (Duncan et al., 2010).  Decreased GABAA α1 on 
pyramidal cells could indicate lower basket cell synaptic inputs since each PV neuron 
typically innervates one postsynaptic targe↓t many times which is also supported by 
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decreased PV presynaptic expression.   
Figure 1.1 depicts altered GABAergic dysfunction in schizophrenics.  As shown, 
disinhibition of PV basket cells is suggested by reduced PV and GAD67 in interneurons 
with lower pyramidal GABAA α1 expression.  Further, evidence supports weaker 
inhibitory basket cell inputs onto pyramidal neurons contributing to loss of 
hyperpolarization which is necessary for pyramidal cell synchronization and gamma 
oscillations (Bartos et al., 2007; Lewis et al., 2012).  Taken together, there is strong 
support for abnormal GABAergic interneuron activity contributing to the loss of gamma 
oscillations necessary for cognition in schizophrenics.   
 
ASTROCYTES: CONTRIBUTION TO NETWORK SYNCHRONIZATION  
 
 A less well studied regulator of network synchronization is the contribution of 
astrocytes.  Astrocytes have minimal overlapping areas (Ogata and Kosaka, 2002; 
Bushong et al., 2002) and one astrocyte contacts approximately 100,000 synapses in 
rodents and up to one million synapses in humans (Bushong et al., 2003; Oberheim et al., 
2006).  As shown in Figure 1.2, astrocytes communicate with pyramidal-pyramidal 
synapses, GABAergic-pyramidal synapses, neuron cell bodies and dendritic processes 
impacting network activity within the entire domain of the astrocyte.  Further, astrocytes 
communicate with neurons by releasing factors which regulate ionotropic receptor 
expression, synaptic activity and neuronal activation.  Brain-derived neurotrophic factor 
(BDNF) is released by astrocytes and regulates GABAA receptor expression and the 
frequency of IPSCs (Elmariah et al., 2005; Barker and Ullian, 2010).  Astrocytes also 
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release tumor necrosis factor-alpha (TNF-α) to increase AMPAR trafficking to synapses 
(Beattie et al., 2002; Barker and Ullian, 2010).  Additionally, astrocytes have the capacity 
to control the number and strength of synapses through the release of glutamate, D-serine 
which is a co-agonist of the NMDA receptor and ATP which can depress synaptic 
activity (for review see Kondziella et al., 2006; Barker and Ullian, 2010; Reichenbach et 
al., 2010).  Of particular importance to this work is the expression of system xc- which is 
capable of regulating glutathione concentrations and extrasynaptic mGluR2/3 activity and 
will be discussed in the following section.  Based on these findings, astrocytes are 
uniquely positioned and contain the necessary transporters to have a profound influence 
on network activity and contribute to network synchronization leading to cognitive 
processes associated with schizophrenia. 
  
 
 
 
 
Figure 1.2 Astrocytes 
are capable of 
communicating with 
neurons including 
pyramidal neurons (PN) 
and GABAergic PV 
containing basket 
interneurons (PV) near 
and away from the 
synapse thereby 
impacting the 
excitiatory environment 
and network 
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CYSTINE- GLUTAMATE EXCHANGE BY SYSTEM XC-  
 
System xc- or the cystine-glutamate antiporter is a critical transporter within the 
central nervous system capable of regulating both oxidative stress and neurotransmission 
(Baker et al., 2002b; Shih et al., 2006).  It is a Na+-independent Cl--dependent transporter 
capable of exchanging intracellular glutamate for extracellular cystine in a 1:1 ratio 
(Baker et al., 2002b).  As shown in Figure 1.3, evidence indicates system xc- is located on 
astrocytes (Allen et al., 2001; Pow, 2001) although there is also evidence of immature 
neuronal expression (Murphy et al., 1989; Murphy et al., 1990).  Extracellular cysteine is 
predominantly expressed in the oxidized form of cystine which is transported by system 
xc
- (Bannai and Tateishi, 1986).  Once taken up, intracellular cystine is rapidly reduced 
into cysteine for glutathione synthesis which is then utilized by the astrocyte or 
transported back into the extrasynaptic space to serve as substrates for neuronal uptake 
for glutathione synthesis (Meister, 1988; Sies, 1999; Dringen and Hirrlinger, 2003).  
Thus, astrocytic cysteine is essential for both astrocytic and neuronal glutathione levels.  
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Externalized glutamate by system xc- is critical for nonvesicular glutamate concentrations 
in the nucleus accumbens and capable of stimulating group II metabotropic glutamate 
receptors (Baker et al., 2002a; Mohan et al., 2011).  Group II mGluRs are G-protein 
coupled heteroreceptors which inhibits intracellular Ca2+ accumulations necessary for 
vesicular neurotransmitter release such as glutamate and dopamine thereby regulating 
neurotransmission (Conn and Pin, 1997; Flor et al., 1995).  Interestingly, these receptors 
serve as a potential therapeutic target in schizophrenia treatments highlighting abnormal 
functioning of this circuit in schizophrenics (Patil et al., 2007; Mosolov et al., 2010; 
although see Kinon et al., 2011).  In addition, enhanced efflux of glutamate via system xc- 
may induce excitotoxicity through increased extrasynaptic NMDA receptor activation 
cascades (for review see Bridges, 2011).   
Due to the unique regulation of both cystine and glutamate cycling, system xc- has 
already been linked to many central nervous system processes including oxidative stress 
and protection (Shih et al., 2006), regulating synaptic transmission (Baker et al., 2002b), 
blood brain barrier regulation (Hosoya et al., 2002), synaptic organization (Augustin et 
al., 2007), viral pathology (Espey et al., 1998), drug addiction (Kalivas, 2009), and brain 
tumor growth (Chung et al., 2005; Lyons et al., 2007; Chen et al., 2009).  Given this, it is 
imperative to understand the structure and regulation of the cystine-glutamate antiporter.  
System xc- is a membrane bound protein of the heteromeric amino acid transporter (HAT) 
family (Broer and Wagner, 2002; Verrey et al., 2004).  It is composed of a hydrophobic 
non-glycosylated light chain (xCT) linked to a type II N-glycosylated heavy chain 
(4F2hc) via a disulfide bond.  While 4F2hc is required for trafficking and cell surface 
expression, xCT is the functioning unit that exchanges glutamate for cystine (Gasol et al., 
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2004; Jimenez-Vidal et al., 2004; Bassi et al., 2001).  Whether full length xCT or splice 
variants are the functional membrane-bound proteins in vivo remains unclear and requires 
further exploration as does the regulation of cystine-glutamate exchange.  Evidence 
suggests that oxidative stress is capable of up regulating system xc- transcription through 
Nuclear factor erythroid-2-related factor (Nrf2) binding to the Antioxidant Response 
Element (ARE) promoter on xCT gene (Bannai, 1984; Ishii et al., 2000) as does depleted 
glutathione concentrations (Seib et al., 2011).  There is a high probability of additional 
factors within the intra and extracellular milieu having an as yet unidentified contribution 
to system xc- regulation which will require future studies. 
While cystine-glutamate exchange has not been extensively studied in 
schizophrenia, there is increasing evidence of altered antiporter activity.  First, there is 
evidence of increased expression of xCT, the active subunit of the cystine-glutamate 
antiporter, in the dorsolateral prefrontal cortex of schizophrenic patients that is not 
present in other brain regions (Baker et al., 2008).  Increased expression may result from 
an inefficient glutathione supply since decreased glutathione has been shown to elevate 
system xc- expression (Seib et al., 2011).  In support, studies have shown an overall 
reduction in glutathione levels in the central nervous system with a 50% reduction in the 
dorsolateral prefrontal cortex of schizophrenics (Do et al., 2000; Gawryluk et al., 2010; 
Raffa et al., 2011).  Whether altered glutathione or system xc- expression occurs first 
remains unclear.  Lastly, the cysteine prodrug, N-acetylcysteine, has shown clinical 
efficacy in treating symptoms of schizophrenia that currently do not have effective 
treatments (Berk et al., 2008c; Lavoie et al., 2008; Carmeli et al., 2012).  Accordingly, 
these data have the potential to identify the cystine-glutamate antiporter as both a novel 
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mechanism contributing to the pathophysiology of schizophrenia and as a potential 
therapeutic target. 
 Interestingly, xCT knockout mice have been generated and they have a normal 
appearance, normal lifespan and no changes in cortical or hippocampal width (De Bundel 
et al., 2011; Sato et al., 2005).  Not surprisingly, decreased extracellular glutamate was 
observed through microdialysis studies in the hippocampus and striatum suggesting that 
system xc- is one of the main contributors to this pool and cannot be replaced (De Bundel 
et al., 2011; Massie et al., 2011).  Surprisingly, there were no changes in tissue 
glutathione concentrations in these regions or other non-CNS organs including the liver 
and pancreas (Sato et al., 2005; Massie et al., 2011; De Bundel et al., 2011) likely due to 
a compensatory increase in other cysteine transporters although this has yet to be 
explored in these animals.  Behavioral measures included locomotion in open field, 
spatial reference memory in Morris water maze and delayed alternation in Y-maze task 
measuring spatial working memory.  No changes in spontaneous locomotor activity to a 
novel environment corresponds with the methylazoxymethanol acetate (MAM) 
neurodevelopmental model which requires a stimulant such as amphetamine or 
phencyclidine to reveal deficits from control animals (Flagstad et al., 2004; Moore et al., 
2006; Lodge and Grace, 2007).  Intact spatial reference memory also corresponds to the 
neurodevelopmental MAM model where deficits emerge after reversal learning challenge 
in the Morris water maze (Flagstad et al., 2005).  Interestingly, xCT knockouts have 
deficits in spatial working memory and make significantly less correct alternations 
compared to control (De Bundel et al., 2011).  Since this occurs in the absence of a 
glutathione deficit, it suggests that spatial working memory tasks require extracellular 
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glutamate which can activate extrasynaptic mGluR2/3 receptors.  This is a very 
interesting mutant model and will require a great amount of further research to 
understand the widespread impact of system xc- on homeostatic mechanisms and 
behavior.   
 
GLUTATHIONE AND SCHIZOPHRENIA 
 
 Glutathione is a critical antioxidant necessary for the scavenging of free radicals, 
protecting cells from oxidative stress and regulating redox potentials (Cooper and Kristal, 
1997; Sies, 1999; Soltaninassab et al., 2000; Dringen, 2000).  Total glutathione is 
decreased by up to 50% in the dorsolateral prefrontal cortex and by 27% in the cerebral 
spinal fluid of schizophrenic patients compared to matched controls (Do et al., 2000; Yao 
et al., 2006; Gawryluk et al., 2010; Raffa et al., 2011).  Secondary to reduced glutathione 
concentrations is an increase in reactive oxygen species and impaired antioxidant defense 
system in schizophrenics (Olney et al., 1999; Yao et al., 2006; Bitanihirwe and Woo, 
2011; Yao and Reddy, 2011).  Further, glutathione reduces the extracellular redox site on 
the NMDA receptor causing potentiation of NMDA receptor currents (Kohr et al., 1994; 
Lipton et al., 2002).  Therefore, reduced glutathione levels leads to NMDA receptor 
hypoactivity (Steullet et al., 2006); NMDA receptor hypofunction is hypothesized to 
contribute to the pathophysiology of schizophrenia (Olney et al., 1999; Coyle, 2006). 
While these reports implicate glutathione, it is necessary to also understand glutathione 
cycling and how it is altered in schizophrenia. 
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Glutathione cycling and concentrations are tightly regulated by a number of 
proteins and checkpoints, some of which have been implicated in schizophrenia (Dringen 
and Hirrlinger, 2003).  First, the rate limiting step of glutathione synthesis is cystine in 
astrocytes and cysteine uptake in neurons (Sagara et al., 1993; Kranich et al., 1998; 
Dringen and Hirrlinger, 2003).  In astrocytes, system xc- is a key transporter for cystine 
(Bannai, 1984; Bridges, 2011) and studies have shown altered protein expression of xCT, 
the active subunit of the cystine-glutamate antiporter in schizophrenics (Baker et al., 
2008).  As indicated in Figure 1.4, intracellular cystine is rapidly reduced to cysteine and 
synthesized into glutathione by the addition of glutamate and glycine in two enzymatic 
processes involving glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS) 
(Meister, 1988; Sies, 1999).  GCL is composed of a catalytic subunit (GCLC) necessary 
for glutathione synthesis and a modifier subunit (GCLM) to increase efficiency (Yang et 
al., 2007).  In schizophrenics, research has shown a decrease in GCLM gene expression, 
reduced GCLC protein expression and GCL activity in fibroblasts (Tosic et al., 2006; 
Gysin et al., 2007) although GCLM genetic linkage remains controversial (Butticaz et al., 
2009).  Further, GSS mRNA levels are also reduced (Tosic et al., 2006).  After 
G G
 
Figure 1.4 Glutathione cycling.  
Cystine uptake by system xc- is the rate 
limiting step in glutathione synthesis.  
Glutamate cysteine ligase (GCL) is the 
rate limiting enzyme in glutathione 
synthesis.  Glutathione synthetase 
(GSS), multidrug resistance protein-1 
(MRP-1) exports glutathione out of the 
astrocyte for degradation by γ-glutamyl 
transpeptidase (GGT) and can undergo 
further degradation to cystine which 
will drive cystine-glutamate exchange. 
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completion of glutathione synthesis, it is utilized intracellularly or exported into the 
extracellular space by multidrug resistance protein 1 (Mrp1).  Glutathione undergoes 
extracellular catabolism by the membrane ectoenzyme γ-glutamyl transpeptidase (GGT) 
into CysGly and γ-glutamylX.  “X” represents an acceptor of the γ-glutamyl moiety.  
CysGly is hydrolyzed into cysteine and glycine by aminopeptidase N (N(ApN)) and 
transported into neurons for neuronal glutathione synthesis (Dringen and Hirrlinger, 
2003).  Additionally, extracellular cysteine is readily oxidized to cystine thus driving 
cystine-glutamate exchange and glutathione cycling (Lu, 1999; Dringen, 2000).  Taken 
together, whether altered cystine-glutamate exchange limits glutathione synthesis or 
altered glutathione synthesis reduces cystine-glutamate exchange, the end result is 
reduced glutathione and altered cell homeostasis potentially contributing to symptoms of 
schizophrenia.  
A promising treatment for schizophrenia is restoration of glutathione levels.  
Clinical trials have administered the cysteine precursor N-acetylcysteine to drive 
glutathione synthesis (Berk et al., 2008c; Lavoie et al., 2008; Carmeli et al., 2012).  
Results show improvements with N-acetylcysteine as adjunctive therapy.  Whether N-
acetylcysteine restores glutathione by driving system xc- in schizophrenics remains 
unclear and will be discussed later. 
 Given the reports of altered glutathione homeostasis in schizophrenia, studies 
have examined animal models of reduced glutathione concentrations and its impact to 
schizophrenic-like symptoms.  One model is a genetic glutamate-cysteine ligase modifier 
(GCLM) knockout mouse.  First, while GCLC knockout mouse is embryonic lethal, 
GCLM -/- reduces glutathione in all regions including the prefrontal cortex, striatum and 
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liver to around 30% of control levels throughout the lifespan (Steullet et al., 2010; Duarte 
et al., 2011).  These animals have a subset of symptoms associated with schizophrenia 
including positive symptoms (increased locomotion to a novel environment and in 
response to amphetamine), negative symptoms (altered social behavior) and cognitive 
deficits (novel object recognition).  Additionally, these animals show deficits in prepulse 
inhibition, increased oxidative stress and reduced parvalbumin expression, the marker for 
fast-spiking interneurons, in the ventral hippocampus.  However it should be noted that 
these animals did not display spatial or short term working memory deficits (Morris 
water maze or Y-maze) or elevated baseline locomotor responses in home cage (Steullet 
et al., 2010; Cole et al., 2011; Kulak et al., 2012).  Interestingly, while N-acetylcysteine 
has not been given as a behavioral treatment, it has been shown to normalize some 
neurochemical indices of knockout mice including glutamate, glutamine, alanine and 
myo-inositol (Duarte et al., 2011) suggesting the therapeutic beneficial effects of N-
acetylcysteine may be independent of glutathione concentrations.    
 Glutathione is essential particularly in the central nervous system to maintain 
cellular redox systems and to protect cells from oxidative damage and cell death.  Many 
labs have shown a significant reduction in dorsolateral prefrontal cortical glutathione 
concentrations in schizophrenia patients.  This accounts for NMDA receptor hypoactivity 
and potentially reduced cystine-glutamate exchange causing dysregulation of GABAergic 
and glutamatergic signaling.  This results in abnormal oscillations and desynchronization 
of cortical activity and symptoms of schizophrenia.       
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NEURODEVELOPMENT 
 
Neurogenesis is a highly regulated process that relies on growth factors and 
neurotransmitters for normal development and migration.  Neuroepithelial cells destined 
to become neocortical pyramidal neurons undergo mitosis in the germinal layers lining 
the ventricular system and migrate to their final destination (Sidman and Rakic, 1973; 
Hatten, 1993).  The first cells to proliferate on rat embryonic day 14 are the Cajal-Retzius 
neurons; these cells become cortical layer I.  Thereafter neurons are generated in an 
inside to out pattern; layers IV-II are born primarily on embryonic days 17-19 (for review 
see Bayer et al., 1993).  Of importance is the contribution of glutamate and GABA 
signaling prior to synapse formation.  Functional ionotropic glutamate receptors are 
expressed during terminal cell division and differentiation in neuroepithelial cells (Maric 
et al., 2000).  Post-mitotic neurons undergo radial migration along radial glial to reach 
their final destination (Parnavelas, 2000; Sidman and Rakic, 1973) usually within 1-2 
days following birth (Bayer et al., 1993).  Interneurons originate in the medial and caudal 
ganglionic eminence in the ventral forebrain and must migrate tangentially to reach the 
cortex; cells undergo radial migration once reaching the cortex (for review see Marin and 
Rubenstein, 2003; Metin et al., 2006; Huang, 2009).  Among many signaling pathways 
required for normal migration, interneurons rely on AMPA mediated receptor signaling 
for migration (Manent et al., 2006).   
 In contrast to interneurons, pyramidal cells require NMDA and GABAA receptor 
signaling to promote radial migration.  In support, immature neurons express NMDA and 
GABA receptors and glutamate and GABA are detected early in the microenvironment of 
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migrating neurons (Nguyen et al., 2001; Lujan et al., 2005; Manent and Represa, 2007).  
Further, non-vesicular glutamate and GABA activate migratory neuronal receptors since 
synapses have yet to develop at this time (Behar et al., 1998; Behar et al., 1999; Behar et 
al., 2000; Behar et al., 2001; Hirai et al., 1999; Simonian and Herbison, 2001; Kihara et 
al., 2002).  In support, animals with a genetic deletion of munc18-1 and munc13-1/2, 
proteins necessary for vesicle priming, are incapable of vesicular neurotransmitter release 
yet have normal cortical layering and synapse formation (Verhage et al., 2000; 
Varoqueaux et al., 2002).   Finally, work in cerebellar granule cells suggests that GABAA 
receptor activity depolarizes immature neurons allowing NMDA receptor activation 
allowing for Ca2+ influx which is necessary for cell migration (Ben-Ari et al., 1997; 
Komuro and Rakic, 1993; Kumada and Komuro, 2004).  While the non-vesicular source 
of glutamate has yet to be established, it is possible that system xc- could contribute to 
this pool and have a critical role in neurodevelopment. 
Synaptogenesis: Synaptogenesis is another regulated process requiring numerous 
signaling cascades to develop first an immature then mature synapse.  Non-vesicular 
glutamate release, specifically from genderblind encoded from ‘genderblind’ gene which 
encodes the xCT subunit in Drosophila, has been shown to modulate postsynaptic 
glutamate receptor clustering at the neuromuscular junction.  Specifically, loss of cystine-
glutamate exchange in genderblind knockouts have a 50% decrease in extracellular 
glutamate resulting in a large increase in postsynaptic glutamate receptors due to reduced 
constitutive desensitization (Featherstone et al., 2002; Augustin et al., 2007).  Further, 
these mutants have behavior deficits including abnormal adult copulation (Grosjean et al., 
2008).  Given the role of cystine-glutamate exchange in Drosophila and the possible 
27 
 
contribution to neurodevelopment in rodents, abnormal cystine-glutamate exchange has 
the capacity of producing profound neurodevelopmental abnormalities that could lead to 
abnormal behavior. 
       
ANIMAL MODELS OF SCHIZOPHRENIA 
 
Phencyclidine: While there is evidence for both an environmental and genetic component 
for the etiology of schizophrenia, the contributions from each on the manifestation of the 
disorder remain largely unknown.  Therefore, a main hurdle in studying the 
pathophysiology and therapeutic potential for schizophrenia research is developing an 
animal model.  Non-competitive NMDA receptor antagonists, such as ketamine 
phencyclidine and MK801, have been shown to produce a schizophrenic-like state with 
positive, negative and cognitive deficits in healthy humans and rodents and exacerbate 
symptoms in schizophrenic patients (Luby et al., 1959; Pearlson, 1981; Javitt and Zukin, 
1991; Krystal et al., 1994; Verma and Moghaddam, 1996; Malhotra et al., 1997b; Adler 
et al., 1999; Newcomer et al., 1999; Coyle, 2004).  Phencyclidine acts as a non-
competitive NMDA receptor antagonist with evidence suggesting it targets PV positive 
GABAergic interneuron NMDA receptors (Jones and Buhl, 1993; Lei and McBain, 2002; 
Maccaferri and Dingledine, 2002; Homayoun and Moghaddam, 2007; Lewis et al., 2012).  
Interestingly, repeated administration of PCP has been shown to decrease GABAergic 
markers, specifically parvalbumin and the GABA synthesizing agent GAD67 (Amitai et 
al., 2011).  NMDA receptor antagonists have been shown to increase extracellular 
glutamate likely due to disinhibition of GABA interneurons in the mPFC which 
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interestingly, is blocked by an mGluR2/3 agonist (Moghaddam et al., 1997; Homayoun et 
al., 2005; Katayama et al., 2007; Baker et al., 2008; Amitai et al., 2011).   
Methylazoxymethanol acetate (MAM): MAM is a DNA methylating agent which targets 
cells undergoing active mitosis producing an antimitotic effect (Nagata and Matsumoto, 
1969; Cattabeni and Di Luca, 1997; Hoareau et al., 2006).  However, there is also 
evidence that MAM effects proteins necessary for cell growth (Singh, 1980; Dambska et 
al., 1982) and impairs neuronal organization (Matricon et al., 2010).  Based on a narrow 
time window for effect (12-24 hours) (Matsumoto et al., 1972), timing of administration 
is critical.  Administration on gestational day 15 leads to whole brain size reductions 
presumably due to antimitotic effects of MAM (Dambska et al., 1982; Jongen-Relo et al., 
2004) whereas gestation day 17 treatment selectively targets regions implicated in 
schizophrenia including the prefrontal cortex, hippocampus and thalamus since 
neurogenesis for these structures is occurring at this time point (Flagstad et al., 2004; 
Moore et al., 2006; Le Pen et al., 2006; Bayer et al., 1993).  Further, gestational day 17 
treatment parallels schizophrenia symptoms including deficits in sensorimotor gating, 
social interaction, hypersensitivity to amphetamines and NMDA receptor antagonists and 
cognitive impairments including executive functions (Flagstad et al., 2004; Flagstad et 
al., 2005; Moore et al., 2006; Le Pen et al., 2006; Featherstone et al., 2007; Featherstone 
et al., 2009; Gill et al., 2011).  These deficits are thought to arise, in part, by abnormal 
prefrontal cortex and hippocampal activity (Lavin et al., 2005; Goto and Grace, 2006; 
Lena et al., 2007; Lodge and Grace, 2007; Lodge et al., 2009; Chin et al., 2011) including 
reduced PV expression (Penschuck et al., 2006; Lodge et al., 2009) and abnormal 
oscillatory activity (Lavin et al., 2005; Goto and Grace, 2006; Phillips et al., 2012).  
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Taken together, MAM models the neurodevelopmental hypothesis of schizophrenia and 
has many morphological, molecular and behavioral aspects that parallel those seen in 
schizophrenia making it a useful model to study.  
Sulfasalazine:  Abnormal system xc- activity is implicated in schizophrenia.  First, 
externalized glutamate is capable of activating extrasynaptic mGluR2/3 receptors which 
modulates neurotransmission (Baker et al., 2002b; Mohan et al., 2011); schizophrenics 
have abnormal glutamatergic activity (for review see Goff and Coyle, 2001; Carlsson, 
2006; Coyle, 2006; Lewis, 2009).  Second, internalized cystine is necessary for 
glutathione synthesis (Bannai and Tateishi, 1986; Meister, 1995; Dringen and Hirrlinger, 
2003); schizophrenics have up to a 50% reduction in dorsolateral prefrontal cortical 
glutathione concentrations (Do et al., 2000; Yao et al., 2006; Gawryluk et al., 2010; Raffa 
et al., 2011).  Further, nonvesicular release of glutamate of unknown origins is necessary 
for normal neurodevelopment (Behar et al., 1999; Hirai et al., 1999; Simonian and 
Herbison, 2001; Kihara et al., 2002).  Therefore, it is necessary to evaluate the 
contribution system xc- activity to schizophrenic-like symptoms by directly modulating 
the cystine-glutamate antiporter.  The xCT genetic knockout mouse evaluated a few 
behavioral measures and found some cognitive deficits however these animals likely 
have compensatory mechanisms for absent cystine-glutamate exchange (De Bundel et al., 
2011).  Instead, a knockdown of xCT or acute inhibition of system xc- is needed to 
evaluate the contribution of altered cystine-glutamate exchange.   
Sulfasalazine is marketed as an anti-inflammatory prodrug which is metabolized 
in the large intestines into sulfapyridine and 5-aminosalicylic acid; the anti-inflammatory 
effect is mediated by 5-aminosalicylic acid (Peppercorn, 1984).  Importantly, 
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sulfasalazine and not the metabolites are capable of potently inhibiting system xc- (Gout 
et al., 2001; Chung and Sontheimer, 2009).  Evidence suggests that sulfasalazine crosses 
the blood brain barrier since intraperitoneal administration limits primary brain tumor 
growth in vivo (Gout et al., 2001; Chung et al., 2005; Lyons et al., 2007).  Further, it has 
been shown to penetrate the placental barrier (Peppercorn, 1984).  Based on the ability of 
sulfasalazine to potently and acutely inhibit cystine-glutamate exchange it is an ideal drug 
to test the contribution of system xc- in behavioral measures of schizophrenia-like 
symptoms. 
Since the etiology of schizophrenia remains unknown and there are many 
inconsistencies across populations there is no perfect schizophrenia model.  Therefore, 
using a range of approaches with similarities in molecular and behavioral symptoms of 
schizophrenia is necessary to examine the contribution of system xc- to schizophrenia. 
 
THERAPEUTIC IMPLICATIONS FOR SYSTEM XC-  
 
 Antipsychotic medications have been around since the 1950’s and all possess 
some D2 receptor antagonism effects (Hill et al., 2010).  All have shown to be effective at 
reducing positive symptoms however most, with the exception of clozapine, show small 
if any improvements in negative or cognitive deficits (for review see Hill et al., 2010).  
Additionally all have serious side effects with low compliance rates (Lieberman et al., 
2005).  Unfortunately, this results in many unmediated schizophrenics or schizophrenics 
with only modest improvements in symptom severity.  Current research seeks to find 
more efficacious and more tolerable treatments for schizophrenia. 
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N-acetylcysteine: N-acetylcysteine has shown efficacy in clinical trials of a number of 
disorders including gambling (Grant et al., 2007), nicotine addiction (Knackstedt et al., 
2009), cocaine addiction (LaRowe et al., 2006; LaRowe et al., 2007; Mardikian et al., 
2007), bipolar disorder (Berk et al., 2008b) and schizophrenia (Berk et al., 2008c; Lavoie 
et al., 2008; Carmeli et al., 2012).  First, preclinical studies have shown that N-
acetylcysteine stimulates system xc- (Baker et al., 2008; Kau et al., 2008).  Clinical 
schizophrenia studies have shown improvements on Positive and Negative Symptoms 
Scale (PANSS) total, PANSS negative, PANSS general and Clinical Global Impression- 
Severity (CGI-S) scales with N-acetylcysteine (Berk et al., 2008c).  Further, mismatch 
negativity, a measure of auditory sensory processing dependent on NMDA receptor 
activity was improved in schizophrenics receiving N-acetylcysteine compared to placebo 
(Lavoie et al., 2008).  Lastly, N-acetylcysteine treatment increases synchronization 
measured by EEG over the left parieto-temporal, the right temporal, and bilateral 
prefrontal regions (Carmeli et al., 2012).  The authors of these studies propose that M-
acetylcysteine increases glutathione to improve symptom severity in schizophrenics.  
While N-acetylcysteine does increase blood glutathione levels in schizophrenics (Lavoie 
et al., 2008), it is likely through stimulation of system xc- to increase astrocytic cysteine 
for glutathione synthesis.  This would also lead to increased extracellular glutamate, 
enhanced mGluR2/3 tone and modulation of synaptic activity.  In support, N-
acetylcysteine normalizes neurochemical deficits in genetic mouse models with chronic 
glutathione deficiency knockout mouse in the absence of glutathione concentration 
restoration (Duarte et al., 2011).  These studies suggest N-acetylcysteine treatment 
improves the severity of negative and cognitive deficits in schizophrenia, symptoms 
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poorly treated with current antipsychotics.  Further, there is support that N-acetylcysteine 
stimulates system xc- for improvements although further preclinical and clinical research 
is necessary. 
Group II Metabotropic Glutamate Receptor Agonists:  Many preclinical studies have 
shown significant improvements in NMDA receptor antagonist schizophrenia models 
including elevated glutamate and behavioral deficits associated with schizophrenia 
(Moghaddam and Adams, 1998; Cartmell et al., 1999; Homayoun et al., 2005; Patil et al., 
2007; Baker et al., 2008; Hackler et al., 2010).  This is interesting since it implicates 
insufficient extrasynaptic glutamate concentrations reducing tone on mGluR2/3 receptors 
which could be a result from altered cystine-glutamate exchange.  Clinical studies have 
also shown improvements in PANSS total, PANSS positive and negative and CGI-S 
scales with the mGluR2/3 agonist LY2140023 without side effects typically seen with 
antipsychotics (Patil et al., 2007; Mosolov et al., 2010).  However, a different study did 
not find any therapeutic potential with the mGluR2/3 agonist LY2140023 in PANSS total 
score but they also did not see any benefit from the atypical antipsychotic olanzapine 
which should have an effect resulting in inconclusive findings (Kinon et al., 2011).  In 
conclusion, while the beneficial effects of mGluR2/3 agonists in clinical trials are 
inconclusive, the results in preclinical and clinical studies suggest that stimulation of the 
mGluR2/3 receptor may lead to improvements in schizophrenic symptoms as would 
increased extrasynaptic glutamate potentially through system xc-. 
 
The primary goal of this body of work is to characterize the contribution of 
cystine-glutamate exchange to symptoms of schizophrenia.  To determine the 
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importance of system xc- dysregulation, the impact of increased or decreased system 
xc
-
 activity to glutamate levels in the prefrontal cortex and behaviors produced by 
the prefrontal cortex that are used to model schizophrenia was examined.  First, 
system xc- activity was assessed in the acute phencyclidine and the 
neurodevelopmental MAM model of schizophrenia and the ability of increased 
cystine-glutamate exchange to reverse behavioral deficits was investigated.  Further, 
the contribution of decreased system xc- activity by sulfasalazine administration and 
behavioral measures of schizophrenia was assessed.  Collectively, these data position 
system xc- as a key regulator of behavioral output from the prefrontal cortex and 
indicate that system xc- dysregulation in schizophrenia may be an important 
component of the pathology of the disease.        
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II. TARGETING SYSTEM XC- IN THE PREFRONTAL CORTEX TO 
REVERSE SENSORIMOTOR GATING DEFICITS PRODUCED BY 
ACUTE PHENCYCLIDINE  
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Introduction 
 
Aspects of schizophrenia, including negative symptoms and cognitive deficits, are 
thought to arise as a result of abnormal signaling in cortical structures such as the 
dorsolateral prefrontal cortex and the hippocampus (Weinberger, 1987; Javitt, 1987; 
Bunney and Bunney, 2000; Chavez-Noriega et al., 2002).  Attempts to understand the 
cellular basis of schizophrenia will be aided by advances in our understanding of the 
mechanisms that regulate cortical activity.  Cystine-glutamate exchange by system xc- 
may be a key component of altered excitatory signaling in the prefrontal cortex observed 
in schizophrenia (Baker et al., 2008; Krystal, 2008; Bridges, 2012).  
System xc- appears to play an important role in normal and pathological brain 
functioning.  First, system xc- exchanges one extracellular molecule of cystine for one 
intracellular molecule of glutamate resulting in an extracellular concentration that is 
sufficient to activate glutamate receptors (Baker et al., 2002b; Moran et al., 2005).  
Extrasynaptic glutamate provides tone on group II metabotropic glutamate receptors 
thereby inhibiting synaptic neurotransmitter release (Battaglia et al., 1997; Moran et al., 
2005). Inside the cell, cystine is reduced into cysteine, which is the rate-limiting 
precursor in the synthesis of the antioxidant glutathione (Bannai, 1984; Sies, 1999).  In 
astrocytes, cystine uptake is predominantly achieved by cystine-glutamate exchange, 
making system xc- a key mechanism in regulating oxidative stress (Cho and Bannai, 
1990).  Thus, changes in system xc- activity could contribute to diseased states involving 
either abnormal glutamate signaling or oxidative stress.  Extant data suggest that the 
activity of system xc- may be altered in the dorsolateral prefrontal cortex of individuals 
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with schizophrenia (Baker et al., 2008).  Specifically, schizophrenia is associated with a 
significant reduction in glutathione levels (Do et al., 2000; Yao et al., 2006; Gawryluk et 
al., 2010; Raffa et al., 2011) coupled with a modest but significant change in the protein 
levels of xCT, which is the active subunit of system xc-, in the dorsolateral prefrontal 
cortex (Baker et al., 2008).  These changes may contribute to the disease since the 
decrease in glutathione has been shown to contribute to negative symptoms of 
schizophrenia (Steullet et al., 2006; Matsuzawa et al., 2008). 
The NMDA receptor antagonist phencyclidine is used as a model of 
schizophrenia based on its ability to create a broad range of schizophrenic-like symptoms 
in humans and rats and exacerbation of symptoms in schizophrenics (Luby et al., 1959; 
Pearlson, 1981; Javitt and Zukin, 1991; Krystal et al., 1994; Malhotra et al., 1997b).  In 
rodents, phencyclidine produces a hyperlocomotive state recapitulating positive 
symptoms of schizophrenia (Sturgeon et al., 1979; Enomoto et al., 2007; Young et al., 
2010), negative symptoms including social interaction deficits (Sams-Dodd, 1999) and 
cognitive deficits including novel object recognition, reversal learning and attentional set 
shift (for review see Coyle et al., 2003; Javitt, 2007; Neill et al., 2010).  Additionally, 
NMDA receptor antagonists have been shown to increase prefrontal glutamate levels 
generating an increase in cortical neuron firing rate which is essential for the 
psychotomimetic effects of phencyclidine (Moghaddam and Adams, 1998; Lorrain et al., 
2003; Homayoun et al., 2005).  Furthermore, group II metabotropic glutamate receptor 
activation has been shown to reverse NMDA receptor antagonist induced disruptions in 
activity (Moghaddam and Adams, 1998; Homayoun et al., 2005). 
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N-acetylcysteine is a cysteine prodrug capable of driving cystine-glutamate 
exchange and preclinical and clinical studies indicate that administration has therapeutic 
potential for the treatment of schizophrenia (Berk et al., 2008d; Lavoie et al., 2008; Bulut 
et al., 2009; Baker et al., 2008).  The therapeutic efficacy of N-acetylcysteine in 
sensorimotor gating has yet to be established.  Sensorimotor gating, a measure of 
executive functioning, reflects the ability of the central nervous system to inhibit 
irrelevant sensory information and allow focus on salient information from the 
environment (Braff et al., 1978).  Schizophrenic patients and rodents treated with the 
non-competitive NMDA receptor antagonist phencyclidine have been shown to produce 
deficits in prepulse inhibition (Mansbach and Geyer, 1989; Geyer et al., 1990; Swerdlow 
et al., 1994; Braff et al., 2001a; Geyer et al., 2001; Swerdlow et al., 2006; Kumari et al., 
2007).  Further, executive functioning deficits are core features of schizophrenia (Szoke 
et al., 2008; Eisenberg and Berman, 2010) and remains poorly treated with antipsychotics 
(for review see Hill et al., 2010).   
 
The primary goal of this chapter was to assess the ability of system xc- 
stimulation by N-acetylcysteine in the prefrontal cortex to attenuate phencyclidine-
induced deficits in sensorimotor gating.    
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Materials and Methods 
 
Animals and Surgeries: Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 
300-400 grams were individually housed in a temperature controlled room with a 12-h 
light/dark cycle with food and water ad libitum.  The housing conditions and care of the 
rats were in accordance with the Animal Welfare Act, and all procedures were approved 
by the Marquette University IACUC Committee.  Rats used in the microdialysis studies 
were anesthetized using pentobarbital (50 mg/kg, IP) with atropine sulfate (1 mg/kg, IP) 
pretreatment to limit tracheobronchial secretions.  Bilateral guide cannula (20 gauge, 14 
mm; Plastics One, Roanoke, VA) were implanted using coordinates +3.1 mm anterior, 
±1.0 mm mediolateral to Bregma, and -0.75 mm ventral from the surface of the skull at a 
6° angle from vertical derived from Paxinos and Watson (Paxinos and Watson, 1986).  
The placement of the active region of the microdialysis probe, which began two mm 
beyond the ventral tip of the guide cannulae, was primarily in the prelimbic cortex, the rat 
equivalent of the human dorsolateral prefrontal cortex (Uylings et al., 2003), although 
regions immediately ventral to this were also likely sampled.  Following surgery, rats 
were provided acetaminophen (480 mg/L) in their drinking water for 2 days and were 
given at least six days to recover prior to testing. 
Drug Treatments: Phencyclidine (0-3 mg/kg; NIDA Drug Supply Program, Research 
Triangle, NC) was dissolved in isotonic saline.  N-acetylcysteine (Sigma Chemical Co., 
St Louis, MO) was dissolved in saline or microdialysis buffer and brought to a pH of 7.0 
using NaOH.  (S)-4-carboxyphenylglycine (CPG, 0.5µM; Tocris-Cooksin, Ellisville, 
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MO) was dissolved in dialysis buffer.  All treatments were administered according to the 
experimental design.  
Prepulse Inhibition:  Rats were placed on a platform in a sound attenuating chamber 
(10.875”x14”x19.5”; Hamilton Kinder, CA) that rested on a motion sensing plate.  A 
matching session was conducted to determine the magnitude of the startle response for 
each rat.  This session consisted of a five minute habituation period followed by 20 trials; 
17 trials involved the presentation of a single auditory stimulus (pulse stimulus; 50 dB 
above the 60 dB background noise) and three trials in which a prepulse stimulus (12 dB 
above background) was presented 100 ms before the pulse stimulus.  Rats were then 
assigned into the various treatment groups based on the magnitude of their startle 
response.  At least one day later, an experimental session was conducted to assess 
sensorimotor gating.  On this day, rats received a 5-10 min habituation period followed 
by 58 discrete trials; eight background trials with only background noise, 26 trials with 
only the pulse stimulus (50 dB above background), and 24 trials with the pulse stimulus 
being preceded by one of three prepulse stimuli (2, 6, or 15 dB above background).  The 
percent of prepulse inhibition was determined as 100-(average prepulse startle 
response/average startle stimulus alone)*100. 
In Vivo Microdialysis:  Microdialysis probes, constructed as previously described 
(Baker et al., 2003), were inserted into indwelling guide cannula.  Dialysis buffer (5 mM 
glucose, 140 mM NaCl, 1.4 mM CaCl2, 1.2 mM MgCl2, 2.2 mM KCl, and 0.15% 
phosphate buffer saline, pH 7.4) was pumped through the probes at a rate of 1 µl/min for 
at least three hours prior to sampling in order for neurotransmitter levels to stabilize.  
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Afterwards, twenty minute samples were collected as described below for each 
experiment.   
In situ hybridization:  Brains were rapidly removed and frozen in OCT (Sakura, 
Torrance, CA) in a dry ice and ethanol bath and then cut into 12 um coronal sections. 
 Standard in vitro transcription methods were used to generate riboprobes against xCT 
(Choi, Milwaukee, WI) which was subsequently diluted in hybridization cocktail 
(Amresco, Solon, OH) and tRNA. Sections were hybridized overnight at 55 ºC in a 
mixture of tRNA, formamide, dextran, NaCl, EDTA, Denhardt’s solution and 33P-labeled 
riboprobe.  After hybridization, slides were rinsed in 2x SSC buffer (pH 7.0). They were 
treated with RNase A in a 0.5 M sodium chloride, 10 mM Tris, 1 mM EDTA buffer for 
30 min at 37 ºC and then washed in the same buffer without RNase A for 30 min at 37 
ºC. Slides were stringently washed in 0.5x SSC for 30 min at 6 ºC and then exposed to 
autoradiographic film (3 days) and then subsequently coated with Kodak 
autoradiographic emulsion NTB (Rochester, NY) and exposed for 9 days to produce 
silver grains. Following standard autoradiography development, NTB emulsion-dipped 
sections were counterstained with 0.5% cresyl violet.  Photodocumentation of silver 
grains was achieved using dark field microscopy (Axioskop-2, Zeiss, Thornwood, NY) 
and Axiovision image analysis software (Zeiss, Thornwood, NY). 
Histology:  Rats included in the microdialysis studies were given an overdose of 
pentobarbital (60 mg/kg, IP), and the brains were fixed by intracardiac infusion of 0.9% 
saline followed by 2.5% formalin solution.  Brains were removed and stored in 2.5% 
formalin for at least seven days prior to sectioning.  The tissue was then blocked and 
coronal sections (100 µM) were cut and stained with cresyl violet to verify probe 
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placements.  Rats determined to have misplaced guide cannula were excluded from all 
analyses.  
Statistics:  Data was analyzed using analysis of variance (ANOVA) with drug treatment 
(e.g., phencyclidine, CPG, N-acetylcysteine) as between-subjects factors and prepulse 
intensity as a repeated measure.  Significant interactions and main effects were further 
analyzed using Tukey HSD. 
 
Experimental Design 
 
Experiment 1: The purpose of this experiment was to select a dose of phencyclidine for 
subsequent experiments.  Rats received an acute injection of phencyclidine (0-3 mg/kg, 
SC) 10 minutes before being placed in the startle chamber and testing was conducted as 
described above and shown in Figure 2.1.   
Experiment 2:  The purpose of this experiment was to assess the capacity of N-
acetylcysteine to reverse phencyclidine-induced deficits in prepulse inhibition when 
given orally, and thus subject to metabolism in the GI tract and liver.  N-acetylcysteine 
(0-600 mg/kg, PO) was given 50 minutes prior to phencyclidine (0 or 1.25 mg/kg, SC).  
Rats were placed in the startle chamber 10 minutes after the phencyclidine injection and 
testing was conducted as described above and shown in Figure 2.2.  Rats were given 1.25 
mg/kg phencyclidine since this dose produced robust and reproducible deficiencies in 
prepulse inhibition.    
Experiment 3: This experiment was designed to identify the expression pattern of xCT 
using in situ hybridization in the medial prefrontal cortex and shown in Figure 2.3a and b.   
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Experiment 4: The purpose of this experiment was to determine the maximal effect that 
N-acetylcysteine would exert on phencyclidine-induced deficits in prepulse inhibition 
absent systemic metabolism or poor blood brain barrier permeability.  To do this, we 
reverse dialyzed N-acetylcysteine (0-100 µM) directly into the prefrontal cortex for one 
hour prior to phencyclidine (0 or 1.5 mg/kg, SC) administration. One hour later, the 
probes were removed and rats underwent prepulse inhibition testing as described above 
and shown in Figure 2.3c.  Phencycldine was administered at 1.5 mg/kg dose since 
similar to 1.25 mg/kg, 1.5 mg/kg also produced robust and reproducible deficiencies in 
prepulse inhibition but the higher dose was administered since animals underwent 
behavioral testing for a longer period after phencyclidine administration. 
Experiment 5: This experiment was designed to verify that N-acetylcysteine reverses 
phencyclidine-induced deficits in prepulse inhibition by increasing cystine-glutamate 
exchange by system xc- in the prefrontal cortex.  To do this, the system xc- inhibitor (S)-
4-carboxyphenylglycine (CPG; 0-0.5 µM), was infused into the prefrontal cortex.  
Twenty min later, N-acetylcysteine (0-30 µM) was added to the dialysis buffer such that 
CPG and NAC were co-infused for one hour prior to phencyclidine administration (0-1.5 
mg/kg, SC).  One hour later, the probes were removed and rats underwent prepulse 
inhibition testing as described above and shown in Figure 2.4a and b. 
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Results 
 
Acute phencyclidine creates a range of schizophrenic-like symptoms (Javitt, 
2007) including deficits in executive function (Swerdlow et al., 1994; Geyer et al., 2001).  
Figure 2.1 depicts the impact of phencyclidine across a range of doses on sensorimotor 
gating.  An ANOVA used to compare different phencyclidine doses in prepulse inhibition 
with drug treatment as a between subjects factor and prepulse intensity as a repeated 
measure yielded a significant interaction (F(12,102) = 5.77 p < 0.001). Analysis of the 
simple main effects revealed a significant main effect of drug treatment at prepulse 
intensities of six (F(6,57) = 9.20 p < 0.001) and 15 dB (F(6,57) = 14.79 p < 0.001), but not at 
two dB (F(6,57) = 0.40 p > 0.05).  Post hoc analyses indicated that phencyclidine produced 
dose-dependent deficits in prepulse 
inhibition (Tukey HSD, p < 0.05).   
The ability of pretreatment 
with N-acetylcysteine on 
phencyclidine-induced prepulse 
inhibition deficit was assessed.  Figure 
2.2 illustrates the impact of acute N-
acetylcysteine pretreatment on 
phencyclidine-induced deficits in 
prepulse inhibition with oral 
administered (Figure 2.2). An 
ANOVA comparing a range of N-
Figure 2.1 Phencyclidine produces a dose-dependent 
disruption of prepulse inhibition.  The data is expressed 
as the mean (+ SEM) percent inhibition Behavior 
depicted was obtained from rats receiving an acute 
injection of phencyclidine (0-3 mg/kg; SC; N = 6-
40/group) ten minutes prior to testing.  * indicates a 
difference from controls receiving 0 mg/kg 
phencyclidine (Tukey HSD, p < 0.05). 
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acetylcysteine doses on phencyclidine-
induced deficits included drug treatment as a between subjects factor and prepulse 
intensity as a repeated measure resulted in a significant interaction (F(14,136) = 2.96 p < 
0.001).  Analysis of the simple main effects revealed a significant main effect at prepulse 
intensities of 6 (F(7,75) = 5.64 p < 0.001) and 15 dB F(7,75) = 5.87 p < 0.001) but not at 2 dB 
(F(7,75) = 1.89 p > 0.05).  Post hoc analyses indicated that phencyclidine produced deficits 
in prepulse inhibition that were not altered by oral administration of N-acetylcysteine 
even at doses up to 600 mg/kg (Tukey HSD, p < 0.05).  This could indicate that 1) N-
acetylcysteine is ineffective at reducing phencyclidine-induced deficits in prepulse 
inhibition or 2) that it is not penetrating the blood brain barrier it produce a therapeutic 
effect.   
To test these possibilities, N-acetylcysteine was infused directly into an area rich 
in system xc-.  In situ hybridization revealed a particularly prominent dorsal-ventral linear 
band located primarily in the prelimbic cortex to be richly innervated with xCT, the 
active subunit of the cystine-glutamate antiporter (Figure 2.3a left panel).  Further, the 
Figure 2.2 The effect of oral N-
acetylcysteine pretreatment on 
phencyclidine-induced disruption of 
prepulse inhibition.   The data is expressed 
as the mean (+ SEM) prepulse inhibition 
displayed by rats receiving oral (0-600 
mg/kg, N = 6-19/group) 50 minutes prior to 
phencyclidine (0 or 1.25 mg/kg, SC) * 
indicates a significant difference from 
control rats receiving only saline (NAC 0 / 
PCP 0; Tukey HSD, p < 0.05).   
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medial prefrontal cortex has been identified as a main integration center for sensorimotor 
gating (Swerdlow et al., 2001).  N-acetylcysteine was therefore administered via reverse 
microdialysis into the medial prefrontal cortex as shown in Figure 2.3a right panel.  
Figure 2.3b shows dark field photomicrograph of xCT mRNA and the representative tract 
created by the insertion of a microdialysis probe in the vicinity of the xCT mRNA linear 
band within the medial prefrontal cortex.   
Figure 2.4 depicts the impact of N-acetylcysteine infused via reverse dialysis 
directly into the prefrontal cortex on phencyclidine-induced deficits in sensorimotor 
gating.  The effect of infused N-acetylcysteine on phencyclidine deficits was measured 
using an ANOVA with drug treatment as a between subjects factor and prepulse intensity 
as a repeated measure yielded a significant interaction (F(8,54) = 2.26 p < 0.05).  Analysis 
of the simple main effects revealed a significant main effect at every prepulse intensity (2 
dB: F(4,31) = 4.12 p = 0. 010; 6 dB: F(4,31) = 10.70 p < 0.001; 15 dB F(4,31) = 7.15 p < 
Figure 2.3 (A) Representative coronal section displaying expression of xCT mRNA via in situ 
hybridization (left, dark field photomicrograph) and subregion targeted in direct infusion studies (right).  
Note, the ventral two mm of the tract, which is primarily contained in the prelimbic cortex, represents the 
site of drug perfusion since this is the portion of the probe containing the active membrane.  (B) 
Expression of xCT mRNA and tract placement using a 5X objective.  The rectangle denotes the portion of 
the tract created by the microdialysis probe that is illustrated in the dark field photomicrograph.  The bar 
represents 1mm. 
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0.001).  Post hoc analyses indicated that 
phencyclidine produced deficits in 
prepulse inhibition at every prepulse 
intensity that were attenuated by N-
acetylcysteine (Figure 2.3c, Tukey HSD, p 
< 0.05). Note, the active region of the 
microdialysis probe was primarily in the 
prelimbic cortex although regions 
immediately ventral to this were also 
likely sampled (Figure 2.3a).  These 
results suggest the ability of N-
acetylcysteine to reverse phencyclidine-
induced deficits in sensorimotor gating in 
the prefrontal cortex.  However, at this point the target of N-acetylcysteine remains 
unclear. 
To determine whether N-acetylcysteine targets system xc- to reverse 
phencyclidine-induced prepulse inhibition deficits it was co-administered with an 
inhibitor of the cystine-glutamate antiporter. Figure 2.5 illustrates the impact of intra-
prefrontal N-acetylcysteine on phencyclidine-induced deficits in prepulse inhibition when 
tested in the absence or presence of the system xc- inhibitor (S)-4-carboxyphenylglycine 
(CPG; 0 or 0.5 µM).  An ANOVA compared CPG and N-acetylcysteine treatment and 
included drug treatments as between subjects variable and prepulse intensity as within 
subjects variable to produce a significant interaction between (F(2,60) = 3.146 p < 0.05).  
Figure 2.4 N-acetylcysteine into the prefrontal 
cortex via reverse dialysis reverses 
phencyclidine-induced deficits in prepulse 
inhibition deficits.   Data is expressed as the 
mean (+ SEM) prepulse inhibition of rats 
receiving direct infusion of N-acetylcysteine into 
the prefrontal cortex (0-100 µM, N = 6-8/group) 
followed 1 hour later by an acute injection of 
phencyclidine (0 or 1.5 mg/kg, SC). * indicates a 
significant difference from control rats receiving 
saline (NAC 0 / PCP 0).  + indicates a significant 
difference from rats receiving phencyclidine 
(NAC 0 / PCP 1.25) using Tukey HSD, p < 0.05. 
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To further deconstruct the interaction, we compared the effect of N-acetylcysteine and 
phencyclidine treatment with or without CPG.   In the absence of CPG (Figure 2.5a), an 
ANOVA with drug treatment as a between subjects and prepulse intensity as a repeated 
measures yielded a significant interaction between phencyclidine with and without 
infused N-acetylcysteine treatment (F(4,60) = 3.07 p < 0.05).  Analysis of the simple main 
effects revealed a significant main effect at every prepulse intensities (2 dB: F(2,32) = 
12.48 p < 0.001); 6 dB  F(2,32) = 14.52 p < 0.001; 15 dB F(2,32) = 12.30 p < 0.001).  Post 
hoc analyses indicated that N-acetylcysteine reversed phencyclidine-induced deficits in 
prepulse inhibition when tested in the absence of CPG (Tukey HSD, p <.05).  In the 
presence of CPG (Figure 2.5a), an ANOVA compared the effect of CPG with and 
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Figure 2.5 N-acetylcysteine targets system xc- to reverse deficits in prepulse inhibition produced by 
phencyclidine.  The data is expressed as mean (+ SEM) prepulse inhibition displayed by rats receiving 
intra-prefrontal N-acetylcysteine (1-30 µM, N = 6-16/group) (a) in the absence or (b) or presence of the 
system xc- inhibitor (S)-4-carboxyphenylglycine (CPG, 0.5µM) co-infused into the prefrontal cortex.  
Note, CPG was infused alone for 20 min, N-acetylcysteine was then added to the microdialysis buffer for 
60 min prior to the injection of phencyclidine (1.5 mg/kg, SC).  * indicates a significant difference from 
respective saline controls (NAC 0 /PCP 0/ + CPG; Tukey HSD, p < 0.05).  + indicates a significant 
difference from respective phencyclidine controls (NAC 0 / PCP 1.5/ + CPG; Tukey HSD, p < 0.05).   
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without phencyclidine and N-acetylcysteine administration with treatment as between 
subjects and prepulse intensity as repeated measures has a significant main effect of 
treatment (F(2,30)= 13.64 p < 0.001) without a significant interaction (F(4,60) = 0.80 p > 
0.05).   Post hoc analyses indicated that N-acetylcysteine failed to alter phencyclidine-
induced deficits in prepulse inhibition when tested in the presence of CPG (Tukey HSD, 
p <.05).  Therefore, these data suggest that N-acetylcysteine targets system xc- in the 
prefrontal cortex to reverse phencyclidine-induced deficits in prepulse inhibition.   
Table 2.1 is the startle magnitude in all prepulse inhibition testing.  As shown, 
when comparing the acute effect of phencyclidine on prepulse inhibition in experiment 1  
 
Table 2.1 
Startle Magnitude 
Drug Treatment 
 
 
a
 PCP = phencyclidine, NAC = N-acetylcysteine, CPG = (S)-4-carboxyphenylglycine 
* P < 0.05, compared to PCP 0 group and are indicated in bold. 
Exp 
1 
PCP 0 PCP 0.3  PCP 1.0  PCP 1.25  PCP 1.5  PCP 2.0  PCP 3.0   
1.82±0.19 1.58±0.47 2.19±0.35 3.37±0.53* 3.18±0.31 3.61±1.77* 1.06±0.32  
Exp 
2 
NAC 0 / 
PCP 0 
NAC 0 / 
PCP 1.25 
NAC 1 / 
PCP 1.25 
NAC 10 /  
PCP 1.5 
NAC 30 / 
PCP 1.25 
NAC 100 / 
PCP 1.25 
NAC 300 / 
PCP 1.25 
NAC 600 / 
PCP 1.25 
1.77±0.26 2.37±0.29 1.83±0.36 1.88±0.34 2.64±0.18 2.60±0.45 2.66±0.42 3.02±0.70 
Exp 
4 
NAC 0 / 
PCP 0 
NAC 0 / 
PCP 1.5 
NAC 10 / 
PCP 1.5 
NAC 30 / 
PCP 1.5 
NAC 100 
/ PCP 1.5 
   
1.63±0.28 1.63±0.34 1.99±0.33 1.92±0.59 1.75±0.26    
Exp 
5 
CPG 0 / 
NAC 0 / 
PCP 0 
CPG 0 / 
NAC 0 / 
PCP 1.5 
CPG 0 / 
NAC 30 / 
PCP 1.5 
CPG 0.5 / 
NAC 0 / 
PCP 0 
CPG 0.5 / 
NAC 0 / 
PCP 1.5 
CPG 0.5 / 
NAC 30 / 
PCP 1.5 
  
1.63±0.29 2.87±0.62 2.31±0.54 1.75±0.27 2.43±0.33 2.20±0.53   
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(Figure 2.1), an ANOVA indicated a main effect of phencyclidine treatment (F(6,57) = 5.80 
p < 0.05) on startle magnitude.  Post-hoc analysis revealed that phencyclidine 1.25 mg/kg 
and 2.0 mg/kg (Table 2.1; Tukey HSD, p < 0.05) were significantly different from vehicle 
alone treated animals.  However there was no effect of phencyclidine in experiment 2 
with oral N-acetylcysteine treatment (F(7,75) = 1.89 p > 0.05), experiment 4 (F(4,33) = 0.21 p 
> 0.05) or experiment 5 (F(5,50) = 0.71 p > 0.05).  
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Discussion 
 
 Abnormal glutamate signaling within cortical structures has been linked to 
negative symptoms and cognitive deficits present in schizophrenia (Weinberger, 1987; 
Bunney and Bunney, 2000).  Identifying cellular mechanisms capable of regulating 
glutamate signaling may advance our understanding of the neurobiological basis of 
schizophrenia and facilitate the development of pharmacotherapies.  A primary finding of 
this chapter is that increasing system xc- activity in the prefrontal cortex by locally 
applying the cysteine prodrug N-acetylcysteine attenuated phencyclidine-induced deficits 
in sensorimotor gating.   Further, we found that the capacity of N-acetylcysteine to 
restore prepulse inhibition was dependent upon the route of administration with oral 
administration failing to produce an effect.  Note, the dose range for N-acetylcysteine 
used was well within the dose range used for other experiments (Harvey et al., 2008).  
Collectively, these data suggest involvement of system xc- in phencyclidine-induced 
schizophrenic-like symptoms. 
A key finding of the current studies is that N-acetylcysteine reverses 
phencyclidine-induced deficits in prepulse inhibition.  Prepulse inhibition refers to a 
reduction in the magnitude of response to an acoustic stimulus when the eliciting auditory 
stimulus (pulse) is preceded by a lower-intensity auditory cue (prepulse); deficits in 
prepulse inhibition have been used to model sensorimotor gating deficits that occur in 
schizophrenic patients (Kumari et al., 2007; Swerdlow et al., 2006; Braff et al., 2001b).  
Sensorimotor gating reflects the ability of the central nervous system to inhibit irrelevant 
sensory information and allow focus on salient information from the environment (Braff 
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et al., 1978).  Restoration of sensorimotor gating as assessed by reversal of 
phencyclidine-induced deficits in prepulse inhibition is used to establish antipsychotic 
activity (Geyer et al., 2001).  These data, taken together with earlier findings that N-
acetylcysteine reverses deficits in prepulse inhibition evident in metabotropic glutamate 
receptor five knockout mice (Chen et al., 2010) provide support for the involvement of 
cystine-glutamate exchange in schizophrenia.  
The effects of N-acetylcysteine on prepulse inhibition of an acoustic startle 
response are likely due to increased activity of system xc- in the prefrontal cortex.  In 
support, reverse dialysis of N-acetylcysteine directly into the medial prefrontal cortex 
produced a near complete reversal of phencyclidine-induced deficits in prepulse 
inhibition and this effect was prevented when the system xc- inhibitor (S)-4-
carboxyphenylglycine (CPG) was co-infused into the prefrontal cortex. This is an 
important finding since the prefrontal cortex, specifically the dorsolateral prefrontal 
cortex, has been implicated in executive functions such as selective attention and task 
management (Smith and Jonides, 1999).  Numerous neuroimaging studies have found 
abnormal dorsolateral prefrontal cortical activation in response to executive functioning 
in schizophrenic patients (for review see Eisenberg and Berman, 2010).  Additionally, 
reductions in dorsolateral prefrontal cortical gray matter volume has been found in 
patients with more pronounced executive functioning dysfunction as measured by the 
Wisconsin card sorting task (Rusch et al., 2007) and a positive correlation between gray 
matter volume and prepulse inhibition (Kumari et al., 2008).  Given the crucial role of the 
dorsolateral prefrontal cortex in normal brain function, the change in xCT expression 
associated with schizophrenia and the abundant expression of xCT mRNA in this region 
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(at least in the rodent), system xc- likely contributes to dorsolateral prefrontal cortical 
activity and tasks associated with schizophrenia. 
The mechanism of N-acetylcysteine and system xc- to reverse phencyclidine-
induced behavioral deficits has not been clearly defined although one possibility that 
merits further testing is that N-acetylcysteine normalizes pyramidal cell firing.  
Symptoms of schizophrenia including executive function are thought to arise, at least in 
part, to desynchronization of dorsolateral prefrontal cortical activity (Haenschel et al., 
2009).  GABAergic, particularly parvalbumin containing fast-spiking interneurons, have 
been shown to regulate network oscillations (for review see Bartos et al., 2007).  
Phencyclidine has been shown to desynchronize oscillatory network activity in rodents 
by preferentially inhibiting GABAergic interneurons thereby causing disinhibition and 
subsequent over-activation of pyramidal cells and increased synaptic glutamate release 
(Moghaddam and Adams, 1998; Homayoun and Moghaddam, 2007; Amitai et al., 2012).  
Further, evidence suggests that phencyclidine increases extracellular glutamate and 
reduces synchronous network activity potentially leading to symptoms of schizophrenia 
(Moghaddam et al., 1997; Moghaddam and Adams, 1998; Homayoun et al., 2005; 
Hakami et al., 2009).  Stimulation of system xc- increases glutamatergic tone on 
metabotropic group II glutamate receptors (Baker et al., 2002b; Moran et al., 2005), 
inhibits phencyclidine-induced glutamate release (Baker et al., 2008), and thereby, may 
restore activity and synchrony of prefrontal cortical outputs.  Further, mGluR2/3 agonists 
have also been shown to inhibit phencyclidine-induced glutamate release (Moghaddam 
and Adams, 1998; Homayoun et al., 2005; Patil et al., 2007).  Another potential 
mechanism of N-acetylcysteine reversal of phencyclidine-induced deficits is the ability of 
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N-acetylcysteine independently or through stimulation of system xc- to alter the activity 
of NMDA receptors.  This could arise as a result of N-acetylcysteine-induced release of 
glutamate, generation of glycine following metabolism of de novo synthesized 
glutathione, or activation of the extracellular redox site on the NMDA receptor by cystine 
or glutathione (Baker et al., 2002b; Dringen et al., 2001; Steullet et al., 2006).  Figure 2.6 
depicts normal prefrontal cortical circuitry.  Note, in the presence of phencyclidine, there 
would be disinhibition of pyramidal cells due to reduced GABAergic firing resulting in 
elevated pyramidal neuron activity and glutamate release. 
Interestingly, extant data suggest that diminished system xc- function may 
contribute to the pathology of schizophrenia.  In support, schizophrenia is associated with 
a significant change in the tissue levels of glutathione, which is dependent upon the 
A 
Figure 2.6 Schematic of neural circuitry and synaptic connections within prefrontal cortex brain.  (A) 
Pyramidal neurons labeled with a P are the main excitatory output of the region and receives inputs 
from other neurons within and outside the structure (black line entering prefrontal cortex) indicated by 
black lines which can be stimulatory, inhibitory or modulatory.  Fast spiking basket cell parvalbumin 
containing GABAergic interneurons (gray marked with G are uniquely positioned to inhibit the soma of 
pyramidal neurons to modulate neuronal activity.  X indicates a nonspecific neuron within the region 
aiding in the synchronization of the circuit.  Panel B depicts the synaptic cleft in the box from panel A.  
The presynaptic neuron may release neurotransmitters such as glutamate (G), dopamine and GABA.  
System xc- exchanges glutamate for cystine (C), allows for glutathione (GSH) synthesis and tonic tone 
on metabotropic group II glutamate receptors (2/3) to modulate synaptic neurotransmitter release.   
 
B 
 
P
 G 
 X 
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uptake of cystine/cysteine, and in the protein levels of xCT, the active subunit for system 
xc-, in the dorsolateral prefrontal cortex (Do et al., 2000; Raffa et al., 2011; Baker et al., 
2008).  Interestingly, a decrease in glutathione or reduced system xc- activity inversely 
correlates with the severity of negative symptoms and is sufficient to produce 
hypoactivity of NMDA or group II metabotropic glutamate receptors, as well as reduced 
expression of parvalbumin (Steullet et al., 2006; Matsuzawa et al., 2008) all of which are 
thought to be central to the pathology of schizophrenia (Javitt, 2004; Lewis and 
Moghaddam, 2006).  Thus, efforts to increase cystine-glutamate exchange represent an 
approach that would be expected to produce a number of therapeutically relevant effects 
in cell functioning including the restoration of glutathione levels and increased activity of 
NMDA and group II metabotropic glutamate receptors.   
These experiments indicate that in the acute phencyclidine model of 
schizophrenia, there are deficits in sensorimotor gating that can be reversed by 
stimulating system xc- in the prefrontal cortex.  Oral treatment was without effect, 
possibly due to the poor bioavailability of oral N-acetylcysteine which has been estimated 
to range between four and ten percent (Borgstrom et al., 1986; Olsson et al., 1988).  
Involvement of system xc- needs to be further investigated to determine whether it is 
involved in the neuropathology of schizophrenia by utilizing a more accurate 
representation of schizophrenia.  The following chapters will examine system xc- in a 
neurodevelopmental approach to model the neurodevelopmental hypothesis of 
schizophrenia.     
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III. EXAMINATION OF CYSTINE-GLUTAMATE EXCHANGE IN 
METHYLAZOXYMETHANOL ACETATE TREATED OFFSPRING; 
A NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA 
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Introduction 
 
 Accumulating evidence supports the neurodevelopmental hypothesis of 
schizophrenia suggesting pre or postnatal environmental complications lead to abnormal 
neurodevelopment and symptoms of schizophrenia (for review see Weinberger, 1987; 
Marenco and Weinberger, 2000; Rapoport et al., 2005).  The neurodevelopmental 
hypothesis posits that a type of insult occurs in the pre or postnatal period leading to 
abnormal neurodevelopment of critical circuits causing the behavioral manifestation of 
schizophrenia later in life.  In support, several prenatal insults including viral, stress or 
delivery complications increase the likelihood of the offspring developing schizophrenia; 
there is also evidence of postnatal complications leading to elevated chance of 
schizophrenia (Brown, 2011; for review see Marenco and Weinberger, 2000; Lewis and 
Levitt, 2002; Brown and Patterson, 2011).  Further, social abnormalities and cognitive 
impairments are often observed for several years prior to diagnosis (Chua and Murray, 
1996; Elvevag and Goldberg, 2000; Blanchard and Cohen, 2006; Lewis and Moghaddam, 
2006) which typically occurs after positive symptoms emerge in late teens to early 20’s 
(Andreasen, 1995; Chua and Murray, 1996; Lewis and Lieberman, 2000) suggesting 
neurodevelopmental manifestation of symptoms of the disorder.  Unlike acute disruption 
models such as phencyclidine, neurodevelopmental models of schizophrenia attempt to 
mimic the lifelong span of symptoms observed in schizophrenics; this chapter seeks to 
determine whether system xc- is involved in the pathophysiology of one of these models. 
Methylazoxymethanol acetate (MAM) is a DNA methylating agent which 
selectively targets neuroepithelial proliferating cells (Matsumoto and Higa, 1966; 
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Cattabeni and Di Luca, 1997) and when given on gestational day 17 will target select 
brain regions undergoing neurogenesis including the prefrontal cortex, hippocampus and 
thalamus (Cattabeni and Di Luca, 1997; Matricon et al., 2010), areas that have also been 
implicated in schizophrenia (Bunney and Bunney, 2000; Heckers and Konradi, 2010; 
Swerdlow, 2010).  MAM administration generates behaviors consistent with symptoms 
of schizophrenia including hyperstimulation in locomotor studies to amphetamine and 
NMDA receptor antagonists (Le Pen et al., 2006; Lodge and Grace, 2007; Flagstad et al., 
2004; Phillips et al., 2012), social interaction deficits (Le Pen et al., 2006; Flagstad et al., 
2004; Lieberman et al., 2001), sensorimotor gating deficits (Moore et al., 2006) and 
cognitive deficits (Gourevitch et al., 2004; Flagstad et al., 2005; Le Pen et al., 2006; 
Featherstone et al., 2007).  Similar to schizophrenia, positive symptoms (humans: 
hallucinations, delusions, paranoia; rat: hyperlocomotion) emerge in adults whereas 
negative symptoms (humans and rats: social withdrawal) occur before puberty (Lewis 
and Levitt, 2002; Le Pen et al., 2006), cognitive deficits, while occurring prior to puberty 
in schizophrenics has not been tested in rats (Lewis and Levitt, 2002).  Furthermore, both 
schizophrenics and MAM offspring have lower prefrontal cortical volumes with no 
change in neuronal density (Selemon et al., 1995; Thune and Pakkenberg, 2000; Moore et 
al., 2006; Penschuck et al., 2006).  Also, abnormal inhibitory circuitry has been shown in 
schizophrenics by a decrease in GAD67, the main GABA synthesizing protein, and 
reduced GABAergic parvalbumin expression in the prefrontal cortex of schizophrenics 
and MAM offspring (Hashimoto et al., 2003b; Lodge et al., 2009) although no change in 
MAM parvalbumin in the prefrontal cortex has also been reported (Penschuck et al., 
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2006).  Collectively, these and other data support and establish the rodent MAM 
neurodevelopmental model of schizophrenia. 
To date, system xc- is poorly studied in neurodevelopmental models with no 
reports of cystine-glutamate exchange or glutathione in MAM treated offspring which is 
interesting since both are changes reported in schizophrenia.  Schizophrenics have 
reduced glutathione by as much as 50% in the dorsolateral prefrontal cortex (Do et al., 
2000; Yao et al., 2006; Gawryluk et al., 2010; Raffa et al., 2011).  The rate limiting step 
in glutathione synthesis is cystine uptake (Sagara et al., 1993; Kranich et al., 1998; 
Dringen and Hirrlinger, 2003) and system xc- is a key transporter for astrocytic cystine 
(Bannai, 1984; Bridges, 2011).  Additionally, expression of xCT, the active subunit of the 
cystine-glutamate antiporter, is elevated in the dorsolateral prefrontal cortex (Baker et al., 
2008).  Further, system xc- is capable of regulating synaptic neurotransmitter release 
through released extrasynaptic glutamate providing tone on extrasynaptic group II 
metabotropic glutamate receptors (Baker et al., 2002b) thereby serving as a 
heteroreceptor regulating synaptic neurotransmitter release (Baskys and Malenka, 1991; 
Conn and Pin, 1997; Xi et al., 2002; Chaki and Hikichi, 2011).  Interestingly preclinical 
and clinical studies have shown that group II agonists have been shown to significantly 
improve symptoms of schizophrenia (Moghaddam and Adams, 1998; Patil et al., 2007; 
Mosolov et al., 2010) although see (Kinon et al., 2011) who did not find improvements 
from placebo for mGluR2/3 agonists however they also failed to see improvements with 
atypical antipsychotic medication.  Additionally, N-acetylcysteine, which preclinically 
was shown to stimulate cystine-glutamate exchange (Baker et al., 2002b; Kau et al., 
2008; Baker et al., 2008; Chapter 2), has also improved clinical symptoms of 
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schizophrenia (Berk et al., 2008c; Lavoie et al., 2008).  Collectively, system xc- is 
implicated in the pathophysiology of schizophrenia.  However, the extent of its 
involvement in neurodevelopmental models and its direct effect on behavior is not yet 
known. 
Cognitive deficits are a core feature of schizophrenia and are the single best 
predictor of long-term outcome (Liddle, 2000; Kurtz et al., 2005; Holthausen et al., 
2007).  Behavioral flexibility tests the ability to shift attention in response to changes in 
one’s environment; schizophrenics have difficulty shifting attention between different 
rules or strategies as measured by the Wisconsin Card Sorting task (Morice, 1990; Gold 
et al., 1997; Prentice et al., 2008; Waford and Lewine, 2010).  Further, schizophrenics 
have also shown deficits in reversal learning (Waltz and Gold, 2007; Murray et al., 2008).  
Deficits in set shifting and reversal learning have been found in multiple models of 
schizophrenia including with NMDA receptor antagonists (Stefani and Moghaddam, 
2005; Abdul-Monim et al., 2006) and neurodevelopmental models including prenatal 
immune challenge (Meyer et al., 2005) and MAM (Featherstone et al., 2007).  The 
attentional set shifting protocol in this chapter examines MAM offspring with a visual 
discrimination task, an attentional set shift and reversal learning while using the same 
stimuli across the different tasks making it similar to the Wisconsin Card Sorting task 
(Floresco et al., 2009).   
 
The primary goal of this chapter is to assess the status of system xc- activity in 
the MAM neurodevelopmental model of schizophrenia and to determine whether 
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stimulation of system xc- by N-acetylcysteine is sufficient to treat MAM-induced 
cognitive deficits.  
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Materials and Methods 
 
Methylazoxymethanol Treatment: Timed pregnant Sprague-Dawley rats were given an 
acute injection of saline or methylazoxymethanol (22 mg/kg, IP; MRIGlobal Chemical 
Carcinogen Repository, Kansas City, MO) on gestational day 17.  Following vaginal 
birth all mothers and offspring were left undisturbed until weaning on postnatal day 22.  
Male offspring were individually housed in a temperature controlled room with a 12-h 
light/dark cycle with food and water ad libitum.  The housing conditions and care of the 
rats were in accordance with the Animal Welfare Act, and all procedures were approved 
by the Marquette University IACUC Committee.  Offspring were tested as juveniles 
(PND 28-40) or adults (PND 60+).   
Drug Treatments: N-acetylcysteine (Sigma Chemical Co., St Louis, MO), when given, 
was dissolved in isotonic saline with NaOH to bring the pH to 7.0 and given acutely or 
Figure 3.1. Acute (A) and chronic with a wash out period (B) administration  of N-acetylcysteine (NAC) in 
behavior and measures of system xc-.  Note, habituation can take anywhere from 2 to 10 days.   
A 
B 
Days 1 
- 7 
Days 8 - X 
     Handling & Food Habituation TB   D1   D2   D3 
Handling & Food 
Deprivation 
Habituation TB   D1   D2   D3 
Days 1 - 14 Days 15 - 17 Days 18 - 25 
2x Daily NAC 
Injections (60 
mg/kg) 
Wash Out 
Period 
Days 26 - X 
Daily NAC Injections  
(60 mg/kg) 
 
Acute NAC 
Chronic NAC Injections With a Wash Out Period 
Day 28: Measures of System X
C
-
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chronically with a wash out period.  With acute administration, N-acetylcysteine (0-60 
mg/kg, IP) was given one hour prior to start of testing in set shifting or measures of 
system xc- (see Figure 3.1a).  Chronic administration involved 14 days of twice daily 
injections (0-60 mg/kg, IP) followed by a 14 day wash out period before behavioral 
testing or measures of system xc- were conducted (see Figure 3.1b) to determine whether 
chronic treatment induced lasting changes in system xc- activity and behavior even after 
cessation of treatment.   
Attentional Set Shifting: The attentional set shifting task was based on work from the 
Floresco lab (Floresco et al., 2006a; Floresco et al., 2008; Floresco et al., 2009).  The 
maze consisted of four-arms (60 x 20 x 12 cm) in the shape of an X connected by a center 
area (12 x 12 cm) constructed of black Plexiglas with a movable wall to block an arm to 
form a “T” configuration.  Dividers at the end of each arm concealed the sugar pellet 
reward such that the rat was unable to see it from the center of the maze. The visual cue, 
when used, was laminated with black and white diagonal stripes and placed on the floor 
of an arm.  Prior to habituation, rats were handled for five minutes each day for seven 
days and food deprived to 85% of their free-feeding weight.  The day before habituation, 
each rat was given approximately 30 sugar pellets in their home cage to acquaint them 
with the pellets.   
Habituation: A habituation period was conducted in order to familiarize the animal to the 
maze and train him to find and eat the food reward within the maze.  Day one, 5 pellets 
were placed in each arm, 3 throughout the length of the arm and 2 behind the divider at 
the end.  The rat was placed in the center of the maze and allowed to freely explore for up 
to 15 minutes.  On the second day, 3 pellets were placed in each arm, one in the center, 
63 
 
the other 2 behind the divider and the rats freely explored for up to 15 minutes.  On the 
third day and all remaining days till criteria was achieved, one pellet was placed behind 
the divider in each arm.  After the rat consumed a pellet behind the divider on any day, he 
was picked up and placed at the entrance to another baited arm to familiariaze him to 
handling within the maze.  If the rat consumed all sugar pellets on any day, the maze was 
rebaited with the following habituation day’s configuration or with 4 pellets, one behind 
each divider after habituation day 2.  Criteria was met after the maze was rebaited 3 times 
and all pellets were consumed within 15 minutes; turn bias was run the following day.  If 
the rat did not consume all sugar pellets within 15 minutes, he continued habituation 
daily until he met criteria.   
Turn bias: Turn bias introduced the animal to the “T” maze configuration and the visual 
cue.  During turn bias and testing, one arm was blocked with the movable wall to form a 
“T” configuration with the visual cue in one of the side arms.  In turn bias, both side arms 
were baited with sugar pellets behind the dividers.  The rat was placed in the stem arm at 
the bottom of the “T” and allowed to enter either arm; after consuming the pellet he was 
placed back in the stem arm and again allowed to enter either arm.  If he entered the same 
arm again, he was returned to the stem arm until he turned into the opposite arm and ate 
the remaining sugar pellet.  When he successfully ate both sugar pellets, he was placed 
back in his home cage signaling the end of the trial.  The next trial, the rat began from a 
different arm such that over 7 trials, the rat started from each of 3 arms 2 times and the 
remaining arm once and the visual cue was placed in either the right or left arm as 
equally as possible.  Inter-trial time was about 10 seconds to rebait the maze.  The 
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direction the rat turned first the most out of 7 
trials was considered his turn bias for the rest 
of testing.   
Testing: As in turn bias, one arm was blocked 
with the movable wall, either the right or left 
arm contained the visual cue and the rat began 
in the stem arm.  Trials were grouped into a 
block of 12 with the stem arm in arms 1-3 as 
shown in Figure 3.2.  In the probe trial, arm 4 
was the stem arm and the visual cue was placed in the turn bias arm.  Within treatment 
groups, the probe arm switched such that at least one animal in each group used each arm 
as the stem arm for the probe trial.  Each testing day required the following:  
• 10 consecutive correct trials using the 12 trial block in stem arms 1-3 
• 1 correct probe trial from stem arm 4 
• If correct probe trial, testing was complete 
o If incorrect probe trial 
 5 consecutive correct trials using the 12 trial blocks 
 1 correct probe trial from stem arm 4 
 This continues till correct probe trial 
Day 1: Visual-cue learning:  On day one, the rat was trained in a simple discrimination 
task to attend to the visual cue such that the food reward was placed in each arm with the 
visual cue 50% of the time.  Turing towards the visual cue and attaining the reward was a 
correct choice.  In the probe trial the rat turned towards the visual cue. 
1 
 2 
 3 
 4 
Figure 3.2 Attentional set shifting diagram 
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Day 2: Attentional Set Shift: On day 2 the complex task of an attentional set shift required 
the rat to switch from a visual to a spatial cue with the new strategy for reward turning 
into the arm opposite of his turn bias.  The probe trial required the rat to turn in the 
opposite direction of the visual cue. 
Day 3: Reversal learning: Reversal learning required the rat to enter the arm opposite the 
strategy from day 2 such that the rats turn bias arm now contained the food reward and 
the rat turned towards the visual cue on the probe trial.  
Tissue Glutathione Analysis: Animals were rapidly decapitated (PND 100+) and 
punches taken from the medial prefrontal cortex.  The tissues were homogenized in a 4:1 
dialysis buffer (5 mM glucose, 140 mM NaCl, 1.4 mM CaCl2, 1.2 mM MgCl2, 2.2 mM 
KCl, and 0.15% phosphate buffer saline, pH 7.4): mobile phase solution (75 mM 
NaH2PO4·H2O, 1.8 mM C8H17O3Sna, 25 μM EDTA, 0.1% TEA and CH3CN pH to 3.0 
with phosphoric acid).  One fraction was analyzed in the BCA method to determine 
protein content.  The other fraction analyzed thiol content using HPLC with EC detection 
(Decade II, MagicDiamond electrode set at +1.89V, Antec Leyden, Netherlands).   
14C Cystine Uptake:  Animals were rapidly decapitated and brains extracted.  All tissue 
punches of the prefrontal cortex were treated with TBOA (100 µM) and in the presence 
14C-L-cystine (approximately 0.3 µM).  Experimental groups were MAM or control rat’s 
male offspring (PND 100+) in the presence or absence of (S)-4-carboxyphenylglycine 
(CPG, 1 mM; Tocris-Cooksin, Ellisville, MO).  The punches were washed and 
solubilized with 1% SDS.  One fraction (200 uL) of the solubilized tissue was used for 
determining [14C]-L-cystine uptake by a scintillation counter.  The other fraction (25 uL) 
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was used to determine protein content by the BCA method.  Uptake was measured in 
counts/µg protein.  
Surgeries: Adult male offspring of control or MAM treated animals weighing 300-400 
grams were anesthetized using pentobarbital (50 mg/kg, IP) with atropine sulfate (1 
mg/kg, IP) pretreatment to limit tracheobronchial secretions.  Bilateral guide cannula (20 
gauge, 14 mm; Plastics One, Roanoke, VA) were implanted using coordinates +3.1 mm 
anterior, ±1.0 mm mediolateral to Bregma, and -0.75 mm ventral from the surface of the 
skull at a 6° angle from vertical derived from Paxinos and Watson (Paxinos and Watson, 
1986).  Rats were given at least 6 days to recover from surgery prior to testing. 
In Vivo Microdialysis:  Microdialysis experiments were conducted as described 
previously (Baker et al, 2002).  Briefly, after a minimum of six days post surgery, 
removable probes extending 2 mm past the guide cannula were inserted through the 
cannulae into the prefrontal cortex and microdialysis buffer (5 mM glucose, 140 mM 
NaCl, 1.4 mM CaCl2, 1.2 mM MgCl2, and 0.15% phosphate-buffered saline, pH 7.4) was 
pumped through the probes at one µl/min for at least three hours prior to collecting 
baseline samples to allow for neurotransmitters to stabilize.  Afterwards, 20-min samples 
were collected for 4 baseline samples followed by 3 samples at each cystine 
concentration in ascending order: 0, 0.01, 0.05, 0.1, 0.15, 1.5µM.   Samples were run for 
on HPLC for thiol and glutamate content. 
Thiol HPLC:  Thiol content was analyzed on HPLC with electrochemical detection.  
Thiols were separated using a reversed-phase column (Kinetex 2.6u XB-C18 100A 
75x4.6mm, Phenomenex, Torrence, CA) and a mobile phase consisting of 25mM 
H3PO4, 25mM Citric Acid, 500mg/L OSA, 0.35% ACN, pH 3.3.  Thiols were detected 
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using a Decade II electrochemical detector (Antec Leyden; The Netherlands) with a 
single cell MagicDiamond electrode set at +1.80V.   
Glutamate HPLC: Baseline samples were run on glutamate HPLC coupled to 
fluorescence detection.  Precolumn derivatization of glutamate with o-pthalaldehyde was 
performed using a Shimadzu LC10AD VP autosampler.  The mobile phase consisted of 
13% acetonitrile, 100 mM Na2HPO4 and 0.1 mM EDTA, pH = 5.90.  Glutamate was 
separated using a reversed-phase column (3 µM; 100 x 4.2 mm; Bioanalytical Systems, 
West Lafayette, IN), and detected using a Shimadzu 10RF-AXL fluorescence detector 
with an excitation and emission wavelength of 320 and 400 nm, respectively (Baker et 
al., 2002). 
Western Blotting:  Animals were rapidly decapitated (PND 100+) and punches taken 
from the medial prefrontal cortex.  Tissue was homogenized in RIPA + protease inhibitor 
cocktail and protein concentration was determined by the BCA assay method.  20 μg of 
homogenized denatured protein was run on 10% tris-gly PAGE gel and transferred to 
PVDF membrane.  The membrane was blocked in 5% non-fat dry milk solution for one 
hour and subsequently incubated with a custom antibody against the C-terminal of xCT 
(Prosci, rabbit anti-xCT 1:500) overnight at 4° C.  The blots were washed and incubated 
with the secondary antibody (Omega anti-rabbit 1:10,000) and the signal was detected 
with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific).  
Bands were quantified using Kodak Molecular Imaging software (Eastman Kodak 
Company) and normalized with GAPDH control.    
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Histology:  Tissue slices obtained from rats included in the microdialysis studies were 
stained with cresyl violet to verify probe placements.  Rats determined to have misplaced 
guide cannula were excluded from all analyses.  
Statistics:  MAM treated offspring were compared to vehicle treated offspring given the 
same treatment as adults using t test. 
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Results 
 
Attentional set shifi:  Evidence supports MAM as a neurodevelopmental model of 
schizophrenia since it produces a range of symptoms similar to those observed in 
schizophrenia.  The contribution of system xc- to MAM-induced cognitive deficits has not 
been established.  Attentional set shifting is a complex cognitive task that tests three 
types of learning and memory: visual cue learning (day 1), attentional set shift (day 2) 
and reversal learning (day 3).  The task presented to the animals is shown in Figure 3.3, 
day one the arm with the visual cue contains the reward (Figure 3.3a), day two requires a 
shift in attention from a visual cue to a spatial cue for reward (Figure 3.3b) and reversal 
learning on day three is when the opposite arm of day 2 contains the reward (Figure 
3.3c).  Acute and chronic with a wash out period treatment of MAM treated offspring is 
shown in Figure 3.1. 
The impact of MAM treatment in offspring in a complex cognitive task is 
illustrated in Figure 3.4.  MAM treated animals showed a significant deficit in visual cue 
learning (Figure 3.4a, T = 2.96, p < 0.05) and not in the attentional set shift task (Figure 
Figure 3.3 Attentional set shifting task.  A) Response discrimination (day 1); animals are trained to turn 
towards the visual cue. B) Attentional set shift (day 2); animals are trained to turn in one direction. C) 
Reversal learning (day 3); animals must turn opposite the direction they went on day 2.   
B C A 
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3.4b, T = 0.21, p > 0.05).  Further, reversal learning deficits were also found in MAM 
treated offspring on day 3 (Figure 3.4c, T = 2.57, p < 0.05).  To test the involvment of 
system xc- in attentional set shifting, direct manipulations of the transporter are necessary.  
 
Next, the impact of system xc- on attentional set shifting were analyzed.  Chapter 5 
will examine the impact of reduced cystine-glutamate exchange; here the effects of 
system xc- stimulation were measured in control and MAM treated offspring by N-
acetylcysteine treatment which has been shown to drive cystine-glutamate exchange.  
Figure 3.5 depicts the effect of N-acetylcysteine administration either acutely one hour 
before each testing day or after chronic treatment with a wash out period (as shown in 
Figure 3.1).  Whereas MAM treated offspring show a deficit in the simple discrimination 
task of visual cue learning (Figure 3.4a), there was no significant difference of MAM 
compared to vehicle treated offspring with acute or chronic with a wash N-acetylcysteine 
treatment (Figure 3.5 a and d, T = 0.74 and T = 0.56 respectively, p > 0.05).  Similarily, 
day 2 attentional set shift had no effect of treatment (Figure 3.5 b and e, T = 0.36, T = 
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Figure 3.4 Attentional set shift in MAM treated offspring.  MAM induced deficits (N = 10-11) in 
attentional set shift on day 1 (visual cue learning) (A), day 2 (attentional set shift) (B) and day 3 (reversal 
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0.21 respectively, p > 0.05).  Interestingly, N-acetylcysteine acute and chronic treatment 
attenuated MAM-induced deficits in reversal learning on day 3 shown by no significant 
difference from control animals with same treatments (Figure 3.5c and f, T = 1.51, T = 
1.43 respectively, p > 0.05) using t test.  These data suggest that system xc- may be altered 
in MAM animals since targeting system xc- is capable ofattenuating cognitive deficits .     
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Figure 3.5 Attentional set shift in MAM with N-acetylcysteine.  Attentional set shifting as shown on day 1 
(visual cue learning), day 2 (attentional set shift) and day 3 (reversal learning).  Panels A-C are the effects 
of acute N-acetylcysteine on each day of testing (60 mg/kg, IP; N = 8-9) and D-F are chronic N-
acetylcysteine with a wash-out period on MAM induced deficits in attentional set shifting (60 mg/kg, IP; 
N = 7-8).  As shown, there are no evident MAM-induced deficits on visual cue learning or reversal 
learning with N-acetylcysteine treatment. 
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Measures of system xc- in MAM treated offspring:  Since N-acetylcysteine attenuated 
MAM-induced deficits in reversal learning, the next step was to investigate the status of 
system xc- activity in MAM offspring.  Glutathione levels are sensitive to cystine-
glutamate exchange since cystine uptake is the rate limiting step in glutathione synthesis 
(Sagara et al., 1993; Dringen and Hirrlinger, 2003).  Figure 3.6a depicts MAM-induced 
reductions in tissue glutathione content in the prefrontal cortex (T = 2.36, p < 0.05). 
Interestingly, both acute (Figure 3.6b, T = 0.30, p > 0.05) and chronic N-acetylcysteine 
with a wash (Figure 3.6c, T = 1.15, p > 0.05) showed no significant differences from their 
respective controls suggesting that N-acetylcysteine is able to restore tissue gltuathione 
levels in the prefrontal cortex.  Deficits in glutathione levels suggest abnormal 
glutathione cycling and or reduced cystine-glutamate exchange.  
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Figure 3.6 Prefrontal glutathione concentrations in 
MAM offspring with or without N-acetylcysteine. 
A) MAM produces a significant decrease in tissue 
glutathione levels (N = 14 per group).  B) Acute 
and C) chronic N-acetylcysteine have no 
significant from their respective controls (N = 6-
11 per group).  * indicates a significant difference 
from control p < 0.05 using t test.    
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 The ability of N-acetylcysteine to improve MAM-induced deficits in glutathione 
concentrations suggests abnormal cystine-glutamate exchange since N-acetylcysteine has 
been shown to drive activity (Baker et al., 2008; Kau et al., 2008).  An ex vivo approach 
was used to measure system xc- activity using 14C cystine uptake with and without a 
system xc- inhibitor (CPG) to measure cystine-glutamate antiporter dependent activity 
within tissue punches taken from the prefrontal cortex.  Suprisingly, MAM treated 
offspring showed a significant increase in ex vivo system xc- dependent uptake from 
punches of the prefrontal cortex (Figure 3.7a, T = 2.62, p < 0.05) that does not return to 
baseline with acute N-acetylcysteine treatment (Figure 3.7b, T = 1.88 p = 0.09).  
Interestingly, Figure 3.7c illustrates that chronic N-acetylcysteine with a wash out period 
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Figure 3.7 Prefrontal system xc- dependent 
cystine uptake in MAM offspring with or 
without N-acetylcysteine.  (A) MAM 
treatment produces a significant increase in 
cystine-glutamate exchange capacity (N = 4-
6).  (B) Acute N-acetylcysteine treatment 
does not appear to reverse MAM-induced 
increase (N = 2-3).  (C) Chronic N-
acetylcysteine brings cystine uptake to 
control levels (N = 5). * indicates a 
significant difference from control animals 
using t test. 
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inhibited the MAM-induced increased capacity in system xc- activity (T = 0.11, p = 0.91).  
An outstanding question of the data showing deficient glutathione in the presence of 
increased potential for system xc- activity is whether this represents an in vivo increase in 
cystine-glutamate exchange as a compensatory effect of reduced glutathione 
concentrations. 
 To examine this question a cystine no-net flux experiment was done to measure 
extracellular cystine concentrations and to determine whether the apparent increase in 
cystine-glutamate exchange suggested by the ex vivo data occurs in vivo.  Figure 3.8a 
illustrates cystine no-net flux microdialysis tartgeting the prefrontal cortex of control and 
MAM offspring.  Both the x-intercept, where the trend line crosses the x-axis which is 
the point with no net flow between the probe and extracellular space which indicates the 
extracellular cystine concentration (control = 0.44 ± 0.13, MAM = 0.40 ± 0.07) and 
extraction fraction indicating cystine clearance rate (control = 0.86 ± 0.05; MAM = 0.96 
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Figure 3.8 Prefrontal cystine no-net flux microdialysis in MAM offspring.  (A) indicates cystine (CC) 
no-net flux in the prefrontal cortex and shows no significant differences between extracellular cystine 
levels or extraction fraction (N = 8).  Additionally, there is no change in baseline glutamate levels (B) in 
the same animals in the prefrontal cortex of MAM offspring compared to control (N = 8).  
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± 0.03) showed no significant differences between the groups (Figure 3.7a; T = 1.78 and 
0.23 respectively, p > 0.05).  Additionally, baseline glutamate levels from this experiment 
also indicate no signficant differences between groups shown in Figure 3.8b.  A repeated 
measure with treatment as a between subjects factor and time as a repeated measure 
shows no interaction (F(4, 52) = 0.23, p > 0.05), main effect of treatment (F(1, 13) = 0.53, p > 
0.05) or time (F(4, 52) = 0.37, p > 0.05).  These results suggest no change in in vivo cystine-
glutamate exchange. 
 An additional measure of in vivo system xc- is measuring protein expression of 
xCT, the active subunit of the cystine-glutamate antiporter.  Using an anti-xCT antibody 
and measuring the projected 55 kDa band which others have used to measure xCT, MAM 
treated offspring have no differences in xCT expression, however there is not a consensus 
regarding anti-xCT antibodies or even which band represents functional xCT expression.  
Figure 3.9a is a representative blot with quantitative values of the 55 kDa band in Figure 
3.9b.  Taken together, these data suggest that adult MAM offspring have decreased 
glutathione concentrations and a potential increase in system xc- activity ex vivo yet no 
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Figure 3.9 Western blot of xCT, the active subunit of system xc-, in the medial prefrontal cortex of 
control and MAM treated offspring.  (A) representation of western blot from control and MAM treated 
animal.  Note, the 55 kDa band was used for quantitative measures of xCT expression (B) using the 
ProSci antibody however the other bands could represent splice variants, degradation products or 
different cellular localization of system xc-.   
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apparent differences in cystine-glutamate exchange in vivo.    
Juvenile measures of system xc- in MAM treated offspring:  Adult MAM-treated 
offspring exhibit diminished glutathione levels (Figure 3.6a) in the prefrontal cortex with 
an apparent compensatory increase in the capacity of system xc-activity (Figure 3.7a),  yet 
in vivo evidence of increased cystine-glutamate exchange was not obtained.  Measures of 
juvenile system xc- activity were conducted in an attempt to learn when these changes 
emerged.  To determine this, juvenile (PND 28-40) measures of glutathione and cystine-
glutamate exchange were examined.  Interestingly, glutathione, as shown in Figure 3.10a 
is not altered compared to controls in prefrontal tissue concentrations (T = 0.79, p > 
0.05).  However, similar to adults, juveniles also have a significant increase in system xc- 
dependent cystine uptake in the prefrontal cortex (Figure 3.10b, T = 2.67, p < 0.05).  One 
possible interpretation of this data is that system  xc- is upregulated in response to an 
earlier deficit in glutathione and, during adolescence, is sufficient to normalize 
glutathione concentrations.  Potentially, as the brain continues to mature and develop, 
elevated system  xc- activity is no longer sufficient and the glutathione deficit emerges. 
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Figure 3.10 Measures of system xc- activity in juvenile MAM offspring.  (A) Prefrontal glutathione in 
MAM offspring (N = 5-9).  (B) Illustrates a significant increase in ex vivo prefrontal cystine uptake 
in MAM offspring compared to control (N = 7-8 per group). * denotes significance from control 
animals using t test. 
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Discussion 
 
 Chapter 2 illustrates the ability of system xc- in the prefrontal cortex to reverse 
phencyclidine-induced deficits in sensorimotor gating.  This chapter seeks to establish the 
activity of the cystine-glutamate antiporter in the MAM neurodevelopmental model of 
schizophrenia.  MAM-induced cognitive deficits in reversal learning, as measured in the 
attentional set shifting task, are attenuated by stimulation of system xc- with N-
acetylcysteine either acutely and even after a two week wash out period from chronic 
dosing.  Furthermore, both acute and chronic N-acetylcysteine treatment restores a 
MAM-induced prefrontal tissue glutathione deficit, and interestingly, chronic N-
acetylcysteine also normalizes the significant increase in ex vivo system xc- activity in 
MAM animals.  However, MAM animals do not show in vivo evidence of increased 
system xc- activity as shown in the cystine no-net flux study and xCT expression.  Lastly, 
juvenile studies of MAM treated offspring have normal prefrontal glutathione tissue 
concentration in the presence of a significant increase in system xc- activity.  Taken 
together, these results indicate abnormal cystine-glutamate exchange in the MAM model 
of schizophrenia. 
 
MAM-induced behavioral deficits:  Many of the diverse range of symptoms associated 
with schizophrenia are induced by prenatal MAM treatment and follow similar 
manifestations.  For example, MAM treated offspring show hyperstimulation to 
amphetamine and phencyclidine in locomotor studies (Le Pen et al., 2006; Lodge and 
Grace, 2007; Flagstad et al., 2004; Phillips et al., 2012) simulating positive symptoms of 
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schizophrenia (Sturgeon et al., 1979; Enomoto et al., 2007; Young et al., 2010).  
Interestingly, similar to schizophrenia, this effect does not emerge until adulthood 
(Lieberman et al., 2001; Le Pen et al., 2006).  Further, negative symptoms are modeled 
with social interaction deficits; MAM treated offspring show deficits both pre and post-
pubertal, also similar to emergence of social deficits prior to diagnosis (Le Pen et al., 
2006; Flagstad et al., 2004; Lieberman et al., 2001).  Finally, there have been numerous 
cognitive deficits reported including sensorimotor gating and behavioral flexibility (Le 
Pen et al., 2006; Moore et al., 2006; Flagstad et al., 2005; Featherstone et al., 2007).  The 
behavioral deficits in the MAM model summarized here and morphological and 
neurochemical data described elsewhere parallels many features of schizophrenia.   
 Executive functioning deficits including behavioral flexibility are core features of 
schizophrenia and are the best predictors of social dysfunction (Kurtz et al., 2005; Liddle, 
2000).  Behavioral flexibility is the ability to shift attention between different rules or 
strategies; the Wisconsin Card Sorting task measures deficits in schizophrenics, 
attentional set shifting measures deficits in rodents (Morice, 1990; Prentice et al., 2008; 
Floresco et al., 2009).  This chapter examines MAM-induced deficits in attentional set 
shifting.  There is a significant increase in trials to criteria in MAM offspring compared 
to control on day one of visual cue learning indicating impairments in a simple 
discrimination task.  It is important to note that control animals that received N-
acetylcysteine show similar trials to criteria with MAM offspring suggesting that while 
interesting, more investigations will need to be conducted to fully understand simple 
discrimination deficits in MAM offspring.  Surprisingly, there was no effect of MAM or 
N-acetylcysteine treatment on day 2 for the attentional set shift.  This was unexpected 
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since attentional set shifting is a complex task mediated by prefrontal cortical activity, an 
area with a significant amount of xCT mRNA (Floresco et al., 2008; see Chapter 2).  
 Reversal learning tests the flexibility of the animal when reinforcement strategies 
are reversed, schizophrenics also have difficulties with reversal learning (Waltz and 
Gold, 2007; Murray et al., 2008).  MAM treated offspring require significantly more 
trials to reach criteria in the reversal learning phase of attentional set shifting (Figure 
3.4c).  This is consistent with reversal learning impairments in MAM offspring in other 
tasks (Flagstad et al., 2005; Featherstone et al., 2007; Gastambide et al., 2012).  Reversal 
learning deficits have been linked to the orbitofrontal cortex in both humans and rodents 
(Waltz and Gold, 2007; Ghods-Sharifi et al., 2008) a region also shown to have lower PV 
expression in MAM treated offspring (Gastambide et al., 2012).  What is unknown is the 
ability of system xc- to regulate reversal learning. 
 Interestingly, stimulation of system xc- with N-acetylcysteine treatment was able 
to attenuate MAM-induced deficits in reversal learning.  N-acetylcystine has been shown 
in preclinical studies to exert its therapeutic potential by stimulation of cystine-glutamate 
exchange (Kau et al., 2008; Baker et al., 2008).  During acute administration, animals 
received N-acetylcysteine injections (60 mg/kg, IP) one hour before testing began on all 
three days.  Whereas acute treatment tests the effect of direct manipulation of cystine-
glutamate exchange, chronic treatment with a wash out period of at least 14 days 
examined the ability of N-acetylcysteine to have therapeutic efficacy even after 
termination of treatment.  This could be due to the normalization of glutathione leading to 
normal glutathione cycling for long term stabilization of system xc- which is driven by 
extrasynaptic cystine.  Interestingly, both treatment regimens attenuate MAM-induced 
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deficits in reversal learning (Figure 3.5c and f).  Of note, N-acetylcysteine had no effect 
in the absence of behavioral deficits in control animals on all three phases of testing or on 
MAM offspring in the absence of deficit (attentional set shift).  This suggests that system 
xc
-
 is working at full capacity and an increase in extracellular cystine is insufficient to 
improve performance or there are compensatory mechanisms within the circuitry to 
prevent a change in system xc- activity in the absence of a deficit.  In order to determine 
the potential effects of N-acetylcysteine, it is important to understand the state of the 
antiporter in MAM treated offspring.   
          
System xc- in MAM treated offspring: One way to examine system xc- activity is by 
measuring glutathione concentrations.  Glutathione is dependent on astrocytic cystine 
uptake for synthesis; system xc- is a key transporter for astrocytic cystine (Dringen and 
Hirrlinger, 2003; Bannai, 1984; Bridges, 2012).  Further, neurons lack the machinery to 
transport cystine and rely on astrocytic glutathione release and breakdown into cysteine 
which is taken up by neurons for glutathione synthesis (for review see Dringen and 
Hirrlinger, 2003).  As such, glutathione levels are a functional measure of in vivo system 
xc
-
 activity and reductions in concentrations suggest decreased cystine-glutamate 
exchange.  Additionally, up to 50% reduction in dorsolateral prefrontal cortical 
glutathione concentrations has been found in schizophrenics (Do et al., 2000; Gawryluk 
et al., 2010; Raffa et al., 2011).  The medial prefrontal cortex was examined since a) there 
is strong mRNA expression of xCT in the area (Chapter 2), b) abnormal dorsolateral 
prefrontal cortical activity is indicated in schizophrenics and prelimbic prefrontal cortex 
is the rodent analog (Callicott et al., 2000; Bunney and Bunney, 2000; Uylings et al., 
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2003) and c) other labs have found morphological differences in MAM treated offspring 
in the prefrontal cortex including volume, neuronal size and disruptions in network 
synchrony (Flagstad et al., 2004; Moore et al., 2006; Goto and Grace, 2006).  Similar to 
human schizophrenics, MAM treated offspring have reduced prefrontal tissue glutathione 
concentrations (Figure 3.6a).  The questions now are why are glutathione levels 
decreased and when do levels change compared to control levels? 
 Deficient glutathione concentrations may result from compromised cystine uptake 
or conversely, cause an increase in cystine transporters.  The results presented in this 
chapter support the latter with a significant increase in ex vivo system xc- dependent 
cystine uptake (Figure 3.7a).  This is not unexpected since depleted glutathione has been 
shown to increase the active subunit of system xc- (xCT) and cystine-glutamate exchange 
as a compensatory response to increase glutathione synthesis (Seib et al., 2011).  Further, 
similar to MAM, schizophrenics have increased expression of xCT in the dorsolateral 
prefrontal cortex (Baker et al., 2008).  However, for some as yet unknown reason, in 
adult MAM treated offspring this response fails to normalize levels of glutathione.  What 
is shown is no evidence for increased cystine-glutamate exchange in vivo in the cystine 
no-net flux study. 
     Microdialysis no-net flux studies are useful experiments to measure in vivo 
concentrations and clearance efficiency (Smith and Justice, 1994).  Cystine no-net flux in 
MAM treated offspring show no changes in baseline extrasynaptic cystine levels nor 
changes in extraction fraction which measures cystine clearance compared to control 
animals (Figure 3.8) even with the potential increase in ex vivo capacity of system xc-.  
Further, there is no change in basal extrasynaptic glutamate levels.  This raises an 
82 
 
interesting question as to why an apparent need (decreased glutathione) and ability 
(increased ex vivo potential) for increased cystine uptake does not result in increased in 
vivo cystine-glutamate exchange compared to controls.  Endogenous regulation of system 
xc
-
 is poorly understood (for review see Bridges, 2012) and likely dependent on a 
multitude of neurotransmitters and protein kinases making it difficult to assess.  What is 
known is the ability of N-acetylcysteine to drive cystine-glutamate exchange (Kau et al., 
2008; Baker et al., 2008; Chapter 2).   
 A western blot analyzed expression of xCT, the active subunit of the cystine-
glutamate antiporter in control and MAM treated offspring.  There is controversy 
surrounding all available antibodies about the specificity to xCT and whether the various 
bands represent different isoforms, expression patterns or degradation products.  Using 
the ProSci antibody against xCT and measuring the 55 kDa band which others have used 
(Knackstedt et al., 2010), there was no difference in MAM expression of xCT compared 
to controls in the medial prefrontal cortex.  So while there does not appear to be a change 
in xCT expression, it is quite possible that a different antibody or a different band would 
give different results and is therefore inconclusive.  
 Glutathione and ex vivo cystine-glutamate exchange were also measured in the 
presence of N-acetylcysteine.  Acute N-acetylcysteine (60 mg/kg, IP) was given one hour 
before animals were euthanized and tissue analyzed.  Treatment normalized prefrontal 
tissue glutathione concentrations to control levels and decreased ex vivo cystine uptake by 
system xc- without returning to control N-acetylcysteine treated animal baseline.  This is 
not an indication of the inability of acute N-acetylcysteine to drive cystine-glutamate 
exchange since some of N-acetylcysteine is likely washed out during the course of the 
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assay.  Interestingly, the ability of chronic N-acetylcysteine treatment with a 14 day wash 
out period similar to the behavioral experiment normalized system xc- activity.  Both 
glutathione and ex vivo system xc- dependent cystine uptake were normalized to control 
N-acetylcysteine animals even after the wash out period suggesting plasticity within the 
circuit to normalize cystine-glutamate exchange that extends beyond the termination of 
treatment.  What is most important is the behavioral translation.  Indeed, both acute and 
chronic with a wash out period attenuated reversal learning deficits in MAM treated 
offspring.  Taken together, N-acetylcysteine treatment normalizes MAM-induced deficits 
in glutathione, ex vivo measures of cystine-glutamate exchange and attenuates MAM-
induced deficits in reversal learning.  A remaining question is when do changes in system 
xc
- occur during neurodevelopment?     
 
Juvenile measures of system xc- in MAM treated offspring:  Juvenile testing of system xc- 
was examined to determine when altered glutathione concentrations and cystine-
glutamate exchange emerge during development.  While there was a modest decrease that 
did not reach significance in tissue prefrontal glutathione levels in juveniles (Figure 
3.10a), there was a significant increase in ex vivo potential for cystine-glutamate 
exchange similar to adults (Figure 3.10b).  This may suggest an earlier developmental 
glutathione deficit causing a compensatory upregulation of system xc-.  Indeed depleted 
glutathione has shown to increase xCT and functional cystine-glutamate exchange (Seib 
et al., 2011).  Further, this may be sufficient to restore glutathione concentrations at this 
age but after puberty, with increased antioxidant demand as a result of aging (for review 
see Hybertson et al., 2011) or another factor preventing elevated cystine-glutamate 
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exchange, is unable to do so.  Interestingly, other labs have reported shifts in behavior 
between juveniles and adults of MAM treated offspring.  Locomotor hyperstimulation to 
amphetamine and NMDA receptor antagonists only occurs after puberty while social 
interaction deficits are evident prior to puberty, similar to human schizophrenia 
development (Le Pen et al., 2006; Lieberman et al., 2001).  Attempts at juvenile set 
shifting were conducted however the animals had difficulties in attending to the task.  
This suggests some process is occurring during puberty allowing additional symptoms to 
emerge.  Evidence presented here indicates a neurodevelopmental shift between 
adolescence and adulthood that may contribute to behavioral manifestation of symptoms 
associated with schizophrenia in MAM treated offspring. 
 
Contribution of glutathione and glutamate to neurotransmission:  An remaining question 
is: how does N-acetylcysteine improve MAM-induced deficits in reversal learning?  As 
described above, acute and chronic with a wash treatment normalizes glutathione and 
chronically restores ex vivo cystine-glutamate exchange.  Glutathione is the main 
antioxidant in the central nervous system and regulates redox potentials (Cooper and 
Kristal, 1997; Sies, 1999; Dringen, 2000).  NMDA receptor currents are potentiated when 
glutathione reduces the NMDA receptor extracellular redox site (Kohr et al., 1994; 
Lipton et al., 2002).  Interestingly, reduced glutathione levels leads to oxidation and 
hypoactivity of the NMDA receptor (Steullet et al., 2006); this is important given the 
critical role NMDA receptor activity has in neurotransmission.  N-acetylcysteine also 
stimulates system xc- elevating extrasynaptic glutamate to a level capable of activating 
mGluR3/2 receptors thereby also regulating synaptic neurotransmission (Kau et al., 2008; 
85 
 
Baker et al., 2008; Baker et al., 2002b; Moran et al., 2005).  This is important since 
studies in the medial prefrontal cortex have shown low or absent slow and fast local field 
potential oscillations in MAM treated offspring (Goto and Grace, 2006) which suggest 
disruption of network synchrony; schizophrenics have evidence of abnormal network 
synchrony as well (Steriade et al., 1993; Traub et al., 1998).  Further, studies in the 
hippocampus have shown increased neuronal excitability (Lodge and Grace, 2007; 
Sanderson et al., 2012).  This is hypothesized to occur by reduced GABAergic 
interneuron activity leading to disinhibition of pyramidal cells in MAM treated offspring 
(Lodge et al., 2009; Gill et al., 2011; Sanderson et al., 2012) which interestingly is also 
observed in schizophrenics (for review see Lewis et al., 2012).  Disinhibition of 
pyramidal neurons results in network desynchronization which is necessary for gamma 
oscillations and cognition (Cobb et al., 1995; Sohal et al., 2009; Cardin et al., 2009; 
Howard et al., 2003; Tallon-Baudry et al., 2004).  While GABA interneurons regulate 
pyramidal neuron activity, system xc- also has the capacity to regulate pyramidal neurons 
through modulation of neurotransmission by stimulation of mGluR2/3 (Conn and Pin, 
1997; Baker et al., 2002b; Baker et al., 2003; Baskys and Malenka, 1991; Chaki and 
Hikichi, 2011). 
Figure 3.11 proposes circuitry in a “normal” (A) and MAM (C) prefrontal cortex 
with a typical (B) and atypical (D) synapse onto a pyramidal dendritic spine.  Note the 
positioning of basket cell parvalbumin positive GABAergic interneurons on soma body 
modulating pyramidal neuron activity and system xc- on astrocytes modulating input onto 
pyramidal neurons.  Both systems regulate pyramidal neuron excitability allowing for 
synchronization and modulation of projections from the region.  GABAergic interneurons 
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are necessary to regulate pyramidal neurons for network oscillations (for review see 
Lewis et al., 2012) and system xc- has been shown to modulate neurotransmitter release 
(Baker et al., 2002b).   
Figure 3.11 Neural circuitry and synaptic connections within brain regions implicated in schizophrenia 
such as the hippocampus and prefrontal cortex.  (A, C) Pyramidal neurons labeled with a P are the main 
excitatory output of the region and receives inputs from other neurons within and outside the structure 
indicated by black lines which can be stimulatory, inhibitory or modulatory.  Fast spiking basket cell 
parvalbumin containing GABAergic interneurons (dark gray marked with G are uniquely positioned to 
inhibit the soma of pyramidal neurons to modulate neuronal activity.  X indicates a nonspecific neuron 
within the region aiding in the synchronization of the circuit.  Normal circuitry is indicated in panel A 
whereas schizophrenic or MAM hypothesized abnormal circuitry is in C.  Notice a decrease in 
GABAergic activity subsequently leading to enhanced pyramidal cell output and desynchronization.  
Panels B and D depict the synaptic cleft in the box from panels A and C respectively.  The presynaptic 
neuron may release neurotransmitters such as glutamate (G), dopamine and GABA.  System xc- 
exchanges glutamate for cystine (C), allows for glutathione (GSH) synthesis and tonic tone on 
metabotropic group II glutamate receptors (2/3) to modulate synaptic neurotransmitter release.  Panel B 
indicates a typical synapse whereas panel D is the hypothesized schizophrenic and MAM synapse.       
 
D C 
B A 
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Conclusion:  One interpretation of the data is that some yet unknown event or process 
prevents normal glutathione levels early in development.  A compensatory response is 
upregulation of cystine-glutamate exchange to elevate intracellular cystine promoting 
glutathione synthesis.  While this appears to compensate for juvenile glutathione levels, it 
is insufficient in adulthood as evidence from decreased glutathione in the presence of 
increased potential for cystine-glutamate exchange.  Further, N-acetylcysteine restores 
glutathione when administered in adulthood and alleviates MAM-induced cognitive 
deficits in reversal learning.  This is possible due to restored glutathione potentiating 
NMDA receptor activity or through increased tone on mGluR2/3 receptors modulating 
synaptic neurotransmitter release likely both aiding in synchronization of pyramidal cells 
necessary for cognitive function. 
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IV. SIMULTANEOUS STIMULATION OF CYSTINE-GLUTAMATE 
EXCHANGE AND METHYLAZOXYMETHANOL ACETATE 
ADMINISTRATION: A TWIST ON A NEURODEVELOPMENTAL 
MODEL OF SCHIZOPHRENIA 
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Introduction 
 
 While the exact etiology of schizophrenia remains elusive, the 
neurodevelopmental hypothesis which posits an environmental insult during pre or 
postnatal neurodevelopment contributes to the symptoms of schizophrenia has emerged 
as likely contributing to the pathophysiology of schizophrenia (Weinberger, 1987; 
Marenco and Weinberger, 2000; Rapoport et al., 2005).  Neurodevelopment is a highly 
regulated process relying on specific sequences of events and molecular machinery for 
normal development (Lewis and Levitt, 2002).  Additionally, the neurotransmitters 
glutamate and GABA have been shown to have a crucial modulatory effect on migrating 
neuroblasts (Behar et al., 1998; Behar et al., 1999) (Behar et al., 2000; Hirai et al., 1999; 
Manent et al., 2005), importantly, nonvesicular neurotransmitter release drives neuronal 
migration.  In support, munc18-1 and munc13-1/2 knockout mice which are incapable of 
vesicular neurotransmitter due to loss of vesicle priming, display normal cortical layering 
and synapse formation (Verhage et al., 2000; Varoqueaux et al., 2002).   
 Interestingly, the cystine-glutamate antiporter, which exchanges one extracellular 
cystine for one intracellular glutamate is capable of nonvesicular glutamate release 
(Baker et al., 2002b) and is thought to be expressed on immature neurons (Murphy et al., 
1989; Murphy et al., 1990).  While there are few if any studies identifying the specific 
source of nonvesicular glutamate or the contribution of system xc- in neuronal migration, 
research has shown the critical role system xc- has in postsynaptic development in 
Drosophila.  Specifically, system xc- has been shown to impact postsynaptic glutamate 
receptor expression (Featherstone et al., 2002; Augustin et al., 2007).   
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 This chapter utilizes the DNA methylating agent methylazoxymethanol acetate 
(MAM) (Nagata and Matsumoto, 1969) which has been shown to be an antimitotic agent 
(Dambska et al., 1982; Jongen-Relo et al., 2004), effect neuronal migration (Hoffman et 
al., 1996; Dehmelt and Halpain, 2004) and neuronal organization (Matricon et al., 2010).  
Furthermore, when given on gestational day 17 offspring have positive, negative and 
cognitive deficits similar to schizophrenia (Flagstad et al., 2004; Gourevitch et al., 2004; 
Flagstad et al., 2005; Le Pen et al., 2006; Moore et al., 2006; Featherstone et al., 2007); 
and specifically, as shown in Chapter 3, deficits in reversal learning.  Also, while MAM-
induced deficits in reversal learning are attenuated by adult stimulation of system xc- by 
N-acetylcysteine, complete reversal of the symptoms was not observed.  Since evidence 
suggests MAM inhibits neuronal migration and extrasynaptic glutamate stimulates 
migration, the goal of this chapter is to ascertain whether stimulation of system xc- at the 
time of MAM insult is capable of reversing behavioral and neurochemical changes 
observed in MAM treated offspring.  
 
 The primary goal of this chapter is to determine whether in utero stimulation 
of system xc- by N-acetylcysteine is capable of reversing MAM-induced deficits in 
adult offspring. 
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Materials and Methods 
 
Methylazoxymethanol Treatment: Pregnant Sprague-Dawley rats were given twice 
daily injections of N-acetylcysteine (0 or 60 mg/kg, IP; Sigma Chemical Co., St Louis, 
MO) dissolved in isotonic saline with NaOH to bring the pH to 7.0, beginning gestational 
day 17 and continuing until day 20.  On gestational day 17 an acute injection of 
methylazoxymethanol acetate was also administered (22 mg/kg, IP; MRIGlobal Chemical 
Carcinogen Repository, Kansas City, MO).  Following vaginal birth all mothers and 
offspring were left undisturbed until weaning on postnatal day 22.  Male offspring were 
single caged for testing as adults (PND 60+). 
Attentional Set Shifting: The maze consisted of four-arms (60 x 20 x 12 cm) in the 
shape of an X connected by a center area (12 x 12 cm); constructed of black Plexiglas 
with a movable wall to block an arm to form a “T” configuration.  Dividers at the end of 
each arm concealed the sugar pellet reward such that the rat was unable to see it from the 
center of the maze. The visual cue, when used, was laminated with black and white 
diagonal stripes and placed on the floor of an arm.  Prior to habituation, rats were handled 
for five minutes each day for seven days and food deprived to 85% of their free-feeding 
weight.  The day before habituation, each rat was given approximately 30 sugar pellets in 
their home cage to acquaint them with the pellets.   
Habituation: Day one, 5 pellets were placed in each arm, 3 throughout the length of the 
arm and 2 behind the divider at the end.  The rat was placed in the center of the maze and 
allowed to freely explore for up to 15 minutes.  On the second day, 3 pellets were placed 
in each arm, one in the center, the other 2 behind the divider and the rats freely explored 
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for up to 15 minutes.  On the third day and all remaining days till criteria was achieved, 
one pellet was placed behind the divider in each arm.  After the rat consumed a pellet 
behind the divider on any day, he was picked up and placed at the entrance to another 
baited arm to habituate him to handling within the maze.  If the rat consumed all sugar 
pellets on any day, the maze was rebaited with the following habituation day’s 
configuration or with 4 pellets, one behind each divider after habituation day 2.  After the 
maze was rebaited 3 times and all pellets consumed within 15 minutes, criteria was met 
and turn bias was run the following day.  If the rat did not consume all sugar pellets 
within 15 minutes, he continued habituation daily until he met criteria.   
Turn bias: During turn bias and testing, one arm was blocked with the movable wall to 
form a “T” configuration with the visual cue in one of the side arms.  In turn bias, both 
side arms were baited with sugar pellets behind the dividers.  The rat was placed in the 
stem arm at the bottom of the “T” and allowed to enter either arm; after consuming the 
pellet he was placed back in the stem arm and again allowed to enter either arm.  If he 
entered the same arm again, he was returned to the stem arm until he turned into the 
opposite arm and ate the remaining sugar pellet.  When he successfully ate both sugar 
pellets, he was placed back in his home cage signaling the end of the trial.  The next trial, 
the rat began from a different arm such that over 7 trials, the rat started from each of 3 
arms 2 times and the remaining arm once and the visual cue was placed in either the right 
or left arm as equally as possible.  Inter-trial time was about 10 seconds to rebait the 
maze.  The direction the rat turned first the most out of 7 trials was considered his turn 
bias for the rest of testing.   
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Testing: As in turn bias, one arm was blocked with the movable wall, either the right or 
left arm contained the visual cue and the rat began in the stem arm.  Trials were grouped 
into a block of 12 with the stem arm in arms 1-3 as shown in Figure 3.2.  In the probe 
trial, arm 4 was the stem arm and the visual cue was placed in the turn bias arm.  Within 
treatment groups, the probe arm switched such that at least one animal in each group used 
each arm as the stem arm for the probe trial.  Each testing day required the following:  
• 10 consecutive correct trials using the 12 trial block in stem arms 1-3 
• 1 correct probe trial from stem arm 4 
• If correct probe trial, testing was complete 
o If incorrect probe trial 
 5 consecutive correct trials using the 12 trial blocks 
 1 correct probe trial from stem arm 4 
 This continues till correct probe trial 
Day 1: Visual-cue learning; see Figure 3.3a:  On day one, the rat was trained in a simple 
discrimination task to attend to the visual cue such that the food reward was placed in 
each arm with the visual cue 50% of the time.  Turing towards the visual cue and 
attaining the reward was a correct choice.  In the probe trial the rat turned towards the 
visual cue. 
Day 2: Attentional Set Shift; see Figure 3.3b: On day 2 the complex task of an attentional 
set shift required the rat to switch from a visual to a spatial cue with the new strategy for 
reward turning into the arm opposite of his turn bias.  The probe trial required the rat to 
turn in the opposite direction of the visual cue. 
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Day 3: Reversal learning; see Figure 3.3c: Reversal learning required the rat to enter the 
arm opposite the strategy from day 2 such that the rats turn bias arm now contained the 
food reward and the rat turned towards the visual cue on the probe trial.  
Tissue Glutathione Analysis: Animals were rapidly decapitated (PND 100+) and 
punches taken from the medial prefrontal cortex.  The tissues were homogenized in a 4:1 
dialysis buffer(5 mM glucose, 140 mM NaCl, 1.4 mM CaCl2, 1.2 mM MgCl2, 2.2 mM 
KCl, and 0.15% phosphate buffer saline, pH 7.4): mobile phase solution (75 mM 
NaH2PO4·H2O, 1.8 mM C8H17O3Sna, 25 μM EDTA, 0.1% TEA and CH3CN pH to 3.0 
with phosphoric acid).  One fraction was analyzed in the BCA method to determine 
protein content.  The other fraction analyzed thiol content using HPLC with EC detection 
(Decade II, MagicDiamond electrode set at +1.89V, Antec Leyden, Netherlands).   
14C Cystine Uptake:  Animals were rapidly decapitated and brains extracted.  All tissue 
punches of the prefrontal cortex were treated with TBOA (100 µM) and in the presence 
14C-L-cystine (approximately 0.3 µM).  Experimental groups are MAM or control rat’s 
male offspring with or without N-acetylcysteine treatments as described in each 
experiment (PND 130) in the presence or absence of (S)-4-carboxyphenylglycine (CPG, 
1mM; Tocris-Cooksin, Ellisville, MO).  The punches were washed and solubilized with 
1% SDS.  One fraction (200 uL) of the solubilized tissue was used for determining [14C]-
L-cystine uptake by a scintillation counter.  The other fraction (25 uL) was used to 
determine protein content by the BCA method.  Uptake was measured in counts/µg 
protein.  
Statistics:  MAM vehicle treated offspring were compared to MAM NAC treated 
offspring when tested as adults using t test. 
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Results 
 
 As shown in chapter 3, MAM treatment produced cognitive deficits and changes 
in system xc- in adult offspring.  N-acetylcysteine treatment attenuated the behavioral 
deficits and, in the case of chronic N-acetylcysteine, normalized ex vivo 14C cystine 
uptake.  The animals presented in this chapter received N-acetylcysteine in utero and 
simultaneously with MAM treatment.  Figure 4.1 depicts the ability of in utero N-
acetylcysteine treatment to reverse MAM-induced deficits in reversal learning on day 3 in 
attentional set shifting.  Similar to results observed in Chapter 3, there is no significant 
difference of N-acetylcysteine in MAM offspring on day one (Figure 4.1a; T = 1.12, p > 
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Figure 4.1 Effect of in utero N-acetylcystine on 
MAM induced deficits in attentional set shifting.  
Animals treated in utero with N-acetylcysteine (0 or 
60 mg/kg, IP) and MAM (22 mg/kg, IP) when 
tested as adults (N = 7-8).  While there is no 
significance on day 1 (A) Visual Cue Learning and 
2 (B) Attentional Set Shift, * indicates significant 
improvement from MAM / Veh treated animals in 
reversal learning on day 3 (C) (t test). 
A 
C 
B 
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0.05) or two (Figure 4.1b; T = 1.53, p > 0.05).  Interestingly, whereas adult administration 
of N-acetylcysteine attenuated MAM-induced deficits in reversal learning, in utero N-
acetylcysteine treatment completely reversed MAM-induced deficits (Figure 4.1c; T = 
2.44 p < 0.05) using t test.     
 Measures of system xc- including glutathione and ex vivo 14C cystine uptake with 
in utero N-acetylcysteine treatment are depicted in Figure 4.3.  Figure 4.2a illustrates 
prefrontal cortical tissue glutathione concentrations with no difference between MAM 
vehicle treated animals and MAM-NAC treated animals (T = 0.57 p > 0.05).  Similarly, 
there is no statistical difference between groups when measuring ex vivo prefrontal 14C 
cystine uptake (Figure 4.2b, T = 1.69 p > 0.05).   
 
 
  
Figure 4.2 Effect of in utero N-acetylcystine on MAM-induced modifications in system xc- activity.  N-
acetylcysteine in utero does not alter adult MAM-induced tissue prefrontal glutathione concentrations (N 
= 14 and 5) but shows a slight but non-significant increase in ex vivo 14C cystine uptake (N = 5 per group) 
using t test. 
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Discussion  
 
 There is a great amount of evidence supporting the neurodevelopmental 
hypothesis of schizophrenia (Weinberger, 1987; Chua and Murray, 1996; Marenco and 
Weinberger, 2000; Lewis and Levitt, 2002; Rapoport et al., 2005; Brown, 2011).  This 
chapter investigates whether in utero stimulation of system xc- is capable of reversing 
behavioral deficits induced by the antimitotic agent MAM.  As shown in Chapter 3 and 
here, MAM induces cognitive deficits in the attentional set shifting reversal learning task.  
As shown in Chapter 3, acute and subchronic adult administration of N-acetylcysteine 
attenuates MAM-induced cognitive deficits (Figure 3.4).  Interestingly, N-acetylcysteine 
in conjunction with MAM administration in utero at the time of cortical neurogenesis and 
neuronal migration is able to completely reverse MAM-induced deficits in reversal 
learning.  This occurs without significant differences in glutathione and system xc- 
activity measures.  These data raise an interesting question, what is N-acetylcysteine 
doing in utero to reverse MAM-induced behavioral deficits in reversal learning?    
To address this, it is necessary to understand the neurodevelopmental effects of 
MAM; it remains unclear the precise neuropathology induced by MAM.  Studies 
conducted as early as the 60’s identified the DNA methylating properties of MAM 
(Nagata and Matsumoto, 1969).  Further research showed that MAM targets and inhibits 
cells undergoing active mitosis (Cattabeni and Di Luca, 1997; Hoareau et al., 2006).  
Following studies investigated timing of MAM administration and found that when given 
on gestational day 14 or 15, which coincides with early neuronal mitosis, MAM targets 
neuroepithelial cells undergoing active mitosis without effect on neuronal precursors or 
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post-mitotic migrating cells (Cattaneo et al., 1995).  Further, it has a 12-24 hour window 
of activity emphasizing the importance of timing of injection, also, there is no known 
effect on other organs and it does not alter gestational parameters of the dam including 
gestation time and litter size (Matsumoto et al., 1972; Balduini et al., 1991).  Before or on 
gestational day 15, treatment was found to produce broad reductions in brain weight 
presumably due to anti-proliferative actions of MAM (Dambska et al., 1982; Jongen-Relo 
et al., 2004).  In the last decade, more labs administer MAM on gestational day 17; 
whereas day 15 affected many structures, day 17 treatment selectively targets regions that 
have been associated with schizophrenia including the prefrontal cortex, hippocampus 
and mediodorsal thalamus (Flagstad et al., 2004; Moore et al., 2006; Le Pen et al., 2006).  
Further, day 17 treatment produces similarities in behavioral symptoms to schizophrenia 
including deficits in sensorimotor gating, social interaction, hypersensitivity to 
amphetamines and NMDA receptor antagonists and cognitive impairments in adult 
offspring (Moore et al., 2006; Le Pen et al., 2006; Featherstone et al., 2007; Flagstad et 
al., 2005). 
 It is widely accepted that MAM is a DNA methylating agent and targets cells 
undergoing mitosis.  Another less widely studied effect of MAM is the ability to affect 
neurite outgrowth, possibly by methylating the DNA of proteins necessary for growth.  In 
support, MAM treated offspring have smaller dendrites with fewer branches and spines 
(Singh, 1980; Dambska et al., 1982) although it should be noted that MAM was 
administered on gestational day 15.  However, when MAM was administered on cultured 
embryonic day 18 post mitotic hippocampal slices there were significant reductions in 
neurite outgrowth leading to decreased dendrite and axon length with no change in cell 
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viability.  They showed a nonspecific process for depleting microtubule proteins 
including microtubule-associated protein 1B (MAP1B) and MAP2 which are required for 
neurite outgrowth (Hoffman et al., 1996; Dehmelt and Halpain, 2004).  This post mitotic 
effect of MAM explains why there is no change in neuronal number with a corresponding 
decrease in volume and increase in cell density seen in gestation day 17 treated offspring 
in the prefrontal cortex and areas of the hippocampus (Moore et al., 2006; Matricon et al., 
2010).  Indeed, soma size correlates with neuropil length (Gilbert and Kelly, 1975; Lund 
et al., 1975) although MAM gestational day 17 effects on dendrites should be confirmed.  
An additional explanation for decrease in structure size is a change in glial cell number or 
morphology by MAM.  While this has not been investigated in vivo, MAM seems 
unlikely to effect astrocytes; astrocyte cultures showed no effect with MAM application 
(Cattaneo et al., 1995).   
 Lastly, MAM has been shown to lead to abnormal neuronal migration or failure of 
neurons to migrate into their proper position.  In support, pyramidal neuron bodies are 
typically arranged in a well defined columnar organization with axon hillocks in parallel 
orientation (Matricon et al., 2010).  Conversely, MAM treatment on gestational day 17 
results in neuronal disorganization, neuronal clusters and axon hillocks in random 
directions as seen in the hippocampus (Matricon et al., 2010) although the prefrontal 
cortex remains to be examined.  Further, administration on gestational day 15 is used to 
study neuronal migration disorders including epilepsy since MAM induces hippocampal 
neuronal clusters, increased susceptibility to seizures and impaired synaptic plasticity 
(Tschuluun et al., 2005; Paredes et al., 2006; Ramakers et al., 1993).  It is important to 
emphasize the importance of timing of injections.  Earlier MAM exposure on day 15 
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produces a more severe phenotype including greater reductions in brain volume and 
behavioral deficits.  Day 17 treatment is a more accurate representation of schizophrenia 
however whether MAM methylating DNA acts as an antimitotic agent, neurite outgrowth 
inhibitor, causes abnormal neuronal organization or a combination leading to deficits has 
yet to be confirmed.   
 To answer the question of the possible effects of N-acetylcysteine on MAM-
induced deficits, an understanding of the possible effects of in utero N-acetylcysteine is 
also necessary.  N-acetylcysteine is a cysteine prodrug capable of stimulating system xc- 
(Baker et al., 2008; Kau et al., 2008) thereby increasing extracellular glutamate through a 
nonvesicular mechanism (Baker et al., 2002b).  Studies have also shown that 
nonvesicular glutamate plays a central role in cortical neuronal migration during 
development (Manent et al., 2005; Manent and Represa, 2007).  In support, migrating 
neurons express NMDA receptors and application of the NMDA receptor antagonists 
MK801 or APV inhibited neuronal migration in vitro (Hirai et al., 1999; Manent et al., 
2005; Behar et al., 1999).  Also, munc18-1 and munc13-1/2 mutants which lack the 
machinery necessary for vesicular priming and are incapable of synaptic release have 
typical neuronal development and organization (Verhage et al., 2000; Varoqueaux et al., 
2002).  Further, these animals do not survive after birth presumably due to loss of 
synaptic activity indicating that nonvesicular and not vesicular neurotransmitter release is 
necessary for development and organization.  While glutamate derived from system xc- 
has not yet been directly linked to neuronal migration, additional evidence indicates that 
system xc- is a key regulator of postsynaptic development in Drosophila, specifically the 
expression of postsynaptic glutamate receptors (Featherstone et al., 2002; Augustin et al., 
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2007).  Taken together, gestational nonvesicular glutamate impacts neurodevelopment 
and abnormal signaling can effect neuronal migration and synaptic formation, similar to 
organizational deficits observed in MAM treated offspring (Matricon et al., 2010).   
A potential answer to why N-acetylcysteine is reversing cognitive deficits can 
now be put forth.  MAM appears to be disrupting cortical neuronal migration and or 
cellular organization leading to a decrease in soma and dendritic size in the absence of 
changes in neuronal expression (as indicated by changes in density and total volume 
without reductions in expression (Moore et al., 2006)) although there have been no 
reports examining cellular organization in MAM treated offspring in the prefrontal 
cortex, neuronal disorganization was observed in the hippocampus (Matricon et al., 
2010).  This is likely occurring via the known mechanism of MAM on DNA methylation 
of proteins involved in neuronal migration.  N-acetylcysteine, through stimulation of 
system xc- elevating extracellular glutamate, either counteracts, restores or in general 
promotes neuronal migratory pathways.  The resulting effect of N-acetylcysteine before, 
during and after MAM administration partially restores neuronal migration and cortical 
organization to normalize behavioral deficits.  Since glutathione and system xc- 
dependent uptake in the prefrontal cortex are not normalized to control levels, it is 
unlikely that N-acetylcysteine completely reverses the effects of MAM.  Of note is the 
upregulation depicted by no difference in MAM alone and MAM N-acetylcysteine 
treated offspring in ex vivo tissue punches of system xc- dependent cystine uptake is only 
capable of maintaining what is considered normal rates of cystine-glutamate exchange in 
MAM treated offspring.  Without this upregulation, there would likely be further 
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depression of glutathione levels.  Additional research is needed to fully understand the 
ability of N-acetylcysteine to reverse MAM-induced changes in behavior and system xc-. 
 This chapter raises a very interesting question, is in vivo gestational stimulation of 
system xc- sufficient to reverse behavioral deficits in a neurodevelopmental model of 
schizophrenia?  These studies examined reversal learning and suggest that it is capable; 
however, further research of additional MAM-induced behavioral abnormalities will need 
to be conducted.  Furthermore, studies examining the structure and function of all cortical 
regions contributing to behavioral symptoms of schizophrenia will identify the impact of 
altered system xc- activity.        
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V. ACUTE SULFASALAZINE TREATMENT PRODUCES DEFICITS 
SIMILAR TO THOSE OBSERVED IN SCHIZOPHRENIA  
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Introduction 
 
 Schizophrenia is a lifelong disorder with positive symptoms (hallucinations, 
delusions, paranoia), negative symptoms (social deficits, anhedonia) and cognitive or 
executive functioning deficits (behavioral flexibility, learning, memory, attention).  
Additionally, most patients have anxiety and depression in conjunction with the core 
symptoms (Huppert et al., 2001; Braga et al., 2005).  Historically, dopamine was 
hypothesized to underlie schizophrenia since traditional antipsychotics are group two 
dopamine receptor antagonists (Snyder, 1976) however these medications effectively 
treat the positive symptoms with little to no therapeutic effect on negative or cognitive 
deficits (Coyle, 2006).  Accumulating evidence has since implicated abnormal 
glutamatergic activity, particularly a hyperglutamatergic state, contributing to symptoms 
of schizophrenia.  In support, research has shown that NMDA receptor antagonists which 
produce a schizophrenic like state in healthy humans and rodents and exacerbation of 
symptoms in schizophrenics (Luby et al., 1959; Pearlson, 1981; Javitt and Zukin, 1991; 
Krystal et al., 1994; Malhotra et al., 1997a) primarily targets and suppresses activity of 
GABAergic interneurons due to their fast spiking properties requiring a greater frequency 
of NMDA receptor activiation resulting in unregulated pyramidal cell activation and 
glutamate release (Moghaddam et al., 1997; Moghaddam and Adams, 1998; Kinney et 
al., 2006; Homayoun and Moghaddam, 2007; Lewis et al., 2012).   
 System xc- appears to be a key component in the regulation of excitatory signaling 
in the normal and pathological brain.  Cystine uptake in exchange for glutamate export is 
important for the antioxidant glutathione synthesis (Bannai, 1984; Sies, 1999).  Further, 
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extrasynaptic glutamate provides tone on group II metabotropic glutamate receptors 
thereby inhibiting synaptic neurotransmitter release (Battaglia et al., 1997; Moran et al., 
2005).  Data suggest that the activity of system xc- may be altered in the dorsolateral 
prefrontal cortex of individuals with schizophrenia.  Specifically, schizophrenia is 
associated with a significant reduction in glutathione levels coupled with a modest but 
significant change in the protein levels of xCT, which is the active subunit of system xc-, 
in the dorsolateral prefrontal cortex (Do et al., 2000; Gawryluk et al., 2010; Raffa et al., 
2011; Baker et al., 2008).  System xc- is positioned to regulate postsynaptic activity, and 
when modulating synapses on dendritic spines of pyramidal neurons, is able to modulate 
pyramidal cell excitability.  Reduced cystine-glutamate exchange would therefore 
decrease group II metabotropic glutamate activity and cause a hyperexcitable 
postsynaptic pyramidal neuron resulting in elevated pyramidal cell activity and a 
hyperglutamatergic state potentially leading to schizophrenic-like symptoms.   
To test this theory, the system xc- inhibitor sulfasalazine was administered and 
behavioral measures were performed.  In vitro studies have demonstrated that 
sulfasalazine potently inhibits system xc- thereby depleting extracellular glutamate and 
reducing glutathione (Gout et al., 2001; Chung et al., 2005).  Further, the sulfasalazine 
metabolites sulfapyridine and 5-aminosalicylic acid do not inhibit system xc-.  With oral 
administration, sulfasalazine is rapidly metabolized in the gut.  However, extant data 
suggest that interperitoneal injections penetrate the blood brain barrier since it reduces 
glial primary tumor growth in mice (Chung and Sontheimer, 2009).  This is important 
since other potent inhibitors of system xc- including (S)-4-carboxyphenylglycine are 
unable to penetrate the blood brain barrier.  Therefore sulfasalazine is able to inhibit 
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cystine-glutamate exchange through acute or chronic administration to all examination of 
the contribution of system xc- to behavioral symptoms of schizophrenia. 
The primary goal of this chapter is to assess the impact of adult central 
nervous system inhibition of system xc- by sulfasalazine on symptoms associated with 
schizophrenia.  This is important since direct manipulation of cystine-glutamate 
exchange on schizophrenic-like behavioral deficits has not yet been established as 
well as the in vivo properties of the sulfasalazine’s effect on behavior. 
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Materials and Methods 
 
Animals and Surgeries: Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 
300-400 grams were individually housed in a temperature controlled room with a 12-h 
light/dark cycle with food and water ad libitum.  The housing conditions and care of the 
rats were in accordance with the Animal Welfare Act, and all procedures were approved 
by the Marquette University IACUC Committee.  Rats used in the microdialysis studies 
were anesthetized using pentobarbital (50 mg/kg, IP) with atropine sulfate (1 mg/kg, IP) 
pretreatment to limit tracheobronchial secretions.  Bilateral guide cannula (20 gauge, 14 
mm; Plastics One, Roanoke, VA) were implanted using coordinates +3.1 mm anterior, 
±1.0 mm mediolateral to Bregma, and -0.75 mm ventral from the surface of the skull at a 
6° angle from vertical derived from Paxinos and Watson (Paxinos and Watson, 1986).  
Rats were given at least 6 days to recover from surgery prior to testing. 
Drug Treatments: Sulfasalazine (SSZ, 0-16 mg/kg; Sigma Chemical Co., St Louis, MO) 
was dissolved in isotonic saline and NaOH to get into solution; pH remained between 
6.0-8.0.  N-acetylcysteine (0-100 mg/kg; Sigma Chemical Co., St Louis, MO) was 
dissolved in saline with NaOH to bring the pH to 7.0.  Treatment was given as described 
for each experiment below.   
In Vivo Microdialysis:  Microdialysis experiments were conducted as described 
previously (Baker et al, 2002).  Briefly, after a minimum of six days post surgery, 
removable probes extending 2 mm past the guide cannula were inserted through the 
cannulae into the prefrontal cortex and microdialysis buffer (5 mM glucose, 140 mM 
NaCl, 1.4 mM CaCl2, 1.2 mM MgCl2, 2.2 mM KCl and 0.15% phosphate-buffered saline, 
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pH 7.4) was pumped through the probes at one µl/min for at least three hours prior to 
collecting baseline samples.  Afterwards, 20-min samples were collected for four baseline 
samples.  Rats were injected with SSZ (0-16 mg/kg, IP) and samples continued to be 
collected for an additional four hours or 12 samples.  Samples were analyzed for 
glutamate on HPLC coupled to fluorescent detection.  Precolumn derivatization of 
glutamate with o-pthalaldehyde was performed using a Shimadzu LC10AD VP 
autosampler.  The mobile phase consisted of 13% acetonitrile, 100 mM Na2HPO4 and 0.1 
mM EDTA, pH = 5.90.  Glutamate was separated using a reversed-phase column (3 µM; 
100 x 4.2 mm; Bioanalytical Systems, West Lafayette, IN), and detected using a 
Shimadzu 10RF-AXL fluorescence detector with an excitation and emission wavelength 
of 320 and 400 nm, respectively (Baker et al., 2002).  Samples were averaged every forty 
minutes as percent last 40 minute baseline. 
Prepulse Inhibition:  Rats were placed on a platform in a sound attenuating chamber 
(10.875”x14”x19.5”; Hamilton Kinder, CA) that rested on a motion sensing plate.  A 
matching session was conducted to determine the magnitude of the startle response for 
each rat.  This session consisted of a five min habituation period followed by 20 trials; 17 
trials involved the presentation of a single auditory stimulus (pulse stimulus; 50 dB above 
the 60 dB background noise) and three trials in which a prepulse stimulus (12 db above 
background) was presented 100 ms before the pulse auditory stimulus.  Rats were then 
assigned into the various treatment groups based on the magnitude of their startle 
response.  Two days later, an experimental session was conducted to assess sensorimotor 
gating.  Rats were giving SSZ (0-8 mg/kg, IP) 2 hours before testing began.  After a 5 
min habituation period, rats received 58 discrete trials; 26 trials during which the pulse 
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stimulus (50 db above background) was presented alone, 8 trials each in which the pulse 
stimulus was preceded by a prepulse stimulus (2, 6, or 15 db above background) and 8 
background trials with no pulse and only background noise.  The first 6 pulse alone trials 
were not included in the average startle stimulus to achieve a relatively stable level of 
startle reactivity.  The percent of prepulse inhibition was determined as 100-(average 
prepulse startle response/average startle stimulus alone)*100. 
Elevated Plus Maze: Rats were placed in a plus maze of 1cm thick black Plexiglas and 
elevated at a height of 55 cm from the floor.  Two open arms (50.8 cm x 10.2 cm) were 
connected to two enclosed arms (50.8 cm x 10.2 cm x 30 cm) by an open square (12.7 cm  
x 12.7 cm). Rats were given a daily SSZ injection (0-8 mg/kg, IP) two hours before 
testing began for five days.  A different group of rats received acute injection of SSZ (0-8 
mg/kg, IP) two hours before testing and N-acetylcysteine (0-100 mg/kg, IP) one hour 
before testing began.  After treatment, the rat was placed in the elevated plus maze for 5 
minutes, alternating the starting position between facing an open arm and facing a closed 
arm. The session was recorded and an observer blind to treatment recorded the number of 
explorations as defined as the rat placing two feet onto an open arm without fully 
entering said arm.  Entries defined as the rat placing all 4 feet in an open arm. Time of 
entry in the open arm was also recorded from the time the rat placed 4 feet in the open 
arm until two of the rats feet entered the open square.   
Open Field Paradigm: Rats were given an injection of SSZ (0-16 mg/kg) two hours 
before being placed facing the wall at one end of a novel open field apparatus measuring 
150 x 100 x 40 cm for 15 minutes.  The time the animals spent in the center zone defined 
as 15 cm from each wall was recorded as well as total distance moved by EthoVision.     
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Social Interaction:  Rats were habituated to an open field apparatus (150 x 100 x 40 cm) 
on each of two days prior to testing for 15 minutes each.  On test day, rats received an 
injection of SSZ (0-16 mg/kg) two hours before testing and marked with either yellow or 
red markers.  Rats with the same treatment and different colors were placed in each end 
of the open field and allowed to interact for 10 minutes.  Social interaction was defined as 
the amount of time spent within 20 cm and measured with EthoVision.   
Attentional Set Shifting: The maze consisted of four-arms (60 x 20 x 12 cm) in the 
shape of an X connected by a center area (12 x 12 cm); constructed of black Plexiglas 
with a movable wall to block an arm to form a “T” configuration.  Dividers at the end of 
each arm concealed the sugar pellet reward such that the rat was unable to see it from the 
center of the maze. The visual cue, when used, was laminated with black and white 
diagonal stripes and placed on the floor of an arm.  Prior to habituation, rats were handled 
for five minutes each day for seven days and food deprived to 85% of their free-feeding 
weight.  The day before habituation, each rat was given approximately 30 sugar pellets in 
their home cage to acquaint them with the pellets.   
Habituation: Day one, 5 pellets were placed in each arm, 3 throughout the length of the 
arm and 2 behind the divider at the end.  The rat was placed in the center of the maze and 
allowed to freely explore for up to 15 minutes.  On the second day, 3 pellets were placed 
in each arm, one in the center, the other 2 behind the divider and the rats freely explored 
for up to 15 minutes.  On the third day and all remaining days till criteria was achieved, 
one pellet was placed behind the divider in each arm.  After the rat consumed a pellet 
behind the divider on any day, he was picked up and placed at the entrance to another 
baited arm to habituate him to handling within the maze.  If the rat consumed all sugar 
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pellets on any day, the maze was rebaited with the following habituation day’s 
configuration or with 4 pellets, one behind each divider after habituation day 2.  After the 
maze was rebaited 3 times and all pellets consumed within 15 minutes, criteria was met 
and turn bias was run the following day.  If the rat did not consume all sugar pellets 
within 15 minutes, he continued habituation daily until he met criteria.   
Turn bias: During turn bias and testing, one arm was blocked with the movable wall to 
form a “T” configuration with the visual cue in one of the side arms.  In turn bias, both 
side arms were baited with sugar pellets behind the dividers.  The rat was placed in the 
stem arm at the bottom of the “T” and allowed to enter either arm; after consuming the 
pellet he was placed back in the stem arm and again allowed to enter either arm.  If he 
entered the same arm again, he was returned to the stem arm until he turned into the 
opposite arm and ate the remaining sugar pellet.  When he successfully ate both sugar 
pellets, he was placed back in his home cage signaling the end of the trial.  The next trial, 
the rat began from a different arm such that over 7 trials, the rat started from each of 3 
arms 2 times and the remaining arm once and the visual cue was placed in either the right 
or left arm as equally as possible.  Inter-trial time was about 10 seconds to rebait the 
maze.  The direction the rat turned first the most out of 7 trials was considered his turn 
bias for the rest of testing.   
Testing: As in turn bias, one arm was blocked with the movable wall, either the right or 
left arm contained the visual cue and the rat began in the stem arm.  Trials were grouped 
into a block of 12 with the stem arm in arms 1-3 as shown in Figure 3.2.  In the probe 
trial, arm 4 was the stem arm and the visual cue was placed in the turn bias arm.  Within 
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treatment groups, the probe arm switched such that at least one animal in each group used 
each arm as the stem arm for the probe trial.  Each testing day required the following:  
• 10 consecutive correct trials using the 12 trial block in stem arms 1-3 
• 1 correct probe trial from stem arm 4 
• If correct probe trial, testing was complete 
o If incorrect probe trial 
 5 consecutive correct trials using the 12 trial blocks 
 1 correct probe trial from stem arm 4 
 This continues till correct probe trial 
Day 1: Visual-cue learning; see Figure 3.3a:  On day one, the rat was trained in a simple 
discrimination task to attend to the visual cue such that the food reward was placed in 
each arm with the visual cue 50% of the time.  Turing towards the visual cue and 
attaining the reward was a correct choice.  In the probe trial the rat turned towards the 
visual cue. 
Day 2: Attentional Set Shift; see Figure 3.3b: On day 2 the complex task of an attentional 
set shift required the rat to switch from a visual to a spatial cue with the new strategy for 
reward turning into the arm opposite of his turn bias.  The probe trial required the rat to 
turn in the opposite direction of the visual cue. 
Day 3: Reversal learning; see Figure 3.3c: Reversal learning required the rat to enter the 
arm opposite the strategy from day 2 such that the rats turn bias arm now contained the 
food reward and the rat turned towards the visual cue on the probe trial.  
ERRORS: Day 2:  As stated above, trials were blocked into groups of 12 with the visual 
cue in each arm 50% of the time.  On day two, within a group of 4 in which the visual 
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cue was placed in the opposite arm of the strategy for the day, until the animal made a 
correct choice more than 50% of the time (i.e. 2 or more correct choices within the group 
of 4) the errors were counted as perseverative signifying the inability to disregard a 
previously learned strategy.  After the animal correctly choose the non-visual cue arm at 
least 50% of the time errors were counted as regressive meaning the inability of the 
animal to maintain a new strategy after perseveration had ceased.  If the animal choose 
the incorrect arm and it did not have the visual cue, the error is a never reinforced error 
since the arm had not been associated with a reward.  This measured how quickly the 
animal phased our incorrect strategies.  
Errors: Day 3: Reversal learning Similar to day 2 errors, the trials were grouped into 4  
Since day three tested reversal learning the animals were required to turn in the opposite 
arm from day two on every trial.  Therefore, every 4 trials were grouped together, when 
the rat choose the correct arm more than 50% of the time the errors were no longer 
considered perseverative and instead regressive.  Additionally, whether the animal went 
towards the visual cue or away was recorded.   
Statistics:  With 3 or more groups analysis was conducted with variance (ANOVA) with 
each drug treatment as a between-subject factor and further analyzed using Tukey HSD 
unless otherwise noted.  Experiments comparing 2 groups were analyzed using t test. 
 
  
114 
 
Results 
 Sulfasalazine has been shown to inhibit system xc- in vitro and reduce 
extracellular glutamate concentrations in culture and surrounding brain tumors in human 
patients (Chung et al., 2005; Chung and Sontheimer, 2009; de Groot and Sontheimer, 
2011), but there is no evidence of sulfasalazine activity in the absence of glioma tumors 
within the prefrontal cortex.  Figure 5.1 illustrates that an acute intraperitoneal injection 
of sulfasalazine reduced extrasynaptic glutamate in the medial prefrontal cortex as 
measured through microdialysis.  An ANOVA was used to analyze glutamate (% 
baseline) with sulfasalazine as a between subjects measure and time as a within subjects 
measure.  A main effect of treatment after sulfasalazine injection was found (F(3,27) = 3.72 
p < 0.05) without an interaction (F(15,135) = 0.80 p > 0.05).  Given that the purpose of the 
experiment was to determine when and if sulfasalazine reduced glutamate, the main 
effect across each dose of sulfasalazine against time was analyzed.  An ANOVA with 
time as a repeated measure revealed no significance in the control group (SSZ 0, F(6,42) = 
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Figure 5.1 Sulfasalazine (0-16 mg/kg, IP) 
reduces glutamate concentrations in the 
medial prefrontal cortex. A) depicts % 
baseline glutamate levels across the 
experiment. Arrow is time of injection.  
Line from time 120-180 indicates when 
behavioral testing is conducted for later 
experiments. N of 7-8 per group. * 
indicates a significant main effect of time 
from baseline within treatments p < 0.05. 
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1.66 p > 0.05).  Sulfasalazine did have a main effect of all doses (SSZ 4, F(6,36) = 2.46 p < 
0.05; SSZ 8, F(6,42) = 7.27 p < 0.001; SSZ 16, F(6,42) = 8.81 p < 0.001).  Further 
deconstruction of the main effect revealed that during all of the following behavioral 
testing as shown by the solid line from 120-180 minutes SSZ 8 and SSZ 16 treatment 
significantly reduced glutamate in the prefrontal cortex. 
Sensorimotor gating reflects the ability of the central nervous system to inhibit 
irrelevant sensory information and allow focus on salient information from the 
environment; deficits in sensorimotor gating occur in schizophrenic patients and prepulse 
inhibition is used to model this phenomenon (Braff et al., 2001b; Geyer et al., 2001; 
Swerdlow et al., 2006; Kumari et al., 2008).  As shown in Figure 5.2, sulfasalazine was 
administered twice daily for five days (8 mg/kg, IP); testing was conducted 2 hours 
following the last injection to examine the effects of sub-chronic inhibition of cystine-
glutamate exchange on sensorimotor gating deficits.  An ANOVA with drug treatment as 
a between subjects measure and prepulse intensity as a repeated measure produced a 
main effect of treatment (F(1,9) = 5.26 p < 0.05) in the absence of a significant interaction 
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Figure 5.2 Effect of sub-chronic 
treatment of sulfasalazine on 
sensorimotor gating.  The data is 
expressed as the mean (+SEM) prepulse 
inhibition displayed by rats receiving 5 
daily injections produced a main effect 
of treatment on prepulse inhibition. (N = 
4-7). * indicates a main effect of 
treatment and significance from SSZ 0. 
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(F(2,18) = 1.10 p > 0.05) indicating that 
subchronic inhibition of system xc- is 
sufficient to produce deficits in 
sensorimotor gating.   
Anxiety, another symptom 
common in schizophrenia and related to 
patients overall satisfaction with life, 
can be measured with the amount of 
time spent in the open arms of the 
elevated plus maze as shown in Figure 
5.3.  As depicted, the amount of time 
spent in the open arms of the maze is significantly reduced with both an acute injection of 
sulfasalazine on day 1 (8mg/kg, IP) and sub-chronic following 5 daily injections with 
testing.  An ANOVA with treatment as a between subjects measure and day of treatment 
as a repeated measure revealed a significant interaction (F(1,6) = 7.76 p < 0.05).  Pairwise 
comparisons revealed a significant difference between SSZ 0 on day 1 and 2 and between 
SSZ 0 and SSZ 8 on day 1 (p < 0.05), with a trend towards significance between SSZ 0 
and SSZ 8 on day 2 (p = 0.07) in the absence of differences with SSZ 8 between days (p 
= 0.83). This indicates that both acute and sub-chronic inhibition of system xc- is 
anxiogenic.  All further sulfasalazine testing was conducted with acute injections. 
  An additional measure of anxiety is the open field paradigm which measures the 
amount of time the animal spends in the center of the maze with a decrease signifying 
anxiety-like behaviors.  In Figure 5.4a animals received an acute injection of 
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Figure 5.3 Effect of acute or sub-chronic 
sulfasalazine treatment on elevated plus maze.  The 
data are shown as the mean (+SEM) time in open arm 
following daily sulfasalazine treatments (0-8 mg/kg, 
IP, N = 4) on day 1 and 5. * indicates significance 
from day 1 SSZ 0 (p < 0.05) and + from day 5 SSZ 0 
p = 0.07 using pairwise comparisons.  
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sulfasalazine (0-16 mg/kg) and the amount of time the animals spent in the center of the 
maze was recorded.  An ANOVA with treatment as a between subjects factor found 
significant differences in the amount of time spent in the center of the maze (F(2,34) = 4.38 
p < 0.05).  Tukey post hoc analyses indicate that both sulfasalazine treatments (8-16 
mg/kg) are significantly different than sulfasalazine 0 (p < 0.05).  Decreased time in the 
center zone is not attributable to a change in locomotor activity since, as depicted  in 
Figure 5.4b, there is no significant 
difference during testing (F(2,34) = 0.02, p > 
0.05).   
Social interaction is a prominent 
negative symptom of schizophrenia and 
measures the amount of time animals 
engage in social behaviors.  Unexpectedly 
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Figure 5.4 Sulfasalazine in the open field paradigm. Animals received an acute injection of sulfasalazine 
(0-16 mg/kg, IP, N = 10-13) and placed in an open field.  A) depicts time spent in the center zone while 
B) represents total locomotion throughout testing.  Data is expressed as the mean (+SEM).  * indicates a 
significant difference from SSZ 0 using Tukey HSD post hoc. 
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Figure 5.5 Sulfasalazine in social interaction.  
Acute sulfasalazine (0-16 mg/kg, IP, N = 5-7) does 
not produce a deficit in social interaction.  
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since it is a prominent negative symptom 
of schizophrenia, as shown in Figure 5.5, 
there are no significant differences in 
social interaction activity following an 
acute injection of sulfasalazine (0-16 
mg/kg, IP) (F(2,16) = 0.12, p > 0.05). 
Since sulfasalazine inhibits 
system xc- the next goal was to test 
whether the behavioral effects could be 
reversed by stimulation of system xc- 
with N-acetylcysteine.  Using elevated 
plus maze, animals received an acute injection of sulfasalazine (0-8 mg/kg, IP) followed 
one hour later by N-acetylcysteine (0-100 mg/kg, IP).   Figure 5.6 depicts time spent in 
open arms.  An ANOVA with treatments as a between subjects factor revealed a 
significant difference (F(3,24) = 16.38 p < 0.01).  Tukey post hoc revealed a significant 
difference between SSZ 0 / NAC 0 and SSZ 0/ NAC 0.  Furthermore, N-acetylcysteine 
reversed the effects of sulfasalazine as both SSZ 0 / NAC   100 and SSZ 8 / NAC 100 
were significant from the sulfasalazine alone treated group. 
Cognitive deficits including working memory, attention and behavioral flexibility 
are the best predictors of functional disability of schizophrenics.  To elucidate the role of 
system xc- in cognitive deficits, acute sulfasalazine was administered prior to each testing 
phase in attentional set shifting which tests visual cue learning, an attentional set shift and 
reversal learning.  An ANOVA was used to analyze cognition with sulfasalazine (8 
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Figure 5.6 Sulfasalazine and N-acetylcysteine in 
elevated plus maze.  Data is expressed as the mean 
(+SEM) of the time spent in the open arms.  
Sulfasalazine (0-8 mg/kg, IP) was given two hours 
and N-acetylcysteine (0-60 mg/kg, IP, N = 4-9) one 
hour before testing. * indicates significant difference 
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mg/kg) as a between subjects factor on each day of testing.  As shown in Figure 5.7, a 
main effect of treatment was found on day two (F(3,50) = 3.55 p < 0.05) and day three 
(F(3,50) = 4.60 p < 0.05) but not day one (Figure 5.7a, F(3,50) = 1.90 p > 0.05).  In Figure 
5.7b, post hoc analysis indicate that on day two, there was a trend towards significance 
between SSZ 0 / NAC 0 and SSZ 8 / NAC 0 (p = 0.08).  Post hoc analysis on day three 
reversal learning revealed sulfasalazine treatment significantly increased the number of 
trials to reach criteria from controls as shown in Figure 5.7c.  Further, N-acetylcysteine 
treatment attenuated sulfasalazine-induced deficits on day three shown by no significant 
difference from N-acetylcysteine alone treated animals.  
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Figure 5.7 Acute sulfasalazine treatment in 
attentional set shifting.  Data represents mean 
(+SEM) of trials to criteria.  Animals received 
sulfasalazine (0-8 mg/kg, IP), and hour later N-
acetylcysteine (0-60 mg/kg, IP, N = 9-21) and 
tested an hour later in (a) visual cue learning on 
day 1, (b) attentional set shift on day 2 and (c) 
reversal learning on day 3.  * indicates significance 
(p < 0.05) using Tukey HSD post hoc.  
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Attentional set shifting allows the analysis of the different types of impairments.  
Perseverative errors are an index of how quickly animals are able to inhibit a previously 
learned strategy which is now incorrect, regressive a measure of the animals ability to 
maintain the new strategy and never reinforced shows the ability of the animal to ignore 
an ineffective strategy.  Figure 5.8a depicts the effect of acute sulfasalazine on set 
shifting specifically increasing the amount of perseverative errors using ANOVA with 
treatment as a between subjects factor (F(3,50) = 3.87 p < 0.05) with no changes in 
regressive or never reinforced errors (F(3,50) = 0.17 and F(3,50) = 0.50, respectively, p > 
0.05).  Post hoc analysis indicates that sulfasalazine vehicle treated animals had increased 
perseverative errors from vehicle treated animals.  Day three reversal learning errors are 
depicted in Figure 5.8b.  An ANOVA with treatment as a between subjects factor reveals 
significance in the regressive towards the visual cue errors (F(3,50) = 2.82 p < 0.05) in the 
absence of significance in perseverative or regressive away from the visual cue errors 
(F(3,50) = 1.13 and F(3,50) = 1.02 respectively, p > 0.05).  Tukey HSD post hoc analysis 
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reveals a trend towards significance for sulfasalazine treated animals compared to 
vehicle. 
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Discussion  
 
 Altered glutamatergic neurotransmission and deficient glutathione may account 
for many of the pathological changes in schizophrenia (Olney et al., 1999; Coyle, 2006; 
Enomoto et al., 2007; Stone et al., 2007; Berk et al., 2008a) although few studies, if any, 
distinguish between synaptic or extrasynaptic glutamate pools.  The primary findings in 
this chapter indicate that inhibition of system xc- is sufficient to produce behavioral 
deficits similar to those observed in schizophrenia.  Importantly, acute sulfasalazine 
treatment reduces medial prefrontal extrasynaptic glutamate for a minimum of four hours.  
Further, inhibition of system xc- produces behavioral deficits in sensorimotor gating, 
measures of anxiety and cognition without effect on other measures of schizophrenia 
including spontaneous locomotion to novel environment or social interaction.  
Collectively, these data further characterize the potential involvement of system xc- in the 
neuropathology of schizophrenic symptoms. 
 Preclinical and clinical reports have shown that administration of N-
acetylcysteine has therapeutic potential for schizophrenic deficits (see Chapters 2, 3, 4;  
Baker et al., 2008; Berk et al., 2008c; Lavoie et al., 2008; Bulut et al., 2009; Carmeli et 
al., 2012).  Chapter 2 provides evidence than phencyclidine-induced deficits are reversed 
by N-acetylcysteine infusion into the prefrontal cortex and this effect was prevented with 
co-administration of the system xc- inhibitor (S)-4-carboxyphenylglycine (CPG) 
suggesting N-acetylcysteine stimulates system xc- to reverse deficits in sensorimotor 
gating.  Chapter 3 and 4 show that system xc- stimulation reverses MAM-induced deficits 
in reversal learning.  Clinically, N-acetylcysteine has been used as an adjunct therapy in 
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the treatment of schizophrenia and shown beneficial effects and improvement in overall 
symptom severity, mismatch negativity and improved prefrontal cortex synchronization 
using EEG recordings (Berk et al., 2008c; Lavoie et al., 2008; Carmeli et al., 2012).  
Authors of these trials suggest that N-acetylcysteine produces therapeutic effects by 
increasing glutathione levels; however, it is likely that N-acetylcysteine stimulates 
cystine-glutamate exchange thereby also exerting an effect on levels of extrasynaptic 
glutamate.  This chapter examined whether system xc- inhibition is sufficient to produce 
behavioral deficits related to schizophrenia. 
Sulfasalazine has been shown in astrocytic cultures to potently inhibit system xc- 
whereas its metabolites, sulfapyridine and 5-aminosalicylic acid fail to do so and in fact 
are anti-inflammatory agents used to treat inflammation in the gut (Gout et al., 2001; 
Chung and Sontheimer, 2009).  These labs have also investigated the ability of 
sulfasalazine to reduce tumor cell growth since primary brain tumors exclusively rely 
cystine uptake by system xc- for glutathione synthesis.  Additionally, elevated 
extrasynaptic glutamate is thought to lead to activated NMDA receptor induced 
excitotoxic neuronal cell death to allow space for tumor growth.  Evidence that 
sulfasalazine penetrates the blood brain barrier includes the observation that chronic 
sulfasalazine treatment limited the growth rate of glial tumors in vivo, an effect 
attributable to central blockade of system xc- (Gout et al., 2001; Chung et al., 2005; Lyons 
et al., 2007).  The microdialysis data presented in this chapter also suggests sulfasalazine 
crosses the blood brain barrier since an acute systemic injection of sulfasalazine dose 
dependently reduces extrasynaptic glutamate in the prefrontal cortex.  This is the first 
report of systemic administration of a system xc- inhibitor leading to a reduction in 
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extrasynaptic glutamate in the prefrontal cortex.  This result is not surprising since 
mRNA of xCT, the active subunit of system xc-, is present in the medial prefrontal cortex, 
the same region microdialysis was conducted in this study (see Chapter 2).  However, 
another study reported no change in baseline extrasynaptic glutamate following system 
xc
-
 inhibition with (S)-4-carboxyphenylglycine (CPG) (Melendez et al., 2005) suggesting 
the possibility that the observed reduction in medial prefrontal glutamate is secondary to 
the main site of sulfasalazine action in a structure which projects to the prefrontal cortex.  
Although this would have to be shown experimentally, sulfasalazine either directly or 
indirectly reduces extrasynaptic medial prefrontal glutamate.  Given the critical role of 
glutamate signaling within the prefrontal cortex and the broad range of systems system 
xc
-
 regulates particularly synaptic signaling and glutathione synthesis (Baker et al., 
2002b; Conn and Pin, 1997; Dringen and Hirrlinger, 2003), it is of little surprise that 
inhibition of cystine-glutamate exchange produces behavioral deficits. 
 Interestingly, system xc- inhibition with sulfasalazine produces deficits in 
sensorimotor gating, models of anxiety and cognitive deficits including attentional set 
shift and reversal learning.  As described in Chapter 2, sensorimotor gating reflects the 
ability of the central nervous system to inhibit irrelevant sensory information and allow 
focus on salient information from the environment; deficits in sensorimotor gating occur 
in schizophrenic patients and prepulse inhibition is used to model this phenomenon (Braff 
et al., 2001b; Geyer et al., 2001; Swerdlow et al., 2006; Kumari et al., 2008).  
Interestingly, sulfasalazine treated animals display sensorimotor gating deficits at lower 
prepulse intensities similar to glutathione deficient mice suggesting the prepulse 
inhibition mediated circuitry  requires a more intense prepulse compared to control 
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animals (Kulak et al., 2011).  Deficits in prepulse inhibition implicate the dorsolateral 
prefrontal cortex since this is a brain region critical for executive functioning and found 
to have altered cortical activation in schizophrenics (Smith and Jonides, 1999; Eisenberg 
and Berman, 2010). 
 Anxiety, while common in many neurological disorders, is present in individuals 
with schizophrenia; studies have shown that anxiety and even depression in patients are 
strongly associated with lower general life satisfaction (Huppert et al., 2001; Braga et al., 
2005).  Two measures of anxiety are employed in this chapter, elevated plus maze and 
open field which both measure the amount of time the animal spends in an open space 
away from the relative safety of walls or enclosed spaces.  The amount of time spent in 
the open arms of the elevated plus maze has been validated as an indicator of anxiety-
related behavior with less time in the open arms signifying increased anxiety (Pellow et 
al., 1985).  Open field measures the amount of time spent in the center of a large open 
space; less time in the center indicates anxiety since traditional anxiolytic compounds 
such as benzodiazepines increase center exploratory behavior (Prut and Belzung, 2003; 
Choleris et al., 2001).  Interestingly, acute inhibition of system xc- with sulfasalazine is 
anxiogenic in both the elevated plus maze and open field paradigm.  Further, subchronic 
daily treatment of sulfasalazine remains anxiogenic in elevated plus maze even after 
repeated testing whereas vehicle treated animals increase the amount of time spent in the 
open arms over time.  Additionally, the effects of sulfasalazine are completely reversed 
with administration of N-acetylcysteine after sulfasalazine treatment in elevated plus 
maze.  This is not surprising since addition of cystine in vitro also reverses sulfasalazine 
effects on system xc- (Gout et al., 2001; Chung et al., 2005).  These results suggest that 
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system xc- contributes to states of anxiety; however the specific brain region and 
neurotransmitter system mediating these behaviors will require further investigations. 
 Of surprise was the inability of sulfasalazine treatment to produce deficits in 
social interaction and to a lesser extent, on locomotion.  Spontaneous locomotor activity 
was not altered with sulfasalazine treatment in a novel environment in the open field 
paradigm; reduced time in the center of the field was not attributable to reduced 
locomotion.  Locomotor activity has been used as an index of the positive symptoms of 
schizophrenia since evidence suggests similar circuitry for psychosis in humans and 
hyperlocomotion in rodents.  In support, compounds shown to enhance dopamine 
signaling such as amphetamine produce psychosis and paranoia in healthy individuals 
and hyperlocomotion in rodents (Robinson and Becker, 1986; Valvassori et al., 2008).  
However, the fact that sulfasalazine does not produce hyperlocomotion is consistent with 
findings that N-acetylcysteine treatment attenuates without complete reversal of 
methamphetamine-induced hyperlocomotion even with a high dose (300 mg/kg, IP) nor 
does it reverse acute cocaine-induced hyperlocomotion at 60 mg/kg, IP (Fukami et al., 
2004; Madayag et al., 2007).  Further, schizophrenia models, including MAM, have 
increased sensitivity to stimulant induced hyperlocomotion in the absence of spontaneous 
hyperlocomotion (Flagstad et al., 2004; Lodge and Grace, 2007; Phillips et al., 2012).  
Social interaction is a very prominent negative symptom of schizophrenia and N-
acetylcysteine reverses phencyclidine-induced deficits thereby suggesting inhibition of 
system xc- would also lead to deficits (Baker et al., 2008).   Surprisingly, acute 
administration of sulfasalazine was insufficient to produce behavioral deficits indicating 
a) social interaction is not directly modulated by system xc- or b) the administration 
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parameters employed here (0, 8 or 16 mg/kg, IP two hours before testing) were not 
sufficient to produce deficits in social interaction and perhaps a higher dose or more 
likely a sub or chronic treatment regimen of sulfasalazine could produce deficits in rodent 
social interaction.  Further investigations need to be conducted to conclusively rule out 
the involvement of system xc- on social behaviors. 
Behavioral flexibility, an additional measure of executive functioning deficient in 
schizophrenics, is thought to be mediated by human dorsolateral prefrontal cortex and 
rodent medial prefrontal cortex (Ravizza and Carter, 2008; Floresco et al., 2009).  
Multiple cortical and subcortical regions form a circuit mediating behavioral flexibility; 
abnormal activity in the different regions produces specific behavioral deficits that can be 
measured using a maze based attentional set shift model (Floresco et al., 2006a; Floresco 
et al., 2006b; Floresco et al., 2008; Ghods-Sharifi et al., 2008).  Whereas MAM 
neurodevelopmental treatment produced deficits in reversal learning in the attentional set 
shifting paradigm, acute sulfasalazine treatment also increased trials to criteria on day 
three (reversal learning) with a  strong trend on day two (attentional set shift).  Prefrontal 
cortical activity has been shown to mediate the set shift on day 2 and the orbitofrontal 
cortex has been linked to reversal learning on day 3 (Floresco et al., 2008; Ghods-Sharifi 
et al., 2008).  Interestingly, this suggests that system xc- contributes to cortical activity in 
both regions; decreased extrasynaptic glutamate has been shown in the prefrontal cortex 
while effects in the orbitofrontal cortex have yet to be examined. The types of errors 
committed by sulfasalazine treated animals further implicates system xc- in the 
modulation of cortical circuitry and activity.  Specifically, a day 2 increase in 
perseverative errors measuring the rats ability to disengage from a previously learned 
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strategy, implies abnormal connections into or out of the prefrontal cortex (Block et al., 
2007).  An increase of day three regressive errors indicates sulfasalazine-induced 
inability to maintain a new strategy; regressive errors towards the visual cue indicate 
impaired ability to overcome a learned non-reward (Ghods-Sharifi et al., 2008).  
Measures in attentional set shifting and the types of errors committed correlate to 
behavioral deficits in schizophrenics that can be measured using the Wisconsin Card 
Sorting test and reversal learning paradigms (Gold et al., 1997; Waltz and Gold, 2007; 
Szoke et al., 2008).  The ability of system xc- to acutely modulate these types of behaviors 
observed in schizophrenics implicates system xc- mediating executive functioning. 
The results presented in this chapter implicate system xc- as a potential underlying 
factor contributing to the pathophysiology of symptoms of schizophrenia.  The 
mechanism of sulfasalazine-induced deficits is likely due to inhibition of system xc- but 
other factors have not been ruled out.  In support, acute sulfasalazine reduces prefrontal 
extrasynaptic glutamate and has been shown to block system xc- in vitro (Figure 5.1, 
(Gout et al., 2001; Chung et al., 2005; Chung and Sontheimer, 2009).  This could a) lead 
to a reduction in glutathione in both astrocytes and neurons since system xc- transports 
cystine which is the rate limiting step in glutathione synthesis and astrocytes provide 
glutathione precursors for neurons (Bannai, 1984; Bridges, 2011; Dringen and Hirrlinger, 
2003), and b) decreased extracellular glutamate reduces tone on metabotropic group two 
glutamate receptors thereby disinhibiting synaptic neurotransmitter release (Baker et al., 
2002b; Mohan et al., 2011).  Unregulated synaptic activity can lead to enhanced post-
synaptic excitation and desynchronization of regional pyramidal cell firing which is 
necessary for cognitive processing (Gonzalez-Burgos and Lewis, 2008).  Whether 
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inhibition of system xc- induces behavioral deficits through decreased glutathione 
synthesis or by depleted extrasynaptic glutamate will need to be further investigated to 
confirm or deny the pathway of acute sulfasalazine treatment on behavioral deficits 
similar to those observed in schizophrenia. 
This chapter examined behavioral measures of adult inhibition of system xc- by 
sulfasalazine on schizophrenia-like symptoms.  Sulfasalazine induces deficits in some 
measures (sensorimotor gating, anxiety and cognition) while having little effect on others 
(hyperlocomotion, social interaction).  This is the first evidence of direct manipulation of 
system xc- leading to symptoms of schizophrenia, and while extremely interesting, will 
need to be further investigated in additional behaviors, potentially non-schizophrenic 
behaviors, as well as mechanistically to understand the potential impact of cystine-
glutamate exchange in a wide range of behaviors and disorders of the nervous system.  
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VI. SULFASALAZINE IN UTERO MODIFIES CYSTINE-
GLUTAMATE EXCHANGE AND BEHAVIOR 
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Introduction 
 
 Abnormal neurodevelopment is hypothesized to contribute to the pathophysiology 
of schizophrenia (Weinberger, 1987; Marenco and Weinberger, 2000; Rapoport et al., 
2005).  In support, prenatal (maternal malnutrition, infection or stress) or perinatal 
(obstetrical complications) insults increases the likelihood of developing schizophrenia.  
Further, motor, social or cognitive deficits are present during childhood before the 
diagnosis which typically occurs after psychosis emerges in late teens to early twenties 
(for review: (Lewis and Levitt, 2002)).  Neurogenesis occurs in utero and is a highly 
regulated process.  Glutamate and GABA are critical neurotransmitters which modulate 
immature neurons migratory pathways and facilitate final positioning and organization 
(Behar et al., 1998; Behar et al., 1999; Behar et al., 2000; Behar et al., 2001; Hirai et al., 
1999; Kihara et al., 2002).  Non-vesicular release of these neurotransmitters act on 
immature neurons NMDA and GABAA ionotropic receptors to facilitate migration 
(Nguyen et al., 2001; Lujan et al., 2005; Manent and Represa, 2007). 
 In the adult brain extrasynaptic glutamate is found in micromolar concentrations 
and are of nonvesicular origin since levels are insensitive to blockade of voltage 
dependent Na+ and Ca2+ receptors (Timmerman and Westerink, 1997; Baker et al., 
2002b).  Further, system xc- has been shown to contribute a significant amount of 
nonvesicular extrasynaptic glutamate in the nucleus accumbens, striatum, hippocampus 
and prefrontal cortex (Baker et al., 2002b; Massie et al., 2011; De Bundel et al., 2011; 
Chapter 5).  System xc- transports one cystine in for every glutamate out into the 
extrasynaptic space (for review see Bridges, 2011).  The contribution of system xc- to in 
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utero nonvesicular glutamate during neurogenesis has not been directly studied however 
system xc- is expressed by immature neurons although it’s role has not been elucidated 
(Murphy et al., 1990).  Sulfasalazine is a potent inhibitor of system xc- (Chung et al., 
2005; Chung and Sontheimer, 2009) and acute administration produces schizophrenic-
like symptoms in rodents (Chapter 5).  Sulfasalazine is capable of crossing the placental 
barrier (Peppercorn, 1984) and the blood-brain barrier (Lyons et al., 2007; de Groot and 
Sontheimer, 2011; Chapter 5).  Using sulfasalazine to inhibit system xc- in utero has not 
been attempted so effective administration parameters and the long-term behavioral 
effects on offspring have not yet been established.   
 This chapter will examine the impact of varying concentrations of sulfasalazine 
on gestation day 17 (same time frame of MAM administration, Chapter 3 and 4) to assess 
whether decreased cystine-glutamate exchange in utero is capable of producing 
schizophrenic-like deficits in adult male offspring.  Specifically, attentional set shifting 
and measures of system xc- will be examined.  The importance of this stems from the lack 
of knowledge on the impact of altered in utero system xc- activity.  Further, cognitive 
deficits including reversal learning are observed in schizophrenics (Waltz and Gold, 
2007; Murray et al., 2008) and poorly treated with current antipsychotics.   
 
 The purpose of this chapter is to assess whether in utero manipulation of 
system xc- is sufficient to produce long lasting changes in cystine-glutamate exchange 
and cognitive measures. 
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Materials and Methods 
 
Sulfasalazine Treatment: Timed pregnant Sprague-Dawley rats were given an acute 
injection of sulfasalazine (0, 8 or 16 mg/kg, IP; Sigma Chemical Co., St Louis, MO) 
dissolved in saline with NaOH on gestational day 17.  Following vaginal birth all mothers 
and offspring were left undisturbed until weaning on postnatal day 22.  Male offspring 
were single caged for testing as adults (PND 60+). 
Attentional Set Shifting: The maze consisted of four-arms (60 x 20 x 12 cm) in the 
shape of an X connected by a center area (12 x 12 cm); constructed of black Plexiglas 
with a movable wall to block an arm to form a “T” configuration.  Dividers at the end of 
each arm concealed the sugar pellet reward such that the rat was unable to see it from the 
center of the maze. The visual cue, when used, was laminated with black and white 
diagonal stripes and placed on the floor of an arm.  Prior to habituation, rats were handled 
for five minutes each day for seven days and food deprived to 85% of their free-feeding 
weight.  The day before habituation, each rat was given approximately 30 sugar pellets in 
their home cage to acquaint them with the pellets.   
Habituation: Day one, 5 pellets were placed in each arm, 3 throughout the length of the 
arm and 2 behind the divider at the end.  The rat was placed in the center of the maze and 
allowed to freely explore for up to 15 minutes.  On the second day, 3 pellets were placed 
in each arm, one in the center, the other 2 behind the divider and the rats freely explored 
for up to 15 minutes.  On the third day and all remaining days till criteria was achieved, 
one pellet was placed behind the divider in each arm.  After the rat consumed a pellet 
behind the divider on any day, he was picked up and placed at the entrance to another 
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baited arm to habituate him to handling within the maze.  If the rat consumed all sugar 
pellets on any day, the maze was rebaited with the following habituation day’s 
configuration or with 4 pellets, one behind each divider after habituation day 2.  After the 
maze was rebaited 3 times and all pellets consumed within 15 minutes, criteria was met 
and turn bias was run the following day.  If the rat did not consume all sugar pellets 
within 15 minutes, he continued habituation daily until he met criteria.   
Turn bias: During turn bias and testing, one arm was blocked with the movable wall to 
form a “T” configuration with the visual cue in one of the side arms.  In turn bias, both 
side arms were baited with sugar pellets behind the dividers.  The rat was placed in the 
stem arm at the bottom of the “T” and allowed to enter either arm; after consuming the 
pellet he was placed back in the stem arm and again allowed to enter either arm.  If he 
entered the same arm again, he was returned to the stem arm until he turned into the 
opposite arm and ate the remaining sugar pellet.  When he successfully ate both sugar 
pellets, he was placed back in his home cage signaling the end of the trial.  The next trial, 
the rat began from a different arm such that over 7 trials, the rat started from each of 3 
arms 2 times and the remaining arm once and the visual cue was placed in either the right 
or left arm as equally as possible.  Inter-trial time was about 10 seconds to rebait the 
maze.  The direction the rat turned first the most out of 7 trials was considered his turn 
bias for the rest of testing.   
 Testing: As in turn bias, one arm was blocked with the movable wall, either the right or 
left arm contained the visual cue and the rat began in the stem arm.  Trials were grouped 
into a block of 12 with the stem arm in arms 1-3 as shown in Figure 3.3.  In the probe 
trial, arm 4 was the stem arm and the visual cue was placed in the turn bias arm.  Within 
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treatment groups, the probe arm switched such that at least one animal in each group used 
each arm as the stem arm for the probe trial.  Each testing day required the following:  
• 10 consecutive correct trials using the 12 trial block in stem arms 1-3 
• 1 correct probe trial from stem arm 4 
• If correct probe trial, testing was complete 
o If incorrect probe trial 
 5 consecutive correct trials using the 12 trial blocks 
 1 correct probe trial from stem arm 4 
 This continues till correct probe trial 
Day 1: Visual-cue learning; see Figure 3.3a:  On day one, the rat was trained in a simple 
discrimination task to attend to the visual cue such that the food reward was placed in 
each arm with the visual cue 50% of the time.  Turing towards the visual cue and 
attaining the reward was a correct choice.  In the probe trial the rat turned towards the 
visual cue. 
Day 2: Attentional Set Shift; see Figure 3.3b: On day 2 the complex task of an attentional 
set shift required the rat to switch from a visual to a spatial cue with the new strategy for 
reward turning into the arm opposite of his turn bias.  The probe trial required the rat to 
turn in the opposite direction of the visual cue. 
Day 3: Reversal learning; see Figure 3.3c: Reversal learning required the rat to enter the 
arm opposite the strategy from day 2 such that the rats turn bias arm now contained the 
food reward and the rat turned towards the visual cue on the probe trial.  
Tissue Glutathione Analysis: Animals were rapidly decapitated (PND 100+) and 
punches taken from the medial prefrontal cortex.  The tissues were homogenized in a 4:1 
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dialysis buffer(5 mM glucose, 140 mM NaCl, 1.4 mM CaCl2, 1.2 mM MgCl2, 2.2 mM 
KCl, and 0.15% phosphate buffer saline, pH 7.4): mobile phase solution (75 mM 
NaH2PO4·H2O, 1.8 mM C8H17O3Sna, 25 μM EDTA, 0.1% TEA and CH3CN pH to 3.0 
with phosphoric acid).  One fraction was analyzed in the BCA method to determine 
protein content.  The other fraction analyzed thiol content using HPLC with EC detection 
(Decade II, MagicDiamond electrode set at +1.89V, Antec Leyden, Netherlands).   
14C Cystine Uptake:  Animals were rapidly decapitated and brains extracted.  All tissue 
punches of the prefrontal cortex were treated with TBOA (100 µM) and 14C-L-cystine 
(approximately 0.3 µM).  Experimental groups are SSZ or control rat’s male offspring 
(PND 100) in the presence or absence of SSZ (500 µM).  The punches were washed and 
solubilized with 1% SDS.  One fraction (200 uL) of the solubilized tissue was used for 
determining [14C]-L-cystine uptake by a scintillation counter.  The other fraction (25 uL) 
was used to determine protein content by the BCA method.  Uptake was measured in 
counts/µg protein.  
Statistics:  Attentional set shifting was analyzed using analysis of variance (ANOVA) 
with treatment as a between subjects variable.  System xc- measures are analyzed with t 
test. 
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Results 
 
 In order to determine whether inhibition of system xc- in utero has a long term 
effect on adult behavior, attentional set shifting measured cognitive functioning in 
sulfasalazine treated offspring as illustrated in  Figure 6.1.  To analyze the effect of 
sulfasalazine on attentional set shifting an ANVOA with treatment as a between subjects 
measure found no significant differences on any of the tasks (day one: F(2,26) = 0.61; day 
two: F(2,26) = 0.188 p > 0.05; day three: F(2,26) = 2.56 p = 0.10).  However, there was a 
trend towards an increase in trials to reach criteria with sulfasalazine 16 mg/kg in utero 
on the reversal learning task. 
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Figure 6.1 Effects of in utero sulfasalazine 
treatment on attentional set shifting.  A) Day 1 
visual cue learning, B) Day 2 attentional set 
shift and C) Day 3 reversal learning.  
Sulfasalazine was given on gestational day 17 
(0-16 mg/kg, IP). Acute inhibition of system 
xc
-
 failed to produce any type of long lasting 
deficits at 8 mg/kg (N = 6), however there 
seems to be a trend towards cognitive deficits 
particularly in reversal learning with 
sulfasalazine 16 mg/kg compared to control  (N 
= 10-11).  All data are presented as mean 
(+SEM). 
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Unlike behavioral effects from in utero sulfasalazine treatment, there are no 
apparent long term changes in system xc- measures in adult offspring.  Only sulfasalazine 
16 mg/kg in utero was tested in these paradigms since there was no behavioral effect in 
attentional set shifting at the 8 mg/kg dose.  In Figure 6.2a there is no effect of in utero 
sulfasalazine treatment on glutathione tissue punches from the prefrontal cortex (T = 1.11 
p > 0.05).  There is also no significant difference in ex vivo system xc- dependent 14C 
cystine uptake in the medial prefrontal cortex.  Figure 6.2b illustrates this effect (T = 1.52 
p > 0.05) using t test. 
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Figure 6.2 In utero sulfasalazine treatment on adult glutathione and system xc- dependent 14C cystine uptake 
in the medial prefrontal cortex.  A) shows no significant difference in tissue punches taken from the medial 
prefrontal cortex on glutathione concentrations (N = 9, 5).  B) indicates no changes in ex vivo cystine uptake 
in the same region (N = 5 per group) using t test. 
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Discussion 
 
 Nonvesicular glutamate release has a central role in cortical neuronal migration 
and organization during development (Behar et al., 1999; Hirai et al., 1999; Manent et al., 
2005; Manent and Represa, 2007).  This chapter examines the impact of in utero 
inhibition of system xc- on long term system xc- activity and behavior in offspring.  
Sulfasalazine administration on gestational day 17 had no long term behavioral effect at 
the lowest dose (8 mg/kg) however there seems to be a modest trend emerging for 
behavioral deficits in the reversal learning task in offspring from a higher dose (16 
mg/kg).  There does not appear to be any long lasting effects from an acute injection on 
gestation day 17 of sulfasalazine on system xc- activity measured through glutathione and 
ex vivo uptake in the prefrontal cortex.  Together, these data indicate that there may be a 
modest long term behavioral deficit from in utero system xc- inhibition without persistent 
changes in system xc- activity. 
 Sulfasalazine treated offspring have normal levels of prefrontal glutathione with 
no apparent change in system xc- activity.  These animals have no deficits in visual cue 
learning or attentional set shift with only a modest yet insignificant deficit in the reversal 
learning task.  This supports the claim that long term changes in system xc- activity 
contributes to cognitive deficits as found in Chapter 3.  MAM treated offspring have a 
long term significant increase in the potential for ex vivo cystine-glutamate exchange 
(present in juveniles and adults) potentially a compensatory response to reduced 
glutathione concentrations.  Offspring also have deficits in reversal learning and adult N-
acetylcysteine treatment is able to attenuate these behavioral deficits (see Chapter 3).  If 
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altered system xc- activity contributes to cognition, why is in utero manipulation of 
system xc- insufficient to produce long term behavioral deficits?   
 Sulfasalazine treated offspring may not have long term behavioral deficits 
because a) altered system xc- activity is unrelated to cognitive deficits.  This seems 
unlikely since N-acetylcysteine attenuates MAM-induced deficits likely by restoration of 
glutathione and system xc- activity and acute sulfasalazine treatment in adults produced 
deficits in cognitive processes (see Chapter 5) likely due to depleted extracellular 
glutamate resulting in unregulated synaptic neurotransmitter release.  These results 
support the involvement of cystine-glutamate exchange to cognitive deficits in attentional 
set shifting.  Or b) the administration parameters employed here (acute sulfasalazine 
injection on gestation day 17) is insufficient to produce long term changes in system xc- 
and behavioral deficits.  This seems more likely since inducing behavioral deficits by in 
utero sulfasalazine treatment has not been attempted and finding the ideal dose, number 
of injections and timing of injections to produce long term changes in cystine-glutamate 
exchange could require a significant amount of work. 
 In utero manipulation of system xc- was hypothesized to produce long term 
changes in behavioral deficits given the critical role glutamate has in neurodevelopment.  
First, sulfasalazine is a potent inhibitor of system xc- activity whereas its metabolites 
sulfapyridine and 5-aminosalicylic are not (Gout et al., 2001; Chung and Sontheimer, 
2009).  Of importance for this chapter is the ability of sulfasalazine to cross the placental 
barrier (Peppercorn, 1984) for fetal penetration of the blood brain barrier.  Inhibition of 
system xc- reduces extracellular glutamate in vitro (Chung and Sontheimer, 2009) and in 
vivo studies show systemic administration of system xc- reduces extracellular glutamate in 
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the prefrontal cortex of adults (see Chapter 5).  It therefore seems likely that sulfasalazine 
is capable of reducing extracellular glutamate in the developing fetus.   
 As stated above, a potential factor limiting the ability of sulfasalazine to produce 
long term deficits is timing of insult. Cortical neurogenesis occurs between gestational 
days 14 to 20 (Bayer et al., 1993).  All cortical principle cells originate from 
neuroepithelial cells lining the ventricles.  Earlier born neurons populate the deepest 
cortical layers while the neurons born later in development form the more superficial 
layers with one exception, layer I neurons adjacent to the pial surface are generated first 
(Sidman and Rakic, 1973; McConnell and Kaznowski, 1991).  Studies with the 
antimitotic agent MAM have shown that treatment on gestation day 17 induces specific 
changes in cortical layers II-IV while leaving the deeper layers V-VI, which are born 
earlier, undisturbed; treatment prior to day 17 leads to reductions in all cortical layers 
(Cattabeni and Di Luca, 1997; Moore et al., 2006) indicating the importance of injection 
timing in neurodevelopmental models of schizophrenia.  Here, sulfasalazine was 
administered on gestation day 17 due to the effects of MAM treatment producing 
schizophrenia-like deficits when administered on day 17.  However, as discussed in 
Chapters 3 and 4, it remains unclear whether MAM’s effects are due to antimitotic 
properties or inhibition of neuronal migration by DNA methylation making in utero 
sulfasalazine timing optimization more difficult since it remains unclear whether 
inhibition of mitosis or migration is ideal to produce long term deficits 
 The ability of sulfasalazine to produce long term deficits was expected given the 
critical role non-vesicular glutamate has in neuronal migration during neurodevelopment.  
Neuroepithelial cells undergo mitosis in the germinal layers lining the ventricular system 
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and must migrate along radial glial cells to their final destination (Sidman and Rakic, 
1973; Hatten, 1993).  Non-vesicular glutamate and GABA have both been shown to 
promote neuronal migration and serve as stop signals when neurons reach their final 
destination (Behar et al., 1998; Behar et al., 1999; Behar et al., 2000; Behar et al., 2001; 
Hirai et al., 1999; Simonian and Herbison, 2001; Kihara et al., 2002).  In support, 
immature neurons express NMDA and GABA receptors and glutamate and GABA are 
detected early in the microenvironment of migrating neurons (Nguyen et al., 2001; Lujan 
et al., 2005; Manent and Represa, 2007).  Further, NMDA antagonists including MK801 
and APV treatment but not other ionotropic glutamate receptor antagonists lead to strong 
impairments in neuronal motility in vitro and in vivo (Behar et al., 1999; Hirai et al., 
1999; Manent et al., 2005).  Work in cerebellar granule cells have shown that NMDA 
receptor activation leads to influx of Ca2+ frequencies necessary for migration and 
insufficient Ca2+ results in loss of movement (Komuro and Rakic, 1993; Kumada and 
Komuro, 2004).  GABAA receptor activation, which has been shown to depolarize 
immature neurons promoting activation of voltage-gated calcium channels and NMDA 
receptors, promotes migration by increasing intracellular Ca2+ concentrations (Ben-Ari et 
al., 1997).  Finally, mutants with genetic deletion of munc18-1 and munc13-1/2, proteins 
necessary for vesicular priming, are incapable of vesicular neurotransmitter release have 
normal cortical layering and synapse formation (Verhage et al., 2000; Varoqueaux et al., 
2002) indicating synaptic neurotransmitter release does not contribute to 
neurodevelopment.  Thus, reduced non-vesicular glutamate has the potential to impair 
neuronal migration and cellular organization.   
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 Given the critical role of glutamate in neurodevelopment and the possible 
contributions of system xc- to extrasynaptic glutamate concentrations, it is interesting that 
xCT knockout mice have a normal appearance, normal lifespan and no changes in 
cortical or hippocampal width (Sato et al., 2005; De Bundel et al., 2011).  As expected, 
there is a decrease in extrasynaptic glutamate but surprisingly, there is comparable 
glutathione concentrations in the hippocampus, striatum and other non-CNS organs such 
as the liver and pancreas (Sato et al., 2005; Massie et al., 2011; De Bundel et al., 2011).  
Behavior measures of xCT mutants include comparable to wild type spontaneous 
locomotion in an open field paradigm and a tendency towards less efficient learning with 
intact reference memory in Morris water maze (De Bundel et al., 2011).  Interestingly, 
mutants have significant deficits in spatial working memory measured in delayed 
alternation Y-maze task (De Bundel et al., 2011); no other behavioral tasks have been 
measured.  The absence of glutathione deficits suggests that behavioral deficits are 
induced by reduced extracellular glutamate or possibly due to abnormal cellular 
organization or circuitry, although this would have to be confirmed.  It would also be 
interesting to evaluate neurodevelopmental processes in the mutants.  As with any genetic 
mutation, there are likely compensatory measures to bring the environment in and around 
a cell to homeostasis making it impossible to assume that a lifetime depletion of cystine-
glutamate exchange would have the same effects as an acute or chronic reduction in 
activity although further studies need to be conducted. 
 As stated above, in utero sulfasalazine treatment does not produce long term 
changes in behavior or system xc- activity.  While it seems unlikely that system xc- 
activity has no effect on cognition (see Chapter 5), it is possible that these administration 
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parameters are insufficient to produce long lasting deficits.  Further, it is possible that 
there is a compensatory upregulation of other nonvesicular glutamate transporters or 
migratory signals in response to insufficient cystine-glutamate exchange.  There are many 
possible explanations for the minimal effect of in utero sulfasalazine; however, the ability 
of sulfasalazine to produce even a modest change in cognitive task is significant in itself, 
has never been shown and will require further characterization.     
  
145 
 
VII. DISCUSSION: 
SCHIZOPHRENIA AND SYSTEM XC- 
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Schizophrenia is a lifelong disorder comprised of a number of symptoms 
including positive (hallucinations, delusions, paranoia), negative (anhedonia, blunted 
affect, social deficits) and cognitive deficits (executive function, behavioral flexibility, 
working memory, attention) (Andreasen, 1995; Elvevag and Goldberg, 2000; Blanchard 
and Cohen, 2006).  The etiology of schizophrenia remains largely unknown however 
current research suggests a combination of multiple factors contributing to schizophrenia 
including a genetic predisposition and pre or postnatal environmental stressors leading to 
abnormal neurodevelopment (Weinberger, 1987; Chua and Murray, 1996; Lewis and 
Levitt, 2002; Lang et al., 2007; Brown, 2011).  Many of the symptoms, particularly the 
cognitive deficits but also the positive and negative symptoms, have been linked to 
abnormal dorsolateral prefrontal cortical activity (Bunney and Bunney, 2000; Callicott et 
al., 2003; Jansma et al., 2004; Aalto et al., 2005; Eisenberg and Berman, 2010).  In 
support, schizophrenics have abnormal pyramidal neuron activation leading to altered 
network oscillatory activity in the dorsolateral prefrontal cortex (Cho et al., 2006; 
Gonzalez-Burgos and Lewis, 2008; Gonzalez-Burgos et al., 2010). 
In the dorsolateral prefrontal cortex schizophrenics have decreased oscillations in 
the gamma range (30-90 Hz) which have been shown to contribute to cognitive deficits 
(Lisman and Idiart, 1995; Lisman, 1999; Howard et al., 2003; Tallon-Baudry et al., 2004; 
Sejnowski and Paulsen, 2006).  Desynchronization is a result of abnormal dorsolateral 
prefrontal cortical pyramidal cell activation.  This is caused by changes in prefrontal 
glutamatergic activity including changes in NMDA receptor activation shown by non-
competitive NMDA receptor antagonists producing all symptoms associated with 
schizophrenia in rodents and healthy individuals (Javitt and Zukin, 1991; Verma and 
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Moghaddam, 1996; Marino and Conn, 2002; Coyle et al., 2003; Vollenweider and Geyer, 
2001; Rung et al., 2005).  Evidence suggests that NMDA receptor antagonists 
preferentially inhibit receptors located on GABAergic interneurons due to their fast 
spiking properties (Jones and Buhl, 1993; Lei and McBain, 2002; Maccaferri and 
Dingledine, 2002; Homayoun and Moghaddam, 2007; Lewis et al., 2012).  Further, 
schizophrenics have shown abnormalities in prefrontal GABAergic interneurons 
(Hashimoto et al., 2003b; Mellios et al., 2009; Fung et al., 2010) suggesting altered 
NMDA receptor mediated GABAergic activity in the dorsolateral prefrontal cortex 
contributing to pyramidal neuron desynchronization and symptoms of schizophrenia.  
Astrocytes have also been shown capable of regulating synaptic plasticity and 
pyramidal cell activity (Barker and Ullian, 2010; Poskanzer and Yuste, 2011).  They are 
uniquely positioned to regulate network synchronization based on the ability of one 
astrocyte to contact approximately 100,000 synapses, pyramidal cell bodies and other 
astrocytes (Bushong et al., 2003; Oberheim et al., 2006).  Communication between 
astrocytes and neurons are critical for normal synaptic functions.  Particularly astrocytic 
glutamate release has been shown to contribute to neuronal oscillatory activity (Fellin et 
al., 2004; Fellin et al., 2006; Carmignoto and Fellin, 2006)  Glutamate is released by 
astrocytes at a concentration sufficient to activate extrasynaptic glutamate receptors 
(Baker et al., 2002b; Fellin et al., 2006; Makani and Zagha, 2007).  System xc- may be a 
critical mechanism whereby astrocytes release glutamate to regulate network activity.  
First, system xc-exchanges one intracellular glutamate for an extracellular cystine (Baker 
et al., 2002b); cystine uptake is the key step in glutathione synthesis (Dringen and 
Hirrlinger, 2003) and externalized nonvesicular glutamate is capable of activating 
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extrasynaptic glutamate receptors particularly mGluR2/3 and NMDA receptors (Baker et 
al., 2002a; Mohan et al., 2011).  Glutathione has been shown to be important in NMDA 
receptor activation by reducing the extracellular redox sites on the NMDA receptor 
potentiating its activity (Kohr et al., 1994; Lipton et al., 2002).  Thus system xc- may 
represent an additional mechanism to regulate network activity based on the capacity to 
release glutamate and modulate synaptic neurotransmitter release through activation of 
mGluR2/3 and NMDA receptors.   
Given the critical role of system xc- for synaptic functioning, altered or diminished 
activity could result in abnormal network synchronization through either 1) a decrease in 
extrasynaptic glutamate or 2) a decrease in glutathione concentrations.  A decrease in 
extrasynaptic glutamate would lead to diminished extrasynaptic glutamate receptor 
activation.  Diminished NMDA receptor activation would alter neuronal intracellular 
functioning (Makani and Zagha, 2007; Hardingham and Bading, 2010) and potentially 
contribute to diminished oscillatory activity (Fellin et al., 2004).  Additionally, reduced 
extrasynaptic glutamate would also decrease activation of metabotropic glutamate 
receptors.  Group II mGluR activation has been shown to negatively modulate 
presynaptic vesicular neurotransmitter release (Conn and Pin, 1997; Xi et al., 2002; 
Melendez et al., 2005).  Therefore, extrasynaptic glutamate released from system xc- may 
regulate synaptic activity and neuronal activation; abnormal exchange could potentially 
lead to abnormal pyramidal neuron activation and synchronization contributing to 
symptoms of schizophrenia.   
System xc- may also contribute to network synchronization via cystine uptake.  
Glutathione synthesis is limited by the availability of astrocytic cysteine (Dringen and 
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Hirrlinger, 2003) and regulates oxidative stress and redox balance (Dringen, 2000).  Of 
particular importance is the ability of glutathione to reduce the extracellular redox site of 
the NMDA receptor to potentiate its activity (Kohr et al., 1994; Sies, 1999; Lipton et al., 
2002).  Given the contribution of NMDA receptor activation on GABAergic interneurons 
to regulate pyramidal network oscillations it is not surprising that deficient glutathione 
concentrations alters short and long term plasticity and induces NMDA receptor 
hypoactivation (Steullet et al., 2006).  Therefore, deficits in glutathione concentrations 
may contribute to abnormal pyramidal neuron activation and desynchronization through 
reduced NMDA receptor activation through abnormal GABAergic interneuron activity. 
Given the critical role of glutamate and glutathione in neuronal activation, altered 
astrocytic system xc- has the potential to lead to pyramidal neuron desynchronization.  
This likely occurs through both reduced extrasynaptic glutamate release and cystine 
uptake resulting in deficits in glutathione synthesis.  Altered cystine-glutamate exchange 
in schizophrenics is supported by evidence of reduced glutathione concentrations (Do et 
al., 2000; Raffa et al., 2009) and increased expression of xCT, the active subunit of 
system xc- (Baker et al., 2008) suggesting abnormal cystine-glutamate exchange in 
schizophrenics and that this may contribute to the pathophysiology of this disorder.  This 
is of great importance and will require more research since targeting system xc- may 
normalize gamma oscillations in the dorsolateral prefrontal cortex and lead to therapeutic 
treatments for the cognitive symptoms of schizophrenia. 
 
  
150 
 
BIBLIOGRAPHY 
 
 
Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, Nagren K, Vilkman 
H, Gustafsson LL, Syvalahti E, Hietala J (2005) Cortical glutamate-dopamine 
interaction and ketamine-induced psychotic symptoms in man. 
Psychopharmacology (Berl) 182:375-383. 
 
Abdul-Monim Z, Reynolds GP, Neill JC (2006) The effect of atypical and classical 
antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-
learning paradigm. Behav Brain Res 169:263-273. 
 
Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) 
Comparison of ketamine-induced thought disorder in healthy volunteers and 
thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649. 
 
Akbarian S, Huang HS (2006) Molecular and cellular mechanisms of altered 
GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 
52:293-304. 
 
Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney WE, Jr., Jones EG 
(1995a) GABAA receptor subunit gene expression in human prefrontal cortex: 
comparison of schizophrenics and controls. Cereb Cortex 5:550-560. 
 
Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jr., Jones EG 
(1995b) Gene expression for glutamic acid decarboxylase is reduced without loss 
of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52:258-
266. 
 
Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, 
Sandman CA, Bunney WE, Jr., Jones EG (1996) Selective alterations in gene 
expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J 
Neurosci 16:19-30. 
 
Allen JW, Shanker G, Aschner M (2001) Methylmercury inhibits the in vitro uptake of 
the glutathione precursor, cystine, in astrocytes, but not in neurons. Brain Res 
894:131-140. 
 
Amitai N, Kuczenski R, Behrens MM, Markou A (2011) Repeated phencyclidine 
administration alters glutamate release and decreases GABA markers in the 
prefrontal cortex of rats. Neuropharmacology. 
 
151 
 
Amitai N, Kuczenski R, Behrens MM, Markou A (2012) Repeated phencyclidine 
administration alters glutamate release and decreases GABA markers in the 
prefrontal cortex of rats. Neuropharmacology 62:1422-1431. 
 
Andreasen NC (1995) Symptoms, signs, and diagnosis of schizophrenia. Lancet 346:477-
481. 
 
Andreasen NC, Flashman L, Flaum M, Arndt S, Swayze V, 2nd, O'Leary DS, Ehrhardt 
JC, Yuh WT (1994) Regional brain abnormalities in schizophrenia measured with 
magnetic resonance imaging. JAMA 272:1763-1769. 
 
Arnold SE, Franz BR, Gur RC, Gur RE, Shapiro RM, Moberg PJ, Trojanowski JQ (1995) 
Smaller neuron size in schizophrenia in hippocampal subfields that mediate 
cortical-hippocampal interactions. Am J Psychiatry 152:738-748. 
 
Asada H, Kawamura Y, Maruyama K, Kume H, Ding RG, Kanbara N, Kuzume H, Sanbo 
M, Yagi T, Obata K (1997) Cleft palate and decreased brain gamma-aminobutyric 
acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc 
Natl Acad Sci U S A 94:6496-6499. 
 
Attucci S, Carla V, Mannaioni G, Moroni F (2001) Activation of type 5 metabotropic 
glutamate receptors enhances NMDA responses in mice cortical wedges. Br J 
Pharmacol 132:799-806. 
 
Augustin H, Grosjean Y, Chen K, Sheng Q, Featherstone DE (2007) Nonvesicular release 
of glutamate by glial xCT transporters suppresses glutamate receptor clustering in 
vivo. J Neurosci 27:111-123. 
 
Bak LK, Schousboe A, Waagepetersen HS (2006) The glutamate/GABA-glutamine 
cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J 
Neurochem 98:641-653. 
 
Baker DA, Shen H, Kalivas PW (2002a) Cystine/glutamate exchange serves as the source 
for extracellular glutamate: modifications by repeated cocaine administration. 
Amino Acids 23:161-162. 
 
Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW (2002b) The origin and neuronal 
function of in vivo nonsynaptic glutamate. J Neurosci 22:9134-9141. 
 
Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I 
(2008) Contribution of cystine-glutamate antiporters to the psychotomimetic 
effects of phencyclidine. Neuropsychopharmacology 33:1760-1772. 
 
152 
 
Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW (2003) 
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat 
Neurosci 6:743-749. 
 
Bannai S (1984) Induction of cystine and glutamate transport activity in human 
fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem 
259:2435-2440. 
 
Bannai S, Tateishi N (1986) Role of membrane transport in metabolism and function of 
glutathione in mammals. J Membr Biol 89:1-8. 
 
Barker AJ, Ullian EM (2010) Astrocytes and synaptic plasticity. Neuroscientist 16:40-50. 
 
Bartos M, Vida I, Jonas P (2007) Synaptic mechanisms of synchronized gamma 
oscillations in inhibitory interneuron networks. Nat Rev Neurosci 8:45-56. 
 
Baskys A, Malenka RC (1991) Agonists at metabotropic glutamate receptors 
presynaptically inhibit EPSCs in neonatal rat hippocampus. J Physiol 444:687-
701. 
 
Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martin R, Zorzano A, Borsani G, 
Palacin M (2001) Identification and characterisation of human xCT that co-
expresses, with 4F2 heavy chain, the amino acid transport activity system xc. 
Pflugers Arch 442:286-296. 
 
Battaglia G, Monn JA, Schoepp DD (1997) In vivo inhibition of veratridine-evoked 
release of striatal excitatory amino acids by the group II metabotropic glutamate 
receptor agonist LY354740 in rats. Neurosci Lett 229:161-164. 
 
Bayer SA, Altman J, Russo RJ, Zhang X (1993) Timetables of neurogenesis in the human 
brain based on experimentally determined patterns in the rat. Neurotoxicology 
14:83-144. 
 
Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie 
MS, Malenka RC (2002) Control of synaptic strength by glial TNFalpha. Science 
295:2282-2285. 
 
Behar TN, Schaffner AE, Scott CA, O'Connell C, Barker JL (1998) Differential response 
of cortical plate and ventricular zone cells to GABA as a migration stimulus. J 
Neurosci 18:6378-6387. 
 
Behar TN, Schaffner AE, Scott CA, Greene CL, Barker JL (2000) GABA receptor 
antagonists modulate postmitotic cell migration in slice cultures of embryonic rat 
cortex. Cereb Cortex 10:899-909. 
 
153 
 
Behar TN, Smith SV, Kennedy RT, McKenzie JM, Maric I, Barker JL (2001) GABA(B) 
receptors mediate motility signals for migrating embryonic cortical cells. Cereb 
Cortex 11:744-753. 
 
Behar TN, Scott CA, Greene CL, Wen X, Smith SV, Maric D, Liu QY, Colton CA, 
Barker JL (1999) Glutamate acting at NMDA receptors stimulates embryonic 
cortical neuronal migration. J Neurosci 19:4449-4461. 
 
Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, Dugan LL (2007) 
Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by 
NADPH-oxidase. Science 318:1645-1647. 
 
Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O, Gaiarsa JL (1997) GABAA, NMDA 
and AMPA receptors: a developmentally regulated 'menage a trois'. Trends 
Neurosci 20:523-529. 
 
Benes FM, Sorensen I, Bird ED (1991) Reduced neuronal size in posterior hippocampus 
of schizophrenic patients. Schizophr Bull 17:597-608. 
 
Benes FM, Vincent SL, Marie A, Khan Y (1996) Up-regulation of GABAA receptor 
binding on neurons of the prefrontal cortex in schizophrenic subjects. 
Neuroscience 75:1021-1031. 
 
Beneyto M, Abbott A, Hashimoto T, Lewis DA (2011) Lamina-specific alterations in 
cortical GABAA receptor subunit expression in schizophrenia. Cereb Cortex 
21:999-1011. 
 
Benson DL, Huntsman MM, Jones EG (1994) Activity-dependent changes in GAD and 
preprotachykinin mRNAs in visual cortex of adult monkeys. Cereb Cortex 4:40-
51. 
 
Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C, Coyle JT (1999) 
Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous 
system. J Comp Neurol 415:52-64. 
 
Berk M, Ng F, Dean O, Dodd S, Bush AI (2008a) Glutathione: a novel treatment target in 
psychiatry. Trends Pharmacol Sci 29:346-351. 
 
Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush 
AI (2008b) N-acetyl cysteine for depressive symptoms in bipolar disorder--a 
double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468-475. 
 
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, 
Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush 
AI (2008c) N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia-A 
154 
 
Double-Blind, Randomized, Placebo-Controlled Trial. Biol Psychiatry 64:361-
368. 
 
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, 
Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush 
AI (2008d) N-acetyl cysteine as a glutathione precursor for schizophrenia--a 
double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64:361-368. 
 
Bitanihirwe BK, Woo TU (2011) Oxidative stress in schizophrenia: an integrated 
approach. Neurosci Biobehav Rev 35:878-893. 
 
Blanchard JJ, Cohen AS (2006) The structure of negative symptoms within 
schizophrenia: implications for assessment. Schizophr Bull 32:238-245. 
 
Block AE, Dhanji H, Thompson-Tardif SF, Floresco SB (2007) Thalamic-prefrontal 
cortical-ventral striatal circuitry mediates dissociable components of strategy set 
shifting. Cereb Cortex 17:1625-1636. 
 
Blomqvist AG, Leger PT, Hoch JS (2006) The cost of schizophrenia: lessons from an 
international comparison. J Ment Health Policy Econ 9:177-183. 
 
Borgstrom L, Kagedal B, Paulsen O (1986) Pharmacokinetics of N-acetylcysteine in 
man. Eur J Clin Pharmacol 31:217-222. 
 
Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on 
human startle reflex in normals and schizophrenics. Psychophysiology 15:339-
343. 
 
Braff DL, Geyer MA, Swerdlow NR (2001a) Human studies of prepulse inhibition of 
startle: normal subjects, patient groups, and pharmacological studies. 
Psychopharmacology (Berl) 156:234-258. 
 
Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR 
(2001b) Impact of prepulse characteristics on the detection of sensorimotor gating 
deficits in schizophrenia. Schizophr Res 49:171-178. 
 
Braga RJ, Mendlowicz MV, Marrocos RP, Figueira IL (2005) Anxiety disorders in 
outpatients with schizophrenia: prevalence and impact on the subjective quality of 
life. J Psychiatr Res 39:409-414. 
 
Braun I, Genius J, Grunze H, Bender A, Moller HJ, Rujescu D (2007) Alterations of 
hippocampal and prefrontal GABAergic interneurons in an animal model of 
psychosis induced by NMDA receptor antagonism. Schizophr Res 97:254-263. 
 
155 
 
Bridges RJ (2011) System x(c) (-) Cystine/Glutamate Antiporter: An Update on 
Molecular Pharmacology and Roles Within the CNS. Br J Pharmacol. 
 
Bridges RJ (2012) System x(c) (-) Cystine/Glutamate Antiporter: An Update on 
Molecular Pharmacology and Roles Within the CNS. Br J Pharmacol. 
 
Broer S, Wagner CA (2002) Structure-function relationships of heterodimeric amino acid 
transporters. Cell Biochem Biophys 36:155-168. 
 
Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 
93:23-58. 
 
Brown AS, Patterson PH (2011) Maternal infection and schizophrenia: implications for 
prevention. Schizophr Bull 37:284-290. 
 
Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R (1993) Significant 
reductions in synapsin but not synaptophysin specific activity in the brains of 
some schizophrenics. Biol Psychiatry 34:529-535. 
 
Bulut M, Savas HA, Altindag A, Virit O, Dalkilic A (2009) Beneficial effects of N-
acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry 
10:626-628. 
 
Bunney WE, Bunney BG (2000) Evidence for a compromised dorsolateral prefrontal 
cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev 31:138-146. 
 
Bushong EA, Martone ME, Ellisman MH (2003) Examination of the relationship 
between astrocyte morphology and laminar boundaries in the molecular layer of 
adult dentate gyrus. J Comp Neurol 462:241-251. 
 
Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002) Protoplasmic astrocytes in 
CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22:183-
192. 
 
Butticaz C, Werge T, Beckmann JS, Cuenod M, Do KQ, Rivolta C (2009) Mutation 
screening of the glutamate cysteine ligase modifier (GCLM) gene in patients with 
schizophrenia. Psychiatr Genet 19:201-208. 
 
Buzsaki G, Draguhn A (2004) Neuronal oscillations in cortical networks. Science 
304:1926-1929. 
 
Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR (2003) 
Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or 
down. Am J Psychiatry 160:2209-2215. 
 
156 
 
Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, Goldberg TE, 
Weinberger DR (2000) Physiological dysfunction of the dorsolateral prefrontal 
cortex in schizophrenia revisited. Cereb Cortex 10:1078-1092. 
 
Cannon TD, Thompson PM, van Erp TG, Toga AW, Poutanen VP, Huttunen M, 
Lonnqvist J, Standerskjold-Nordenstam CG, Narr KL, Khaledy M, Zoumalan CI, 
Dail R, Kaprio J (2002) Cortex mapping reveals regionally specific patterns of 
genetic and disease-specific gray-matter deficits in twins discordant for 
schizophrenia. Proc Natl Acad Sci U S A 99:3228-3233. 
 
Cardin JA, Carlen M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai LH, Moore CI 
(2009) Driving fast-spiking cells induces gamma rhythm and controls sensory 
responses. Nature 459:663-667. 
 
Carlino E, Sigaudo M, Pollo A, Benedetti F, Mongini T, Castagna F, Vighetti S, Rocca P 
(2012) Nonlinear analysis of electroencephalogram at rest and during cognitive 
tasks in patients with schizophrenia. J Psychiatry Neurosci 37:110030. 
 
Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 
Suppl 1:S10-14. 
 
Carmeli C, Knyazeva MG, Cuenod M, Do KQ (2012) Glutathione precursor N-acetyl-
cysteine modulates EEG synchronization in schizophrenia patients: a double-
blind, randomized, placebo-controlled trial. PLoS One 7:e29341. 
 
Carmignoto G, Fellin T (2006) Glutamate release from astrocytes as a non-synaptic 
mechanism for neuronal synchronization in the hippocampus. J Physiol Paris 
99:98-102. 
 
Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor 
agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-
amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170. 
 
Cattabeni F, Di Luca M (1997) Developmental models of brain dysfunctions induced by 
targeted cellular ablations with methylazoxymethanol. Physiol Rev 77:199-215. 
 
Chaki S, Hikichi H (2011) Targeting of metabotropic glutamate receptors for the 
treatment of schizophrenia. Curr Pharm Des 17:94-102. 
 
Chard PS, Bleakman D, Christakos S, Fullmer CS, Miller RJ (1993) Calcium buffering 
properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol 
472:341-357. 
 
157 
 
Chavez-Noriega LE, Schaffhauser H, Campbell UC (2002) Metabotropic glutamate 
receptors: potential drug targets for the treatment of schizophrenia. Curr Drug 
Targets CNS Neurol Disord 1:261-281. 
 
Chen HH, Stoker A, Markou A (2010) The glutamatergic compounds sarcosine and N-
acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 
receptor knockout mice. Psychopharmacology (Berl) 209:343-350. 
 
Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, Guo XL, Dong LJ, He X, Qiao HX, 
Zhan QM, Li W (2009) Disruption of xCT inhibits cancer cell metastasis via the 
caveolin-1/beta-catenin pathway. Oncogene 28:599-609. 
 
Chin CL, Curzon P, Schwartz AJ, O'Connor EM, Rueter LE, Fox GB, Day M, Basso AM 
(2011) Structural abnormalities revealed by magnetic resonance imaging in rats 
prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in 
schizophrenia. Synapse 65:393-403. 
 
Cho RY, Konecky RO, Carter CS (2006) Impairments in frontal cortical gamma 
synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci U S A 
103:19878-19883. 
 
Cho Y, Bannai S (1990) Uptake of glutamate and cysteine in C-6 glioma cells and in 
cultured astrocytes. J Neurochem 55:2091-2097. 
 
Choleris E, Thomas AW, Kavaliers M, Prato FS (2001) A detailed ethological analysis of 
the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely 
low frequency pulsed magnetic field. Neurosci Biobehav Rev 25:235-260. 
 
Chua SE, Murray RM (1996) The neurodevelopmental theory of schizophrenia: evidence 
concerning structure and neuropsychology. Ann Med 28:547-555. 
 
Chung WJ, Sontheimer H (2009) Sulfasalazine inhibits the growth of primary brain 
tumors independent of nuclear factor-kappaB. J Neurochem 110:182-193. 
 
Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H 
(2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J 
Neurosci 25:7101-7110. 
 
Cobb SR, Buhl EH, Halasy K, Paulsen O, Somogyi P (1995) Synchronization of neuronal 
activity in hippocampus by individual GABAergic interneurons. Nature 378:75-
78. 
 
Cole TB, Giordano G, Co AL, Mohar I, Kavanagh TJ, Costa LG (2011) Behavioral 
Characterization of GCLM-Knockout Mice, a Model for Enhanced Susceptibility 
to Oxidative Stress. J Toxicol 2011:157687. 
158 
 
 
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. 
Annu Rev Pharmacol Toxicol 37:205-237. 
 
Cooper AJ, Kristal BS (1997) Multiple roles of glutathione in the central nervous system. 
Biol Chem 378:793-802. 
 
Coyle JT (2004) The GABA-glutamate connection in schizophrenia: which is the 
proximate cause? Biochem Pharmacol 68:1507-1514. 
 
Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell 
Mol Neurobiol 26:365-384. 
 
Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction 
in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003:318-327. 
 
Curley AA, Arion D, Volk DW, Asafu-Adjei JK, Sampson AR, Fish KN, Lewis DA 
(2011) Cortical deficits of glutamic acid decarboxylase 67 expression in 
schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry 
168:921-929. 
 
Dambska M, Haddad R, Kozlowski PB, Lee MH, Shek J (1982) Telencephalic 
cytoarchitectonics in the brains of rats with graded degrees of micrencephaly. 
Acta Neuropathol 58:203-209. 
 
De Blasi A, Conn PJ, Pin J, Nicoletti F (2001) Molecular determinants of metabotropic 
glutamate receptor signaling. Trends Pharmacol Sci 22:114-120. 
 
De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, 
Vermoesen K, Bannai S, Sato H, Michotte Y, Smolders I, Massie A (2011) Loss 
of system x(c)- formula does not induce oxidative stress but decreases 
extracellular glutamate in hippocampus and influences spatial working memory 
and limbic seizure susceptibility. J Neurosci 31:5792-5803. 
 
de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59:1181-
1189. 
 
DeFelipe J (1997) Types of neurons, synaptic connections and chemical characteristics of 
cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the 
neocortex. J Chem Neuroanat 14:1-19. 
 
Dehmelt L, Halpain S (2004) Actin and microtubules in neurite initiation: are MAPs the 
missing link? J Neurobiol 58:18-33. 
 
159 
 
Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, 
Boesiger P, Cuenod M (2000) Schizophrenia: glutathione deficit in cerebrospinal 
fluid and prefrontal cortex in vivo. Eur J Neurosci 12:3721-3728. 
 
Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, 
Schoepp DD, Lodge D, Collingridge GL (2000) A novel, competitive mGlu(5) 
receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA 
responses but not the induction of LTP in rat hippocampal slices. Br J Pharmacol 
131:239-244. 
 
Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V (2001) N-
methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of 
elderly patients with schizophrenia. Am J Psychiatry 158:1400-1410. 
 
Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 
62:649-671. 
 
Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505-
516. 
 
Dringen R, Gutterer JM, Gros C, Hirrlinger J (2001) Aminopeptidase N mediates the 
utilization of the GSH precursor CysGly by cultured neurons. J Neurosci Res 
66:1003-1008. 
 
Duarte JM, Kulak A, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ (2011) N-
Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient 
Schizophrenia Mouse Model During Development. Biol Psychiatry. 
 
Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Shannon Weickert C 
(2010) Prefrontal GABA(A) receptor alpha-subunit expression in normal 
postnatal human development and schizophrenia. J Psychiatr Res 44:673-681. 
 
Ehlers MD (1999) Synapse structure: glutamate receptors connected by the shanks. Curr 
Biol 9:R848-850. 
 
Eisenberg DP, Berman KF (2010) Executive function, neural circuitry, and genetic 
mechanisms in schizophrenia. Neuropsychopharmacology 35:258-277. 
 
Elmariah SB, Oh EJ, Hughes EG, Balice-Gordon RJ (2005) Astrocytes regulate 
inhibitory synapse formation via Trk-mediated modulation of postsynaptic 
GABAA receptors. J Neurosci 25:3638-3650. 
 
Elvevag B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the 
disorder. Crit Rev Neurobiol 14:1-21. 
 
160 
 
Enomoto T, Noda Y, Nabeshima T (2007) Phencyclidine and genetic animal models of 
schizophrenia developed in relation to the glutamate hypothesis. Methods Find 
Exp Clin Pharmacol 29:291-301. 
 
Esclapez M, Houser CR (1999) Up-regulation of GAD65 and GAD67 in remaining 
hippocampal GABA neurons in a model of temporal lobe epilepsy. J Comp 
Neurol 412:488-505. 
 
Espey MG, Kustova Y, Sei Y, Basile AS (1998) Extracellular glutamate levels are 
chronically elevated in the brains of LP-BM5-infected mice: a mechanism of 
retrovirus-induced encephalopathy. J Neurochem 71:2079-2087. 
 
Featherstone DE, Rushton E, Broadie K (2002) Developmental regulation of glutamate 
receptor field size by nonvesicular glutamate release. Nat Neurosci 5:141-146. 
 
Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ (2007) Gestational 
methylazoxymethanol acetate treatment impairs select cognitive functions: 
parallels to schizophrenia. Neuropsychopharmacology 32:483-492. 
 
Featherstone RE, Burton CL, Coppa-Hopman R, Rizos Z, Sinyard J, Kapur S, Fletcher PJ 
(2009) Gestational treatment with methylazoxymethanol (MAM) that disrupts 
hippocampal-dependent memory does not alter behavioural response to cocaine. 
Pharmacol Biochem Behav 93:382-390. 
 
Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G (2004) Neuronal 
synchrony mediated by astrocytic glutamate through activation of extrasynaptic 
NMDA receptors. Neuron 43:729-743. 
 
Fellin T, Sul JY, D'Ascenzo M, Takano H, Pascual O, Haydon PG (2006) Bidirectional 
astrocyte-neuron communication: the many roles of glutamate and ATP. Novartis 
Found Symp 276:208-217; discussion 217-221, 233-207, 275-281. 
 
Flagstad P, Glenthoj BY, Didriksen M (2005) Cognitive deficits caused by late 
gestational disruption of neurogenesis in rats: a preclinical model of 
schizophrenia. Neuropsychopharmacology 30:250-260. 
 
Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael-Titus AT, Didriksen M (2004) 
Disruption of neurogenesis on gestational day 17 in the rat causes behavioral 
changes relevant to positive and negative schizophrenia symptoms and alters 
amphetamine-induced dopamine release in nucleus accumbens. 
Neuropsychopharmacology 29:2052-2064. 
 
Fletcher PC, McKenna PJ, Frith CD, Grasby PM, Friston KJ, Dolan RJ (1998) Brain 
activations in schizophrenia during a graded memory task studied with functional 
neuroimaging. Arch Gen Psychiatry 55:1001-1008. 
161 
 
 
Flor PJ, Lindauer K, Puttner I, Ruegg D, Lukic S, Knopfel T, Kuhn R (1995) Molecular 
cloning, functional expression and pharmacological characterization of the human 
metabotropic glutamate receptor type 2. Eur J Neurosci 7:622-629. 
 
Floresco SB, Block AE, Tse MT (2008) Inactivation of the medial prefrontal cortex of 
the rat impairs strategy set-shifting, but not reversal learning, using a novel, 
automated procedure. Behav Brain Res 190:85-96. 
 
Floresco SB, Zhang Y, Enomoto T (2009) Neural circuits subserving behavioral 
flexibility and their relevance to schizophrenia. Behav Brain Res 204:396-409. 
 
Floresco SB, Ghods-Sharifi S, Vexelman C, Magyar O (2006a) Dissociable roles for the 
nucleus accumbens core and shell in regulating set shifting. J Neurosci 26:2449-
2457. 
 
Floresco SB, Magyar O, Ghods-Sharifi S, Vexelman C, Tse MT (2006b) Multiple 
dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-
shifting. Neuropsychopharmacology 31:297-309. 
 
Fornito A, Yucel M, Patti J, Wood SJ, Pantelis C (2009) Mapping grey matter reductions 
in schizophrenia: an anatomical likelihood estimation analysis of voxel-based 
morphometry studies. Schizophr Res 108:104-113. 
 
Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M (2004) Effect of 
antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats 
after administration of methamphetamine. Brain Res 1016:90-95. 
 
Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS 
(2010) Expression of interneuron markers in the dorsolateral prefrontal cortex of 
the developing human and in schizophrenia. Am J Psychiatry 167:1479-1488. 
 
Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000) Ionotropic 
glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in 
subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 
157:1141-1149. 
 
Gasol E, Jimenez-Vidal M, Chillaron J, Zorzano A, Palacin M (2004) Membrane 
topology of system xc- light subunit reveals a re-entrant loop with substrate-
restricted accessibility. J Biol Chem 279:31228-31236. 
 
Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins TW, Tricklebank MD (2012) 
Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental 
MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator. 
Neuropsychopharmacology 37:1057-1066. 
162 
 
 
Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2010) Decreased levels of 
glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from 
patients with psychiatric disorders. Int J Neuropsychopharmacol 14:123-130. 
 
Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of 
sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 
25:485-498. 
 
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies 
of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a 
decade in review. Psychopharmacology (Berl) 156:117-154. 
 
Ghods-Sharifi S, Haluk DM, Floresco SB (2008) Differential effects of inactivation of 
the orbitofrontal cortex on strategy set-shifting and reversal learning. Neurobiol 
Learn Mem 89:567-573. 
 
Gilbert CD, Kelly JP (1975) The projections of cells in different layers of the cat's visual 
cortex. J Comp Neurol 163:81-105. 
 
Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA (2011) A novel alpha5GABA(A)R-
positive allosteric modulator reverses hyperactivation of the dopamine system in 
the MAM model of schizophrenia. Neuropsychopharmacology 36:1903-1911. 
 
Giuliani NR, Calhoun VD, Pearlson GD, Francis A, Buchanan RW (2005) Voxel-based 
morphometry versus region of interest: a comparison of two methods for 
analyzing gray matter differences in schizophrenia. Schizophr Res 74:135-147. 
 
Glantz LA, Lewis DA (1997) Reduction of synaptophysin immunoreactivity in the 
prefrontal cortex of subjects with schizophrenia. Regional and diagnostic 
specificity. Arch Gen Psychiatry 54:943-952. 
 
Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and 
treatment of schizophrenia. Am J Psychiatry 158:1367-1377. 
 
Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997) Auditory 
working memory and Wisconsin Card Sorting Test performance in schizophrenia. 
Arch Gen Psychiatry 54:159-165. 
 
Gonzalez-Burgos G, Lewis DA (2008) GABA neurons and the mechanisms of network 
oscillations: implications for understanding cortical dysfunction in schizophrenia. 
Schizophr Bull 34:944-961. 
 
163 
 
Gonzalez-Burgos G, Hashimoto T, Lewis DA (2010) Alterations of cortical GABA 
neurons and network oscillations in schizophrenia. Curr Psychiatry Rep 12:335-
344. 
 
Goto Y, Grace AA (2006) Alterations in medial prefrontal cortical activity and plasticity 
in rats with disruption of cortical development. Biol Psychiatry 60:1259-1267. 
 
Gottesman, II, Erlenmeyer-Kimling L (2001) Family and twin strategies as a head start in 
defining prodromes and endophenotypes for hypothetical early-interventions in 
schizophrenia. Schizophr Res 51:93-102. 
 
Gottesman II, Wolfgram DL (1991) Schizophrenia genesis : the origins of madness. New 
York: Freeman. 
 
Gourevitch R, Rocher C, Le Pen G, Krebs MO, Jay TM (2004) Working memory deficits 
in adult rats after prenatal disruption of neurogenesis. Behav Pharmacol 15:287-
292. 
 
Gout PW, Buckley AR, Simms CR, Bruchovsky N (2001) Sulfasalazine, a potent 
suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a 
new action for an old drug. Leukemia 15:1633-1640. 
 
Grant JE, Kim SW, Odlaug BL (2007) N-acetyl cysteine, a glutamate-modulating agent, 
in the treatment of pathological gambling: a pilot study. Biol Psychiatry 62:652-
657. 
 
Grosjean Y, Grillet M, Augustin H, Ferveur JF, Featherstone DE (2008) A glial amino-
acid transporter controls synapse strength and courtship in Drosophila. Nat 
Neurosci 11:54-61. 
 
Gulyas AI, Szabo GG, Ulbert I, Holderith N, Monyer H, Erdelyi F, Szabo G, Freund TF, 
Hajos N (2010) Parvalbumin-containing fast-spiking basket cells generate the 
field potential oscillations induced by cholinergic receptor activation in the 
hippocampus. J Neurosci 30:15134-15145. 
 
Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, 
Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, Do KQ (2007) Impaired 
glutathione synthesis in schizophrenia: convergent genetic and functional 
evidence. Proc Natl Acad Sci U S A 104:16621-16626. 
 
Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, Grier MD, 
Avison M, Conn PJ, Gore JC (2010) Selective potentiation of the metabotropic 
glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and 
brain activation. Neuroscience 168:209-218. 
 
164 
 
Haenschel C, Bittner RA, Waltz J, Haertling F, Wibral M, Singer W, Linden DE, 
Rodriguez E (2009) Cortical oscillatory activity is critical for working memory as 
revealed by deficits in early-onset schizophrenia. J Neurosci 29:9481-9489. 
 
Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, 
Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of 
myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 
98:4746-4751. 
 
Hakami T, Jones NC, Tolmacheva EA, Gaudias J, Chaumont J, Salzberg M, O'Brien TJ, 
Pinault D (2009) NMDA receptor hypofunction leads to generalized and 
persistent aberrant gamma oscillations independent of hyperlocomotion and the 
state of consciousness. PLoS One 4:e6755. 
 
Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor 
signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 
11:682-696. 
 
Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and 
neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68; 
image 45. 
 
Harrison PJ, McLaughlin D, Kerwin RW (1991) Decreased hippocampal expression of a 
glutamate receptor gene in schizophrenia. Lancet 337:450-452. 
 
Harvey BH, Joubert C, du Preez JL, Berk M (2008) Effect of chronic N-acetyl cysteine 
administration on oxidative status in the presence and absence of induced 
oxidative stress in rat striatum. Neurochem Res 33:508-517. 
 
Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato 
M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003a) Decreased serum 
levels of D-serine in patients with schizophrenia: evidence in support of the N-
methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen 
Psychiatry 60:572-576. 
 
Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA (2008a) Conserved 
regional patterns of GABA-related transcript expression in the neocortex of 
subjects with schizophrenia. Am J Psychiatry 165:479-489. 
 
Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis 
DA (2003b) Gene expression deficits in a subclass of GABA neurons in the 
prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315-6326. 
 
Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, Mirnics 
K, Lewis DA (2008b) Alterations in GABA-related transcriptome in the 
165 
 
dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 
13:147-161. 
 
Hatten ME (1993) The role of migration in central nervous system neuronal 
development. Curr Opin Neurobiol 3:38-44. 
 
Hayes TL, Lewis DA (1996) Magnopyramidal neurons in the anterior motor speech 
region. Dendritic features and interhemispheric comparisons. Arch Neurol 
53:1277-1283. 
 
Heckers S, Konradi C (2010) Hippocampal pathology in schizophrenia. Curr Top Behav 
Neurosci 4:529-553. 
 
Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a 
quantitative review of the evidence. Neuropsychology 12:426-445. 
 
Highley JR, Walker MA, McDonald B, Crow TJ, Esiri MM (2003) Size of hippocampal 
pyramidal neurons in schizophrenia. Br J Psychiatry 183:414-417. 
 
Hill SK, Bishop JR, Palumbo D, Sweeney JA (2010) Effect of second-generation 
antipsychotics on cognition: current issues and future challenges. Expert Rev 
Neurother 10:43-57. 
 
Hirai K, Yoshioka H, Kihara M, Hasegawa K, Sakamoto T, Sawada T, Fushiki S (1999) 
Inhibiting neuronal migration by blocking NMDA receptors in the embryonic rat 
cerebral cortex: a tissue culture study. Brain Res Dev Brain Res 114:63-67. 
 
Hoareau C, Hazane F, Le Pen G, Krebs MO (2006) Postnatal effect of embryonic 
neurogenesis disturbance on reelin level in organotypic cultures of rat 
hippocampus. Brain Res 1097:43-51. 
 
Hoffman JR, Boyne LJ, Levitt P, Fischer I (1996) Short exposure to 
methylazoxymethanol causes a long-term inhibition of axonal outgrowth from 
cultured embryonic rat hippocampal neurons. J Neurosci Res 46:349-359. 
 
Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 
17:31-108. 
 
Holthausen EA, Wiersma D, Cahn W, Kahn RS, Dingemans PM, Schene AH, van den 
Bosch RJ (2007) Predictive value of cognition for different domains of outcome 
in recent-onset schizophrenia. Psychiatry Res 149:71-80. 
 
Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite 
effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 
27:11496-11500. 
166 
 
 
Homayoun H, Jackson ME, Moghaddam B (2005) Activation of metabotropic glutamate 
2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal 
cortex unit activity in awake rats. J Neurophysiol 93:1989-2001. 
 
Honea R, Crow TJ, Passingham D, Mackay CE (2005) Regional deficits in brain volume 
in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J 
Psychiatry 162:2233-2245. 
 
Hosoya K, Tomi M, Ohtsuki S, Takanaga H, Saeki S, Kanai Y, Endou H, Naito M, 
Tsuruo T, Terasaki T (2002) Enhancement of L-cystine transport activity and its 
relation to xCT gene induction at the blood-brain barrier by diethyl maleate 
treatment. J Pharmacol Exp Ther 302:225-231. 
 
Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, Aschenbrenner-Scheibe R, 
Schulze-Bonhage A, Kahana MJ (2003) Gamma oscillations correlate with 
working memory load in humans. Cereb Cortex 13:1369-1374. 
 
Huang Z (2009) Molecular regulation of neuronal migration during neocortical 
development. Mol Cell Neurosci 42:11-22. 
 
Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE (2001) Quality of life in schizophrenia: 
contributions of anxiety and depression. Schizophr Res 51:171-180. 
 
Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress in health and 
disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 32:234-
246. 
 
Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M 
(2000) Transcription factor Nrf2 coordinately regulates a group of oxidative 
stress-inducible genes in macrophages. J Biol Chem 275:16023-16029. 
 
Jackson ME, Homayoun H, Moghaddam B (2004) NMDA receptor hypofunction 
produces concomitant firing rate potentiation and burst activity reduction in the 
prefrontal cortex. Proc Natl Acad Sci U S A 101:8467-8472. 
 
Jacobs B, Driscoll L, Schall M (1997) Life-span dendritic and spine changes in areas 10 
and 18 of human cortex: a quantitative Golgi study. J Comp Neurol 386:661-680. 
 
Jansma JM, Ramsey NF, van der Wee NJ, Kahn RS (2004) Working memory capacity in 
schizophrenia: a parametric fMRI study. Schizophr Res 68:159-171. 
 
Javitt DC (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) 
model of schizophrenia. Hillside J Clin Psychiatry 9:12-35. 
 
167 
 
Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol 
Psychiatry 9:984-997, 979. 
 
Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate 
receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69-108. 
 
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of 
schizophrenia. Am J Psychiatry 148:1301-1308. 
 
Jiao Y, Zhang C, Yanagawa Y, Sun QQ (2006) Major effects of sensory experiences on 
the neocortical inhibitory circuits. J Neurosci 26:8691-8701. 
 
Jimenez-Vidal M, Gasol E, Zorzano A, Nunes V, Palacin M, Chillaron J (2004) Thiol 
modification of cysteine 327 in the eighth transmembrane domain of the light 
subunit xCT of the heteromeric cystine/glutamate antiporter suggests close 
proximity to the substrate binding site/permeation pathway. J Biol Chem 
279:11214-11221. 
 
Jones EG (1990) The role of afferent activity in the maintenance of primate 
neocorticalfunction. J Exp Biol 153:155-176. 
 
Jones RS, Buhl EH (1993) Basket-like interneurones in layer II of the entorhinal cortex 
exhibit a powerful NMDA-mediated synaptic excitation. Neurosci Lett 149:35-39. 
 
Jongen-Relo AL, Leng A, Luber M, Pothuizen HH, Weber L, Feldon J (2004) The 
prenatal methylazoxymethanol acetate treatment: a neurodevelopmental animal 
model for schizophrenia? Behav Brain Res 149:159-181. 
 
Kalivas PW (2009) The glutamate homeostasis hypothesis of addiction. Nat Rev 
Neurosci 10:561-572. 
 
Katayama T, Jodo E, Suzuki Y, Hoshino KY, Takeuchi S, Kayama Y (2007) Activation 
of medial prefrontal cortex neurons by phencyclidine is mediated via 
AMPA/kainate glutamate receptors in anesthetized rats. Neuroscience 150:442-
448. 
 
Kau KS, Madayag A, Mantsch JR, Grier MD, Abdulhameed O, Baker DA (2008) 
Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes 
cocaine-induced drug seeking. Neuroscience 155:530-537. 
 
Kendler KS (2001) Twin studies of psychiatric illness: an update. Arch Gen Psychiatry 
58:1005-1014. 
 
Kihara M, Yoshioka H, Hirai K, Hasegawa K, Kizaki Z, Sawada T (2002) Stimulation of 
N-methyl-D-aspartate (NMDA) receptors inhibits neuronal migration in 
168 
 
embryonic cerebral cortex: a tissue culture study. Brain Res Dev Brain Res 
138:195-198. 
 
Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM (2006) A specific 
role for NR2A-containing NMDA receptors in the maintenance of parvalbumin 
and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26:1604-1615. 
 
Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson 
K, Kryzhanovskaya L, Jarkova N (2011) A multicenter, inpatient, phase 2, 
double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate 
in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31:349-355. 
 
Knackstedt LA, Melendez RI, Kalivas PW (2010) Ceftriaxone restores glutamate 
homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 67:81-84. 
 
Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, Markou 
A, Kalivas PW (2009) The role of cystine-glutamate exchange in nicotine 
dependence in rats and humans. Biol Psychiatry 65:841-845. 
 
Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH (1994) NMDA receptor 
channels: subunit-specific potentiation by reducing agents. Neuron 12:1031-1040. 
 
Komuro H, Rakic P (1993) Modulation of neuronal migration by NMDA receptors. 
Science 260:95-97. 
 
Kondziella D, Brenner E, Eyjolfsson EM, Markinhuhta KR, Carlsson ML, Sonnewald U 
(2006) Glial-neuronal interactions are impaired in the schizophrenia model of 
repeated MK801 exposure. Neuropsychopharmacology 31:1880-1887. 
 
Kranich O, Dringen R, Sandberg M, Hamprecht B (1998) Utilization of cysteine and 
cysteine precursors for the synthesis of glutathione in astroglial cultures: 
preference for cystine. Glia 22:11-18. 
 
Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH (2006) Changes in 
NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal 
and anterior cingulate cortex indicate abnormal regional expression in 
schizophrenia. Mol Psychiatry 11:737-747, 705. 
 
Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007) NMDA receptors and 
schizophrenia. Curr Opin Pharmacol 7:48-55. 
 
Krystal JH (2008) Capitalizing on extrasynaptic glutamate neurotransmission to treat 
antipsychotic-resistant symptoms in schizophrenia. Biol Psychiatry 64:358-360. 
 
169 
 
Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA 
receptor antagonist effects, cortical glutamatergic function, and schizophrenia: 
toward a paradigm shift in medication development. Psychopharmacology (Berl) 
169:215-233. 
 
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, 
Bowers MB, Jr., Charney DS (1994) Subanesthetic effects of the noncompetitive 
NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, 
and neuroendocrine responses. Arch Gen Psychiatry 51:199-214. 
 
Kulak A, Cuenod M, Do KQ (2011) Behavioral phenotyping of glutathione-deficient 
mice: Relevance to schizophrenia and bipolar disorder. Behav Brain Res. 
 
Kulak A, Cuenod M, Do KQ (2012) Behavioral phenotyping of glutathione-deficient 
mice: Relevance to schizophrenia and bipolar disorder. Behav Brain Res. 
 
Kumada T, Komuro H (2004) Completion of neuronal migration regulated by loss of 
Ca(2+) transients. Proc Natl Acad Sci U S A 101:8479-8484. 
 
Kumari V, Antonova E, Geyer MA, Ffytche D, Williams SC, Sharma T (2007) A fMRI 
investigation of startle gating deficits in schizophrenia patients treated with 
typical or atypical antipsychotics. Int J Neuropsychopharmacol 10:463-477. 
 
Kumari V, Fannon D, Geyer MA, Premkumar P, Antonova E, Simmons A, Kuipers E 
(2008) Cortical grey matter volume and sensorimotor gating in schizophrenia. 
Cortex 44:1206-1214. 
 
Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE (2005) Symptoms versus 
neurocognitive test performance as predictors of psychosocial status in 
schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 31:167-174. 
 
Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J (2007) Molecular mechanisms 
of schizophrenia. Cell Physiol Biochem 20:687-702. 
 
Lante F, Meunier J, Guiramand J, Maurice T, Cavalier M, de Jesus Ferreira MC, Aimar 
R, Cohen-Solal C, Vignes M, Barbanel G (2007) Neurodevelopmental damage 
after prenatal infection: role of oxidative stress in the fetal brain. Free Radic Biol 
Med 42:1231-1245. 
 
LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, 
McRae A, Brady K (2006) Safety and tolerability of N-acetylcysteine in cocaine-
dependent individuals. Am J Addict 15:105-110. 
 
170 
 
LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas 
PW, Malcolm R (2007) Is cocaine desire reduced by N-acetylcysteine? Am J 
Psychiatry 164:1115-1117. 
 
Lavin A, Moore HM, Grace AA (2005) Prenatal disruption of neocortical development 
alters prefrontal cortical neuron responses to dopamine in adult rats. 
Neuropsychopharmacology 30:1426-1435. 
 
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, 
Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuenod M, Buclin 
T, Do KQ (2008) Glutathione precursor, N-acetyl-cysteine, improves mismatch 
negativity in schizophrenia patients. Neuropsychopharmacology 33:2187-2199. 
 
Le Pen G, Gourevitch R, Hazane F, Hoareau C, Jay TM, Krebs MO (2006) Peri-pubertal 
maturation after developmental disturbance: a model for psychosis onset in the 
rat. Neuroscience 143:395-405. 
 
Lei S, McBain CJ (2002) Distinct NMDA receptors provide differential modes of 
transmission at mossy fiber-interneuron synapses. Neuron 33:921-933. 
 
Lena I, Chessel A, Le Pen G, Krebs MO, Garcia R (2007) Alterations in prefrontal 
glutamatergic and noradrenergic systems following MK-801 administration in rats 
prenatally exposed to methylazoxymethanol at gestational day 17. 
Psychopharmacology (Berl) 192:373-383. 
 
Lewis DA (2004) Structure of the human prefrontal cortex. Am J Psychiatry 161:1366. 
 
Lewis DA (2009) Neuroplasticity of excitatory and inhibitory cortical circuits in 
schizophrenia. Dialogues Clin Neurosci 11:269-280. 
 
Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and 
neurobiology. Neuron 28:325-334. 
 
Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev 
Neurosci 25:409-432. 
 
Lewis DA, Moghaddam B (2006) Cognitive dysfunction in schizophrenia: convergence 
of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 63:1372-
1376. 
 
Lewis DA, Curley AA, Glausier JR, Volk DW (2012) Cortical parvalbumin interneurons 
and cognitive dysfunction in schizophrenia. Trends Neurosci 35:57-67. 
 
Liang F, Jones EG (1997) Differential and time-dependent changes in gene expression 
for type II calcium/calmodulin-dependent protein kinase, 67 kDa glutamic acid 
171 
 
decarboxylase, and glutamate receptor subunits in tetanus toxin-induced focal 
epilepsy. J Neurosci 17:2168-2180. 
 
Liddle PF (2000) Cognitive impairment in schizophrenia: its impact on social 
functioning. Acta Psychiatr Scand Suppl 400:11-16. 
 
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J (2001) 
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, 
and therapeutic approaches. Biol Psychiatry 50:884-897. 
 
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe 
RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness 
of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 
353:1209-1223. 
 
Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002) Neonatal 
damage of the ventral hippocampus impairs working memory in the rat. 
Neuropsychopharmacology 27:47-54. 
 
Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, Bankston LA (2002) 
Cysteine regulation of protein function--as exemplified by NMDA-receptor 
modulation. Trends Neurosci 25:474-480. 
 
Lisman JE (1999) Relating hippocampal circuitry to function: recall of memory 
sequences by reciprocal dentate-CA3 interactions. Neuron 22:233-242. 
 
Lisman JE, Idiart MA (1995) Storage of 7 +/- 2 short-term memories in oscillatory 
subcycles. Science 267:1512-1515. 
 
Lodge DJ, Grace AA (2007) Aberrant hippocampal activity underlies the dopamine 
dysregulation in an animal model of schizophrenia. J Neurosci 27:11424-11430. 
 
Lodge DJ, Behrens MM, Grace AA (2009) A loss of parvalbumin-containing 
interneurons is associated with diminished oscillatory activity in an animal model 
of schizophrenia. J Neurosci 29:2344-2354. 
 
Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003) Effects of ketamine 
and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal 
cortex: modulation by a group II selective metabotropic glutamate receptor 
agonist LY379268. Neuroscience 117:697-706. 
 
Lu SC (1999) Regulation of hepatic glutathione synthesis: current concepts and 
controversies. FASEB J 13:1169-1183. 
 
172 
 
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new 
schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363-369. 
 
Lujan R, Shigemoto R, Lopez-Bendito G (2005) Glutamate and GABA receptor 
signalling in the developing brain. Neuroscience 130:567-580. 
 
Lund JS, Lund RD, Hendrickson AE, Bunt AH, Fuchs AF (1975) The origin of efferent 
pathways from the primary visual cortex, area 17, of the macaque monkey as 
shown by retrograde transport of horseradish peroxidase. J Comp Neurol 
164:287-303. 
 
Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine 
glutamate signaling promotes glioma cell invasion. Cancer Res 67:9463-9471. 
 
Maccaferri G, Dingledine R (2002) Control of feedforward dendritic inhibition by 
NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci 
22:5462-5472. 
 
Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, Grier MD, 
Baker DA (2007) Repeated N-acetylcysteine administration alters plasticity-
dependent effects of cocaine. J Neurosci 27:13968-13976. 
 
Makani S, Zagha E (2007) Out of the cleft: the source and target of extra-synaptic 
glutamate in the CA1 region of the hippocampus. J Physiol 582:479-480. 
 
Malaspina D, Corcoran C, Kleinhaus KR, Perrin MC, Fennig S, Nahon D, Friedlander Y, 
Harlap S (2008) Acute maternal stress in pregnancy and schizophrenia in 
offspring: a cohort prospective study. BMC Psychiatry 8:71. 
 
Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997a) Clozapine 
blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with 
ketamine. Biol Psychiatry 42:664-668. 
 
Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997b) 
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment 
in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150. 
 
Manent JB, Represa A (2007) Neurotransmitters and brain maturation: early paracrine 
actions of GABA and glutamate modulate neuronal migration. Neuroscientist 
13:268-279. 
 
Manent JB, Jorquera I, Ben-Ari Y, Aniksztejn L, Represa A (2006) Glutamate acting on 
AMPA but not NMDA receptors modulates the migration of hippocampal 
interneurons. J Neurosci 26:5901-5909. 
 
173 
 
Manent JB, Demarque M, Jorquera I, Pellegrino C, Ben-Ari Y, Aniksztejn L, Represa A 
(2005) A noncanonical release of GABA and glutamate modulates neuronal 
migration. J Neurosci 25:4755-4765. 
 
Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ (2001) Metabotropic 
glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J 
Neurosci 21:5925-5934. 
 
Manoach DS (2003) Prefrontal cortex dysfunction during working memory performance 
in schizophrenia: reconciling discrepant findings. Schizophr Res 60:285-298. 
 
Manoach DS, Press DZ, Thangaraj V, Searl MM, Goff DC, Halpern E, Saper CB, 
Warach S (1999) Schizophrenic subjects activate dorsolateral prefrontal cortex 
during a working memory task, as measured by fMRI. Biol Psychiatry 45:1128-
1137. 
 
Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on 
sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308. 
 
Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ (2007) An open-label 
trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. 
Prog Neuropsychopharmacol Biol Psychiatry 31:389-394. 
 
Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of 
schizophrenia: following a trail of evidence from cradle to grave. Dev 
Psychopathol 12:501-527. 
 
Maric D, Liu QY, Grant GM, Andreadis JD, Hu Q, Chang YH, Barker JL, Joseph J, 
Stenger DA, Ma W (2000) Functional ionotropic glutamate receptors emerge 
during terminal cell division and early neuronal differentiation of rat 
neuroepithelial cells. J Neurosci Res 61:652-662. 
 
Marin O, Rubenstein JL (2003) Cell migration in the forebrain. Annu Rev Neurosci 
26:441-483. 
 
Marino MJ, Conn PJ (2002) Direct and indirect modulation of the N-methyl D-aspartate 
receptor. Curr Drug Targets CNS Neurol Disord 1:1-16. 
 
Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, De Bundel D, 
Vermoesen K, Bannai S, Smolders I, Conrad M, Plesnila N, Sato H, Michotte Y 
(2011) Dopaminergic neurons of system xFormula-deficient mice are highly 
protected against 6-hydroxydopamine-induced toxicity. FASEB J 25:1359-1369. 
 
Matricon J, Bellon A, Frieling H, Kebir O, Le Pen G, Beuvon F, Daumas-Duport C, Jay 
TM, Krebs MO (2010) Neuropathological and Reelin deficiencies in the 
174 
 
hippocampal formation of rats exposed to MAM; differences and similarities with 
schizophrenia. PLoS One 5:e10291. 
 
Matsumoto H, Higa HH (1966) Studies on methylazoxymethanol, the aglycone of 
cycasin: methylation of nucleic acids in vitro. Biochem J 98:20C-22C. 
 
Matsumoto H, Spatz M, Laqueur GL (1972) Quantitative changes with age in the DNA 
content of methylazoxymethanol-induced microencephalic rat brain. J Neurochem 
19:297-306. 
 
Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi 
J, Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K (2008) Negative 
correlation between brain glutathione level and negative symptoms in 
schizophrenia: a 3T 1H-MRS study. PLoS One 3:e1944. 
 
McConnell SK, Kaznowski CE (1991) Cell cycle dependence of laminar determination in 
developing neocortex. Science 254:282-285. 
 
McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of 
incidence, prevalence, and mortality. Epidemiol Rev 30:67-76. 
 
Meister A (1988) Glutathione metabolism and its selective modification. J Biol Chem 
263:17205-17208. 
 
Meister A (1995) Glutathione biosynthesis and its inhibition. Methods Enzymol 252:26-
30. 
 
Melendez RI, Vuthiganon J, Kalivas PW (2005) Regulation of extracellular glutamate in 
the prefrontal cortex: focus on the cystine glutamate exchanger and group I 
metabotropic glutamate receptors. J Pharmacol Exp Ther 314:139-147. 
 
Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E, Akbarian S (2009) Molecular 
determinants of dysregulated GABAergic gene expression in the prefrontal cortex 
of subjects with schizophrenia. Biol Psychiatry 65:1006-1014. 
 
Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in 
drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 
27:1159-1172. 
 
Metin C, Baudoin JP, Rakic S, Parnavelas JG (2006) Cell and molecular mechanisms 
involved in the migration of cortical interneurons. Eur J Neurosci 23:894-900. 
 
Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR, 
Berman KF (2005) Regionally specific disturbance of dorsolateral prefrontal-
175 
 
hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 
62:379-386. 
 
Meyer U, Feldon J, Schedlowski M, Yee BK (2005) Towards an immuno-precipitated 
neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 
29:913-947. 
 
Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000) Molecular 
characterization of schizophrenia viewed by microarray analysis of gene 
expression in prefrontal cortex. Neuron 28:53-67. 
 
Misgeld U, Bijak M, Jarolimek W (1995) A physiological role for GABAB receptors and 
the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 
46:423-462. 
 
Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II 
metabotropic glutamate receptor agonist in rats. Science 281:1349-1352. 
 
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic 
neurotransmission by ketamine: a novel step in the pathway from NMDA receptor 
blockade to dopaminergic and cognitive disruptions associated with the prefrontal 
cortex. J Neurosci 17:2921-2927. 
 
Mohan A, Pendyam S, Kalivas PW, Nair SS (2011) Molecular diffusion model of 
neurotransmitter homeostasis around synapses supporting gradients. Neural 
Comput 23:984-1014. 
 
Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA (2006) A neurobehavioral 
systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: 
implications for the neuropathology of schizophrenia. Biol Psychiatry 60:253-
264. 
 
Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK (2005) 
Cystine/glutamate exchange regulates metabotropic glutamate receptor 
presynaptic inhibition of excitatory transmission and vulnerability to cocaine 
seeking. J Neurosci 25:6389-6393. 
 
Morice R (1990) Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and 
mania. Br J Psychiatry 157:50-54. 
 
Mosolov SN, Smulevich AB, Neznanov NG, Tochilov VA, Andreev BV, Avedisova AS, 
Bardenshtein LM, Gurovich I, Reznik AM, Zharkova NB, Martenyi F (2010) The 
use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a 
randomized double-blind trial. Zh Nevrol Psikhiatr Im S S Korsakova 110:16-23. 
 
176 
 
Murphy TH, Schnaar RL, Coyle JT (1990) Immature cortical neurons are uniquely 
sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4:1624-
1633. 
 
Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in 
a neuronal cell line involves inhibition of cystine transport leading to oxidative 
stress. Neuron 2:1547-1558. 
 
Murray GK, Cheng F, Clark L, Barnett JH, Blackwell AD, Fletcher PC, Robbins TW, 
Bullmore ET, Jones PB (2008) Reinforcement and reversal learning in first-
episode psychosis. Schizophr Bull 34:848-855. 
 
Nagata Y, Matsumoto H (1969) Studies on methylazoxymethanol: methylation of nucleic 
acids in the fetal rat brain. Proc Soc Exp Biol Med 132:383-385. 
 
Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U 
(2005) Relation of plasma glycine, serine, and homocysteine levels to 
schizophrenia symptoms and medication type. Am J Psychiatry 162:1738-1740. 
 
Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, 
Harte MK (2010) Animal models of cognitive dysfunction and negative 
symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol 
Ther 128:419-432. 
 
Nelson MD, Saykin AJ, Flashman LA, Riordan HJ (1998) Hippocampal volume 
reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-
analytic study. Arch Gen Psychiatry 55:433-440. 
 
Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, 
Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a 
model of memory impairment and psychosis. Neuropsychopharmacology 20:106-
118. 
 
Nguyen L, Rigo JM, Rocher V, Belachew S, Malgrange B, Rogister B, Leprince P, 
Moonen G (2001) Neurotransmitters as early signals for central nervous system 
development. Cell Tissue Res 305:187-202. 
 
Nopoulos P, Torres I, Flaum M, Andreasen NC, Ehrhardt JC, Yuh WT (1995) Brain 
morphology in first-episode schizophrenia. Am J Psychiatry 152:1721-1723. 
 
Oberheim NA, Wang X, Goldman S, Nedergaard M (2006) Astrocytic complexity 
distinguishes the human brain. Trends Neurosci 29:547-553. 
 
Ogata K, Kosaka T (2002) Structural and quantitative analysis of astrocytes in the mouse 
hippocampus. Neuroscience 113:221-233. 
177 
 
 
Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of 
schizophrenia. J Psychiatr Res 33:523-533. 
 
Olsson B, Johansson M, Gabrielsson J, Bolme P (1988) Pharmacokinetics and 
bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 
34:77-82. 
 
Parnavelas JG (2000) The origin and migration of cortical neurones: new vistas. Trends 
Neurosci 23:126-131. 
 
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, 
Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, 
Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD 
(2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: 
a randomized Phase 2 clinical trial. Nat Med 13:1102-1107. 
 
Pauls TL, Cox JA, Berchtold MW (1996) The Ca2+(-)binding proteins parvalbumin and 
oncomodulin and their genes: new structural and functional findings. Biochim 
Biophys Acta 1306:39-54. 
 
Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates. New York: 
Academic Press. 
 
Pearlson GD (1981) Psychiatric and medical syndromes associated with phencyclidine 
(PCP) abuse. Johns Hopkins Med J 148:25-33. 
 
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an 
elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-
167. 
 
Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT (2006) Decrease in 
parvalbumin-expressing neurons in the hippocampus and increased 
phencyclidine-induced locomotor activity in the rat methylazoxymethanol 
(MAM) model of schizophrenia. Eur J Neurosci 23:279-284. 
 
Peppercorn MA (1984) Sulfasalazine. Pharmacology, clinical use, toxicity, and related 
new drug development. Ann Intern Med 101:377-386. 
 
Perlstein WM, Dixit NK, Carter CS, Noll DC, Cohen JD (2003) Prefrontal cortex 
dysfunction mediates deficits in working memory and prepotent responding in 
schizophrenia. Biol Psychiatry 53:25-38. 
 
Phillips KG, Cotel MC, McCarthy AP, Edgar DM, Tricklebank M, O'Neill MJ, Jones 
MW, Wafford KA (2012) Differential effects of NMDA antagonists on high 
178 
 
frequency and gamma EEG oscillations in a neurodevelopmental model of 
schizophrenia. Neuropharmacology. 
 
Phillips T, Rees S, Augood S, Waldvogel H, Faull R, Svendsen C, Emson P (2000) 
Localization of metabotropic glutamate receptor type 2 in the human brain. 
Neuroscience 95:1139-1156. 
 
Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA (2001) Decreased somal size of deep 
layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. 
Arch Gen Psychiatry 58:466-473. 
 
Poskanzer KE, Yuste R (2011) Astrocytic regulation of cortical UP states. Proc Natl 
Acad Sci U S A 108:18453-18458. 
 
Potkin SG, Turner JA, Brown GG, McCarthy G, Greve DN, Glover GH, Manoach DS, 
Belger A, Diaz M, Wible CG, Ford JM, Mathalon DH, Gollub R, Lauriello J, 
O'Leary D, van Erp TG, Toga AW, Preda A, Lim KO (2009) Working memory 
and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull 
35:19-31. 
 
Pow DV (2001) Visualising the activity of the cystine-glutamate antiporter in glial cells 
using antibodies to aminoadipic acid, a selectively transported substrate. Glia 
34:27-38. 
 
Prentice KJ, Gold JM, Buchanan RW (2008) The Wisconsin Card Sorting impairment in 
schizophrenia is evident in the first four trials. Schizophr Res 106:81-87. 
 
Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on 
anxiety-like behaviors: a review. Eur J Pharmacol 463:3-33. 
 
Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A (2011) Decreased glutathione levels 
and impaired antioxidant enzyme activities in drug-naive first-episode 
schizophrenic patients. BMC Psychiatry 11:124. 
 
Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A (2009) Decreased 
glutathione levels and antioxidant enzyme activities in untreated and treated 
schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 33:1178-
1183. 
 
Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in 
the prefrontal cortex: a postmortem morphometric study of schizophrenia and 
Huntington disease. Arch Gen Psychiatry 55:215-224. 
 
Rapoport JL, Addington AM, Frangou S, Psych MR (2005) The neurodevelopmental 
model of schizophrenia: update 2005. Mol Psychiatry 10:434-449. 
179 
 
 
Ravizza SM, Carter CS (2008) Shifting set about task switching: behavioral and neural 
evidence for distinct forms of cognitive flexibility. Neuropsychologia 46:2924-
2935. 
 
Reichenbach A, Derouiche A, Kirchhoff F (2010) Morphology and dynamics of 
perisynaptic glia. Brain Res Rev 63:11-25. 
 
Ribeiro FM, Paquet M, Cregan SP, Ferguson SS (2010) Group I metabotropic glutamate 
receptor signalling and its implication in neurological disease. CNS Neurol 
Disord Drug Targets 9:574-595. 
 
Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by 
chronic amphetamine administration: a review and evaluation of animal models of 
amphetamine psychosis. Brain Res 396:157-198. 
 
Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N, Hays AP, Dwork AJ 
(2000) Structural abnormalities of subicular dendrites in subjects with 
schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 
57:349-356. 
 
Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW 
(1994) Localization of neuronal and glial glutamate transporters. Neuron 13:713-
725. 
 
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, 
Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of glutamate 
transporters reveals a major role for astroglial transport in excitotoxicity and 
clearance of glutamate. Neuron 16:675-686. 
 
Rung JP, Carlsson A, Ryden Markinhuhta K, Carlsson ML (2005) (+)-MK-801 induced 
social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog 
Neuropsychopharmacol Biol Psychiatry 29:827-832. 
 
Rusch N, Spoletini I, Wilke M, Bria P, Di Paola M, Di Iulio F, Martinotti G, Caltagirone 
C, Spalletta G (2007) Prefrontal-thalamic-cerebellar gray matter networks and 
executive functioning in schizophrenia. Schizophr Res 93:79-89. 
 
Sagara JI, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial cells. J 
Neurochem 61:1672-1676. 
 
Sams-Dodd F (1999) Phencyclidine in the social interaction test: an animal model of 
schizophrenia with face and predictive validity. Rev Neurosci 10:59-90. 
 
180 
 
Sanderson TM, Cotel MC, O'Neill MJ, Tricklebank MD, Collingridge GL, Sher E (2012) 
Alterations in hippocampal excitability, synaptic transmission and synaptic 
plasticity in a neurodevelopmental model of schizophrenia. Neuropharmacology 
62:1349-1358. 
 
Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama 
F, Yagami K, Moriguchi T, Takahashi S, Bannai S (2005) Redox imbalance in 
cystine/glutamate transporter-deficient mice. J Biol Chem 280:37423-37429. 
 
Savic N, Pedarzani P, Sciancalepore M (2001) Medium afterhyperpolarization and firing 
pattern modulation in interneurons of stratum radiatum in the CA3 hippocampal 
region. J Neurophysiol 85:1986-1997. 
 
Sawada K, Barr AM, Nakamura M, Arima K, Young CE, Dwork AJ, Falkai P, Phillips 
AG, Honer WG (2005) Hippocampal complexin proteins and cognitive 
dysfunction in schizophrenia. Arch Gen Psychiatry 62:263-272. 
 
Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) 
Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-
530. 
 
Seib TM, Patel SA, Bridges RJ (2011) Regulation of the system x(C)- cystine/glutamate 
exchanger by intracellular glutathione levels in rat astrocyte primary cultures. 
Glia 59:1387-1401. 
 
Sejnowski TJ, Paulsen O (2006) Network oscillations: emerging computational 
principles. J Neurosci 26:1673-1676. 
 
Selemon LD, Goldman-Rakic PS (1999) The reduced neuropil hypothesis: a circuit based 
model of schizophrenia. Biol Psychiatry 45:17-25. 
 
Selemon LD, Rajkowska G, Goldman-Rakic PS (1995) Abnormally high neuronal 
density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 
and occipital area 17. Arch Gen Psychiatry 52:805-818; discussion 819-820. 
 
Selemon LD, Rajkowska G, Goldman-Rakic PS (1998) Elevated neuronal density in 
prefrontal area 46 in brains from schizophrenic patients: application of a three-
dimensional, stereologic counting method. J Comp Neurol 392:402-412. 
 
Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001) Psychosis: pathological 
activation of limbic thalamocortical circuits by psychomimetics and 
schizophrenia? Trends Neurosci 24:330-334. 
 
181 
 
Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH (2006) Cystine/glutamate 
exchange modulates glutathione supply for neuroprotection from oxidative stress 
and cell proliferation. J Neurosci 26:10514-10523. 
 
Sidman RL, Rakic P (1973) Neuronal migration, with special reference to developing 
human brain: a review. Brain Res 62:1-35. 
 
Sies H (1999) Glutathione and its role in cellular functions. Free Radic Biol Med 27:916-
921. 
 
Simonian SX, Herbison AE (2001) Differing, spatially restricted roles of ionotropic 
glutamate receptors in regulating the migration of gnrh neurons during 
embryogenesis. J Neurosci 21:934-943. 
 
Singh SC (1980) Deformed dendrites and reduced spine numbers on ectopic neurones in 
the hippocampus of rats exposed to methylazoxymethanol-acetate. A Golgi-Cox 
study. Acta Neuropathol 49:193-198. 
 
Smith AD, Justice JB (1994) The effect of inhibition of synthesis, release, metabolism 
and uptake on the microdialysis extraction fraction of dopamine. J Neurosci 
Methods 54:75-82. 
 
Smith EE, Jonides J (1999) Storage and executive processes in the frontal lobes. Science 
283:1657-1661. 
 
Snyder SH (1976) The dopamine hypothesis of schizophrenia: focus on the dopamine 
receptor. Am J Psychiatry 133:197-202. 
 
Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009) Parvalbumin neurons and gamma 
rhythms enhance cortical circuit performance. Nature 459:698-702. 
 
Soltaninassab SR, Sekhar KR, Meredith MJ, Freeman ML (2000) Multi-faceted 
regulation of gamma-glutamylcysteine synthetase. J Cell Physiol 182:163-170. 
 
Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW 
(2003) Abnormal neural synchrony in schizophrenia. J Neurosci 23:7407-7411. 
 
Stefani MR, Moghaddam B (2005) Systemic and prefrontal cortical NMDA receptor 
blockade differentially affect discrimination learning and set-shift ability in rats. 
Behav Neurosci 119:420-428. 
 
Steriade M, Nunez A, Amzica F (1993) Intracellular analysis of relations between the 
slow (< 1 Hz) neocortical oscillation and other sleep rhythms of the 
electroencephalogram. J Neurosci 13:3266-3283. 
 
182 
 
Steullet P, Neijt HC, Cuenod M, Do KQ (2006) Synaptic plasticity impairment and 
hypofunction of NMDA receptors induced by glutathione deficit: relevance to 
schizophrenia. Neuroscience 137:807-819. 
 
Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Chen Y, Dalton TP, Cuenod M, Do KQ 
(2010) Redox dysregulation affects the ventral but not dorsal hippocampus: 
impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J 
Neurosci 30:2547-2558. 
 
Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine dysregulation in 
schizophrenia--a synthesis and selective review. J Psychopharmacol 21:440-452. 
 
Sturgeon RD, Fessler RG, Meltzer HY (1979) Behavioral rating scales for assessing 
phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. 
Eur J Pharmacol 59:169-179. 
 
Sullivan PF, Kendler KS, Neale MC (2003) Schizophrenia as a complex trait: evidence 
from a meta-analysis of twin studies. Arch Gen Psychiatry 60:1187-1192. 
 
Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine 
and serine levels in schizophrenia compared to normal controls and major 
depression: relation to negative symptoms. Int J Neuropsychopharmacol 7:1-8. 
 
Sweet RA, Pierri JN, Auh S, Sampson AR, Lewis DA (2003) Reduced pyramidal cell 
somal volume in auditory association cortex of subjects with schizophrenia. 
Neuropsychopharmacology 28:599-609. 
 
Sweet RA, Bergen SE, Sun Z, Sampson AR, Pierri JN, Lewis DA (2004) Pyramidal cell 
size reduction in schizophrenia: evidence for involvement of auditory feedforward 
circuits. Biol Psychiatry 55:1128-1137. 
 
Swerdlow NR (2010) Integrative circuit models and their implications for the 
pathophysiologies and treatments of the schizophrenias. Curr Top Behav Neurosci 
4:555-583. 
 
Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse 
inhibition of startle in the rat: current knowledge and future challenges. 
Psychopharmacology (Berl) 156:194-215. 
 
Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal 
model of deficient sensorimotor gating in schizophrenic patients. Arch Gen 
Psychiatry 51:139-154. 
 
Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006) Startle 
gating deficits in a large cohort of patients with schizophrenia: relationship to 
183 
 
medications, symptoms, neurocognition, and level of function. Arch Gen 
Psychiatry 63:1325-1335. 
 
Szoke A, Meary A, Trandafir A, Bellivier F, Roy I, Schurhoff F, Leboyer M (2008) 
Executive deficits in psychotic and bipolar disorders - implications for our 
understanding of schizoaffective disorder. Eur Psychiatry 23:20-25. 
 
Tallon-Baudry C, Mandon S, Freiwald WA, Kreiter AK (2004) Oscillatory synchrony in 
the monkey temporal lobe correlates with performance in a visual short-term 
memory task. Cereb Cortex 14:713-720. 
 
Tamaru Y, Nomura S, Mizuno N, Shigemoto R (2001) Distribution of metabotropic 
glutamate receptor mGluR3 in the mouse CNS: differential location relative to 
pre- and postsynaptic sites. Neuroscience 106:481-503. 
 
Tamas G, Buhl EH, Lorincz A, Somogyi P (2000) Proximally targeted GABAergic 
synapses and gap junctions synchronize cortical interneurons. Nat Neurosci 
3:366-371. 
 
Tandon R (1999) Cholinergic aspects of schizophrenia. Br J Psychiatry Suppl:7-11. 
 
Thune JJ, Pakkenberg B (2000) Stereological studies of the schizophrenic brain. Brain 
Res Brain Res Rev 31:200-204. 
 
Thune JJ, Uylings HB, Pakkenberg B (2001) No deficit in total number of neurons in the 
prefrontal cortex in schizophrenics. J Psychiatr Res 35:15-21. 
 
Timmerman W, Westerink BH (1997) Brain microdialysis of GABA and glutamate: what 
does it signify? Synapse 27:242-261. 
 
Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, Matthey ML, Parnas J, 
Preisig M, Saraga M, Solida A, Timm S, Wang AG, Werge T, Cuenod M, Do KQ 
(2006) Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a 
susceptibility gene. Am J Hum Genet 79:586-592. 
 
Traub RD, Spruston N, Soltesz I, Konnerth A, Whittington MA, Jefferys GR (1998) 
Gamma-frequency oscillations: a neuronal population phenomenon, regulated by 
synaptic and intrinsic cellular processes, and inducing synaptic plasticity. Prog 
Neurobiol 55:563-575. 
 
Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) 
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch 
Gen Psychiatry 52:829-836. 
 
184 
 
Uhlhaas PJ, Linden DE, Singer W, Haenschel C, Lindner M, Maurer K, Rodriguez E 
(2006) Dysfunctional long-range coordination of neural activity during Gestalt 
perception in schizophrenia. J Neurosci 26:8168-8175. 
 
Uylings HB, Groenewegen HJ, Kolb B (2003) Do rats have a prefrontal cortex? Behav 
Brain Res 146:3-17. 
 
Vaisanen J, Ihalainen J, Tanila H, Castren E (2004) Effects of NMDA-receptor 
antagonist treatment on c-fos expression in rat brain areas implicated in 
schizophrenia. Cell Mol Neurobiol 24:769-780. 
 
Valvassori SS, Petronilho FC, Reus GZ, Steckert AV, Oliveira VB, Boeck CR, 
Kapczinski F, Dal-Pizzol F, Quevedo J (2008) Effect of N-acetylcysteine and/or 
deferoxamine on oxidative stress and hyperactivity in an animal model of mania. 
Prog Neuropsychopharmacol Biol Psychiatry 32:1064-1068. 
 
Varoqueaux F, Sigler A, Rhee JS, Brose N, Enk C, Reim K, Rosenmund C (2002) Total 
arrest of spontaneous and evoked synaptic transmission but normal 
synaptogenesis in the absence of Munc13-mediated vesicle priming. Proc Natl 
Acad Sci U S A 99:9037-9042. 
 
Verhage M, Maia AS, Plomp JJ, Brussaard AB, Heeroma JH, Vermeer H, Toonen RF, 
Hammer RE, van den Berg TK, Missler M, Geuze HJ, Sudhof TC (2000) 
Synaptic assembly of the brain in the absence of neurotransmitter secretion. 
Science 287:864-869. 
 
Verma A, Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortex 
function as assessed via spatial delayed alternation performance in rats: 
modulation by dopamine. J Neurosci 16:373-379. 
 
Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and HATs: 
the SLC7 family of amino acid transporters. Pflugers Arch 447:532-542. 
 
Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000) Decreased glutamic 
acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical 
gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen 
Psychiatry 57:237-245. 
 
Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: 
integrating natural and drug-induced psychoses. Brain Res Bull 56:495-507. 
 
Waagepetersen HS, Sonnewald U, Schousboe A (1999) The GABA paradox: multiple 
roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem 
73:1335-1342. 
 
185 
 
Waford RN, Lewine R (2010) Is perseveration uniquely characteristic of schizophrenia? 
Schizophr Res 118:128-133. 
 
Waltz JA, Gold JM (2007) Probabilistic reversal learning impairments in schizophrenia: 
further evidence of orbitofrontal dysfunction. Schizophr Res 93:296-303. 
 
Weinberger DR (1987) Implications of normal brain development for the pathogenesis of 
schizophrenia. Arch Gen Psychiatry 44:660-669. 
 
Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman 
KF, Goldberg TE (2001) Prefrontal neurons and the genetics of schizophrenia. 
Biol Psychiatry 50:825-844. 
 
Weiss AP, Dewitt I, Goff D, Ditman T, Heckers S (2005) Anterior and posterior 
hippocampal volumes in schizophrenia. Schizophr Res 73:103-112. 
 
Woo TU, Miller JL, Lewis DA (1997) Schizophrenia and the parvalbumin-containing 
class of cortical local circuit neurons. Am J Psychiatry 154:1013-1015. 
 
Woo TU, Whitehead RE, Melchitzky DS, Lewis DA (1998) A subclass of prefrontal 
gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. 
Proc Natl Acad Sci U S A 95:5341-5346. 
 
Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET (2000) 
Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 
157:16-25. 
 
Xi ZX, Baker DA, Shen H, Carson DS, Kalivas PW (2002) Group II metabotropic 
glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J 
Pharmacol Exp Ther 300:162-171. 
 
Yang Y, Chen Y, Johansson E, Schneider SN, Shertzer HG, Nebert DW, Dalton TP 
(2007) Interaction between the catalytic and modifier subunits of glutamate-
cysteine ligase. Biochem Pharmacol 74:372-381. 
 
Yao JK, Reddy R (2011) Oxidative stress in schizophrenia: pathogenetic and therapeutic 
implications. Antioxid Redox Signal 15:1999-2002. 
 
Yao JK, Leonard S, Reddy R (2006) Altered glutathione redox state in schizophrenia. Dis 
Markers 22:83-93. 
 
Young CE, Arima K, Xie J, Hu L, Beach TG, Falkai P, Honer WG (1998) SNAP-25 
deficit and hippocampal connectivity in schizophrenia. Cereb Cortex 8:261-268. 
 
186 
 
Young JW, Zhou X, Geyer MA (2010) Animal models of schizophrenia. Curr Top Behav 
Neurosci 4:391-433. 
 
Zaidel DW, Esiri MM, Harrison PJ (1997) Size, shape, and orientation of neurons in the 
left and right hippocampus: investigation of normal asymmetries and alterations 
in schizophrenia. Am J Psychiatry 154:812-818. 
 
 
 
